U.S. patent application number 17/627170 was filed with the patent office on 2022-09-15 for recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus.
The applicant listed for this patent is CHARLES RIVER LABORATORIES, INC.. Invention is credited to Qizhao WANG.
Application Number | 20220290178 17/627170 |
Document ID | / |
Family ID | 1000006351860 |
Filed Date | 2022-09-15 |
United States Patent
Application |
20220290178 |
Kind Code |
A1 |
WANG; Qizhao |
September 15, 2022 |
RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS HELPER VECTORS AND
THEIR USE TO IMPROVE THE PACKAGING EFFICIENCY OF
RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS
Abstract
The present invention is directed to recombinantly-modified
adeno-associated virus (AAV) helper vectors that are capable of
increasing the packaging efficiency of recombinantly-modified
adeno-associated virus (rAAV) and their use to improve the
packaging efficiency of such rAAV. The present invention is
particularly directed to recombinantly-modified adeno-associated
virus (AAV) helper vectors that have been further modified to
replace (or augment) the P5 and/or P40 promoter sequences that are
natively associated with the Rep proteins encoded by such rAAV with
AAV P5 and/or P40 promoters that are associated with the Rep
proteins of an rAAV of different serotype. The use of such
substitute or additional promoter sequences causes increased
production of recombinantly-modified adeno-associated virus.
Inventors: |
WANG; Qizhao; (Rockville,
MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CHARLES RIVER LABORATORIES, INC. |
WILMINGTON |
MA |
US |
|
|
Family ID: |
1000006351860 |
Appl. No.: |
17/627170 |
Filed: |
January 24, 2020 |
PCT Filed: |
January 24, 2020 |
PCT NO: |
PCT/US2020/014945 |
371 Date: |
January 14, 2022 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16512194 |
Jul 15, 2019 |
10557149 |
|
|
17627170 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 15/86 20130101;
C12N 5/0686 20130101; C12N 5/0601 20130101 |
International
Class: |
C12N 15/86 20060101
C12N015/86; C12N 5/071 20060101 C12N005/071; C12N 5/07 20060101
C12N005/07 |
Claims
1. A recombinantly-modified adeno-associated virus (AAV) helper
vector that comprises an AAV helper function-providing
polynucleotide, wherein said polynucleotide comprises a non-native
AAV serotype P5 or P40 promoter sequence.
2. The recombinantly-modified adeno-associated virus (AAV) helper
vector of claim 1, wherein said AAV helper function-providing
polynucleotide vector comprises a non-native AAV serotype P5
promoter sequence.
3. The recombinantly-modified adeno-associated virus (AAV) helper
vector of claim 1, wherein said AAV helper function-providing
polynucleotide vector comprises a non-native AAV serotype P40
promoter sequence.
4. The recombinantly-modified adeno-associated virus (AAV) helper
vector of claim 1, wherein said vector is a plasmid vector.
5. The recombinantly-modified adeno-associated virus (AAV) helper
vector of claim 1, wherein said non-native AAV serotype P5 or P40
promoter sequence replaces a native AAV serotype promoter
sequence.
6. The recombinantly-modified adeno-associated virus (AAV) helper
vector of claim 1, wherein said vector additionally comprises a
non-AAV helper function-providing polynucleotide.
7. A method for increasing the production titer of a
recombinantly-modified adeno-associated virus (rAAV) that comprises
a transgene cassette, wherein said method comprises culturing cells
that have been transfected with: (1) said rAAV; and (2) the
recombinantly-modified adeno-associated virus (AAV) helper vector
of claim 6; wherein said culturing is conducted in a culture medium
under conditions sufficient to permit the production of said rAAV
and wherein the presence of said non-native AAV serotype P5 or P40
promoter sequence causes said cells to produce said rAAV at an
increased production titer relative to that which would be attained
if said AAV helper function-providing polynucleotide contained
native serotype P5 and P40 promoters.
8. The method of claim 7, wherein said transgene cassette encodes a
protein, or comprises a transcribed nucleic acid, that is
therapeutic for a genetic or heritable disease or condition.
9. The method of claim 7, wherein: (A) said AAV helper
function-providing polynucleotide of said vector encodes an AAV1
Cap protein, and said non-native AAV serotype promoter sequence is
a promoter sequence of an AAV of serotype AAV3, AAV4, AAV5, AAV6,
AAV7 or AAV8, or a hybrid of one or more of said serotypes; (B)
said AAV helper function-providing polynucleotide of said vector
encodes an AAV2 Cap protein, and said non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or
more of said serotypes; (C) said AAV helper function-providing
polynucleotide of said vector encodes an AAV3 Cap protein, and said
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV4, AAV5, AAV6, AAV7 or AAV8, or a
hybrid of one or more of said serotypes; (D) said AAV helper
function-providing polynucleotide of said vector encodes an AAV4
Cap protein, and said non-native AAV serotype promoter sequence is
a promoter sequence of an AAV of serotype AAV1, AAV3, AAV5, AAV6,
AAV7 or AAV8, or a hybrid of one or more of said serotypes; (E)
said AAV helper function-providing polynucleotide of said vector
encodes an AAV5 Cap protein, and said non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV6, AAV7 or AAV8, or a hybrid of one or more of
said serotypes; (F) said AAV helper function-providing
polynucleotide of said vector encodes an AAV6 Cap protein, and said
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV7 or AAV8, or a
hybrid of one or more of said serotypes; (G) said AAV helper
function-providing polynucleotide of said vector encodes an AAV7
Cap protein, and said non-native AAV serotype promoter sequence is
a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5,
AAV6 or AAV8, or a hybrid of one or more of said serotypes; or (H)
said AAV helper function-providing polynucleotide of said vector
encodes an AAV8 Cap protein, and said non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7, or a hybrid of one or more of
said serotypes.
10. The method of claim 7, wherein said cells are human embryonic
kidney cells, baby hamster kidney cells or sf9 insect cells.
11. The method of claim 10, wherein said cells are HEK293 human
embryonic kidney cells.
12. The method of claim 10, wherein said cells are BHK21 baby
hamster kidney cells.
13. A method for increasing the production titer of a
recombinantly-modified adeno-associated virus (rAAV) that comprises
a transgene cassette, wherein said method comprises culturing cells
that have been transfected with: (1) said rAAV; (2) the
recombinantly-modified adeno-associated virus (AAV) helper vector
of claims 1; and (3) an additional vector that comprises a non-AAV
helper function-providing polynucleotide; wherein said culturing is
conducted in a culture medium under conditions sufficient to permit
the production of said rAAV and wherein the presence of said
non-native AAV serotype P5 or P40 promoter sequence causes said
cells to produce said rAAV at an increased production titer
relative to that which would be attained if said AAV helper
function-providing polynucleotide contained native serotype P5 and
P40 promoters.
14. The method of claim 13, wherein said transgene cassette encodes
a protein, or comprises a transcribed nucleic acid, that is
therapeutic for a genetic or heritable disease or condition.
15. The method of claim 13, wherein: (A) said AAV helper
function-providing polynucleotide of said vector encodes an AAV1
Cap protein, and said non-native AAV serotype promoter sequence is
a promoter sequence of an AAV of serotype AAV3, AAV4, AAV5, AAV6,
AAV7 or AAV8, or a hybrid of one or more of said serotypes; (B)
said AAV helper function-providing polynucleotide of said vector
encodes an AAV2 Cap protein, and said non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or
more of said serotypes; (C) said AAV helper function-providing
polynucleotide of said vector encodes an AAV3 Cap protein, and said
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV4, AAV5, AAV6, AAV7 or AAV8, or a
hybrid of one or more of said serotypes; (D) said AAV helper
function-providing polynucleotide of said vector encodes an AAV4
Cap protein, and said non-native AAV serotype promoter sequence is
a promoter sequence of an AAV of serotype AAV1, AAV3, AAV5, AAV6,
AAV7 or AAV8, or a hybrid of one or more of said serotypes; (E)
said AAV helper function-providing polynucleotide of said vector
encodes an AAV5 Cap protein, and said non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV6, AAV7 or AAV8, or a hybrid of one or more of
said serotypes; (F) said AAV helper function-providing
polynucleotide of said vector encodes an AAV6 Cap protein, and said
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV7 or AAV8, or a
hybrid of one or more of said serotypes; (G) said AAV helper
function-providing polynucleotide of said vector encodes an AAV7
Cap protein, and said non-native AAV serotype promoter sequence is
a promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5,
AAV6 or AAV8, or a hybrid of one or more of said serotypes; or (H)
said AAV helper function-providing polynucleotide of said vector
encodes an AAV8 Cap protein, and said non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7, or a hybrid of one or more of
said serotypes.
16. The method of claim 13, wherein said cells are human embryonic
kidney cells, baby hamster kidney cells or sf9 insect cells.
17. The method of claim 16, wherein said cells are HEK293 human
embryonic kidney cells.
18. The method of claim 16, wherein said cells are BHK21 baby
hamster kidney cells.
19. A pharmaceutical composition that comprises
recombinantly-modified adeno-associated virus (rAAV) produced by
the method of claim 6, and a pharmaceutically acceptable
carrier.
20. A pharmaceutical composition that comprises
recombinantly-modified adeno-associated virus (rAAV) produced by
the method of claim 13, and a pharmaceutically acceptable carrier.
Description
FIELD OF THE INVENTION
[0001] The present invention is directed to recombinantly-modified
adeno-associated virus (AAV) helper vectors that are capable of
increasing the packaging efficiency of recombinantly-modified
adeno-associated virus (rAAV) and their use to improve the
packaging efficiency of such rAAV. The present invention is
particularly directed to recombinantly-modified adeno-associated
virus (AAV) helper vectors that have been further modified to
replace (or augment) the P5 and/or P40 promoter sequences that are
natively associated with the Rep proteins encoded by such rAAV with
AAV P5 and/or P40 promoters that are associated with the Rep
proteins of an rAAV of different serotype. The use of such
substitute or additional promoter sequences causes increased
production of recombinantly-modified adeno-associated virus.
REFERENCE TO SEQUENCE LISTING
[0002] This application includes one or more Sequence Listings
pursuant to 37 C.F.R. 1.821 et seq., which are disclosed in
computer-readable media (file name: 2650-0004US_ST25.txt, created
on Jul. 15, 2019, and having a size of 84,101 bytes), which file is
herein incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
[0003] I. Adeno-Associated Virus (AAV)
[0004] Adeno-Associated Virus (AAV) is a small,
naturally-occurring, non-pathogenic virus belonging to the
Dependovirus genus of the Parvoviridae (Balakrishnan, B. et al.
(2014) "Basic Biology of Adeno Associated Virus (AAV) Vectors Used
in Gene Therapy," Curr. Gene Ther. 14(2):86-100; Zinn, E. et al.
(2014) "Adeno-Associated Virus: Fit To Serve," Curr. Opin. Virol.
0:90-97). Despite not causing disease, AAV is known to be able to
infect humans and other primates and is prevalent in human
populations (Johnson, F. B. et al. (1972) "Immunological Reactivity
of Antisera Prepared Against the Sodium Dodecyl Sulfate-Treated
Structural Polypeptides of Adenovirus-Associated Virus," J. Virol.
9(6):1017-1026). AAV infect a broad range of different cell types
(e.g., cells of the central nervous system, heart, kidney, liver,
lung, pancreas, retinal pigment epithelium or photoreceptor cells,
or skeletal muscle cells). Twelve serotypes of the virus (e.g.,
AAV2, AAV5, AAV6, etc.), exhibiting different tissue infection
capabilities ("tropisms"), have been identified (Colella, P. et al.
(2018) "Emerging Issues in AAV-Mediated In Vivo Gene Therapy,"
Molec. Ther. Meth. Clin. Develop. 8:87-104; Hocquemiller, M. et al.
(2016) "Adeno-Associated Virus-Based Gene Therapy for CNS
Diseases," Hum. Gene Ther. 27(7):478-496; Lisowski, L. et al.
(2015) "Adeno-Associated Virus Serotypes For Gene Therapeutics,"
24:59-67).
[0005] AAV is a single-stranded DNA virus that is composed of
approximately 4,800 nucleotides. The viral genome may be described
as having a 5' half and a 3' half which together comprise the genes
that encode the virus' proteins (FIG. 1). The 5' half of the AAV
genome comprises the AAV rep gene, which, through the use of
multiple reading frames, staggered initiating promoters (P5, P19
and P40) and alternate splicing, encodes four non-structural Rep
proteins (Rep40, Rep52, Rep68 and Rep78) that are required for
viral transcription control and replication and for the packaging
of viral genomes into the viral capsule (Lackner, D. F. et al.
(2002) "Studies of the Mechanism of Transactivation of the
Adeno-Associated Virus p19 Promoter by Rep Protein," J. Virol.
76(16):8225-8235). In the presence of viral proteins (such as Ad
proteins), the P5 promoter becomes activated and mediates the
transcription of the Rep68 and Rep78 proteins, which are involved
in transcriptional control, in latency, in rescue, and in viral DNA
replication and thus function as master controllers of the AAV life
cycle (Murphy, M. et al. (2007) "Adeno-Associated Virus Type 2 p5
Promoter: a Rep-Regulated DNA Switch Element Functioning in
Transcription, Replication, and Site-Specific Integration," J.
Virol. 81(8):3721-3730). Expression of the Rep68 and Rep78 proteins
activates the P19 promoter, which is responsible for the
transcription of the Rep40 and Rep52 proteins (Lackner, D. F. et
al. (2002) "Studies of the Mechanism of Transactivation of the
Adeno-Associated Virus p19 Promoter by Rep Protein," J. Virol.
76(16):8225-8235; Ogasawara, Y. et al. (1998) "The Use of
Heterologous Promoters for Adeno Associated Virus (AAV) Protein
Expression in AAV Vector Production," Microbiol. Immunol.
42(3):177-185). The 3' half the AAV genome comprises the AAV capsid
gene (cap), which encodes three capsid proteins (VP): VP1, VP2 and
VP3. The three capsid proteins are translated from a single mRNA
transcript that is controlled by a single promoter (P40 in case of
AAV2). The 3' half of the AAV genome also comprises the AAP gene,
which encodes the AAV assembly-activating protein (AAP). Sixty VP
monomers (comprising approximately 5 copies of VP1, 5 copies of
VP2, and 50 copies of VP3) self-assemble around the AAV genome to
form the icosahedral protein shell (capsid) of the mature viral
particle (Buning, H. et al. (2019) "Capsid Modifications for
Targeting and Improving the Efficacy of AAV Vectors," Mol. Ther.
Meth. Clin. Devel. 12:P248-P265; Van Vliet K. M. et al. (2008) The
Role of the Adeno-Associated Virus Capsid in Gene Transfer. In:
DRUG DELIVERY SYSTEMS, Jain, K. K. (eds.), Meth. Molec. Biol.
437:51-91). The AAV AAP protein is believed to be required for
stabilizing and transporting newly produced VP proteins from the
cytoplasm into the cell nucleus. The 3' half of the AAV genome also
comprises the AAV X gene, which is believed to encode a protein
that supports genome replication (Colella, P. et al. (2018)
"Emerging Issues in AAV-Mediated In Vivo Gene Therapy," Molec.
Ther. Meth. Clin. Develop. 8:87-104; Buning, H. et al. (2019)
"Capsid Modifications for Targeting and Improving the Efficacy of
AAV Vectors," Mol. Ther. Meth. Clin. Devel. 12:P248-P265; Cao, M.
et al. (2014) "The X Gene Of Adeno-Associated Virus 2 (AAV2) Is
Involved In Viral DNA Replication," PLoS ONE 9, e104596:1-10).
[0006] The above-described AAV gene-coding sequences are flanked by
two AAV-specific palindromic inverted terminal repeated sequences
(ITR) of 145 nucleotides (Balakrishnan, B. et al. (2014) "Basic
Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene
Therapy," Curr. Gene Ther. 14(2):86-100; Colella, P. et al. (2018)
"Emerging Issues in AAV-Mediated In Vivo Gene Therapy," Molec.
Ther. Meth. Clin. Develop. 8:87-104).
[0007] AAV is an inherently defective virus, lacking the capacity
to perform at least two critical functions: the ability to initiate
the synthesis of viral-specific products and the ability to
assemble such products to form the icosahedral protein shell
(capsid) of the mature infectious viral particle. It thus requires
a co-infecting "helper" virus, such as adenovirus (Ad), herpes
simplex virus (HSV), cytomegalovirus (CMV), vaccinia virus or human
papillomavirus to provide the viral-associated (VA) RNA that is not
encoded by the genes of the AAV genome. Such VA RNA is not
translated, but plays a role in regulating the translation of other
viral genes. Similarly, the AAV genome does not include genes that
encode the viral proteins E1a, E1b, E2a, and E4; thus, these
proteins must also be provided by a co-infecting "helper" virus.
The E1a protein greatly stimulate viral gene transcription during
the productive infection. The E1b protein block apoptosis in
adenovirus-infected cells, and thus allow productive infection to
proceed. The E2a protein plays a role in the elongation phase of
viral strand displacement replication by unwinding the template and
enhancing the initiation of transcription. The E4 protein has been
shown to affect transgene persistence, vector toxicity and
immunogenicity (see, Grieger, J. C. et al. (2012) "Adeno-Associated
Virus Vectorology, Manufacturing, and Clinical Applications," Meth.
Enzymol. 507:229-254; Dyson, N. et al. (1992) "Adenovirus E1A
Targets Key Regulators Of Cell Proliferation," Canc. Surv.
12:161-195; Jones N.C. (1990) "Transformation By The Human
Adenoviruses," Semin. Cancer Biol. 1(6):425-435; Ben-Israel, H. et
al. (2002) "Adenovirus and Cell Cycle Control," Front. Biosci.
7:d1369-d1395; Hoeben, R. C. et al. (2013) "Adenovirus DNA
Replication," Cold Spring Harb. Perspect. Biol. 5:a013003 (pages
1-11); Berk, A. J. (2013) "Adenoviridae: The Viruses And Their
Replication, In: FIELDS VIROLOGY, 6.sup.th Edition (Knipe, D. M. et
al., Eds.), Vol. 2., Lippincott Williams & Wilkins,
Philadelphia, pages 1704-1731; Weitzman, M. D. (2005) "Functions Of
The Adenovirus E4 Proteins And Their Impact On Viral Vectors,"
Front. Biosci. 10:1106-1117).
[0008] AAV viruses infect both dividing and non-dividing cells, and
persist as circular episomal molecules or can be integrated into
the DNA of a host cell at specific chromosomic loci
(Adeno-Associated Virus Integration Sites or AAVS) (Duan, D. (2016)
"Systemic Delivery Of Adeno-Associated Viral Vectors," Curr. Opin.
Virol. 21:16-25; Grieger, J. C. et al. (2012) "Adeno-Associated
Virus Vectorology, Manufacturing, and Clinical Applications," Meth.
Enzymol. 507:229-254). AAV remains latent in such infected cells
unless a helper virus is present to provide the functions needed
for AAV replication and maturation.
[0009] II. rAAV and Their Use in Gene Therapy
[0010] In light of AAV's properties, recombinantly-modified
versions of AAV (rAAV) have found substantial utility as vectors
for gene therapy (see, Naso, M. F. et al. (2017) "Adeno Associated
Virus (AAV) as a Vector for Gene Therapy," BioDrugs 31:317-334;
Berns, K. I. et al. (2017) "AAV. An Overview of Unanswered
Questions," Human Gene Ther. 28(4):308-313; Berry, G. E. et al.
(2016) "Cellular Transduction Mechanisms Of Adeno-Associated Viral
Vectors," Curr. Opin. Virol. 21:54-60; Blessing, D. et al. (2016)
"Adeno-Associated Virus And Lentivirus Vectors: A Refined Toolkit
For The Central Nervous System," 21:61-66; Santiago-Ortiz, J. L.
(2016) "Adeno-Associated Virus (AAV) Vectors in Cancer Gene
Therapy," J. Control Release 240:287-301; Salganik, M. et al.
(2015) "Adeno-Associated Virus As A Mammalian DNA Vector,"
Microbiol. Spectr. 3(4):1-32; Hocquemiller, M. et al. (2016)
"Adeno-Associated Virus-Based Gene Therapy for CNS Diseases," Hum.
Gene Ther. 27(7):478-496; Lykken, E. A. et al. (2018) "Recent
Progress And Considerations For AAV Gene Therapies Targeting The
Central Nervous System," J. Neurodevelop. Dis. 10:16:1-10; Buning,
H. et al. (2019) "Capsid Modifications for Targeting and Improving
the Efficacy of AAV Vectors," Mol. Ther. Meth. Clin. Devel.
12:P248-P265; During, M. J. et al. (1998) "In Vivo Expression Of
Therapeutic Human Genes For Dopamine Production In The Caudates Of
MPTP-Treated Monkeys Using An AAV Vector," Gene The. 5:820-827;
Grieger, J. C. et al. (2012) "Adeno-Associated Virus Vectorology,
Manufacturing, and Clinical Applications," Meth. Enzymol.
507:229-254; Kotterman, M. A. et al. (2014) "Engineering
Adeno-Associated Viruses For Clinical Gene Therapy," Nat. Rev.
Genet. 15(7):445-451; Kwon, I. et al. (2007) "Designer Gene
Delivery Vectors: Molecular Engineering and Evolution of
Adeno-Associated Viral Vectors for Enhanced Gene Transfer," Pharm.
Res. 25(3):489-499; U.S. Pat. Nos. 10,266,845; 10,081,659;
9,890,396; 9,840,719; 9,839,696; 9,834,789; 9,803,218; 9,783,825;
9,777,291; 9,540,659; 9,527,904; 8,236,557; 7,972,593 and
7,943,374).
[0011] rAAV are typically produced using circular plasmids ("rAAV
plasmid vector"). The AAV rep and cap genes are typically deleted
from such constructs and replaced with a promoter, .alpha.
.beta.-globin intron, a cloning site into which a therapeutic gene
of choice (transgene) has been inserted, and a poly-adenylation
("polyA") site. The inverted terminal repeated sequences (ITR) of
the rAAV are, however, retained, so that the transgene expression
cassette of the rAAV plasmid vector is flanked by AAV ITR sequences
(Colella, P. et al. (2018) "Emerging Issues in AAV-Mediated In Vivo
Gene Therapy," Molec. Ther. Meth. Clin. Develop. 8:87-104; Buning,
H. et al. (2019) "Capsid Modifications for Targeting and Improving
the Efficacy of AAV Vectors," Mol. Ther. Meth. Clin. Devel.
12:P248-P265). Thus, in the 5' to 3' direction, the rAAV comprises
a 5' ITR, the transgene expression cassette of the rAAV, and a 3'
ITR.
[0012] rAAV have been used to deliver a transgene to patients
suffering from any of a multitude of genetic diseases (e.g.,
hereditary lipoprotein lipase deficiency (LPLD), Leber's congenital
amaurosis (LCA), aromatic L-amino acid decarboxylase deficiency
(AADC), choroideremia and hemophilia), and have utility in new
clinical modalities, such as in interfering RNA (RNAi) therapy and
gene-modifying strategies such as Crispr/Cas9 (U.S. Pat. Nos.
8,697,359, 10,000,772, 10,113,167, 10,227,611; Lino, C. A. et al.
(2018) "Delivering CRISPR: A Review Of The Challenges And
Approaches," Drug Deliv. 25(1):1234-1237; Ferreira, V. et al.
(2014) "Immune Responses To AAV-Vectors, The Glybera Example From
Bench To Bedside" Front. Immunol. 5(82):1-15), Buning, H. et al.
(2019) "Capsid Modifications for Targeting and Improving the
Efficacy of AAV Vectors," Mol. Ther. Meth. Clin. Devel.
12:P248-P265; Rastall, D. P. W. (2017) "Current and Future
Treatments for Lysosomal Storage Disorders," Curr. Treat Options
Neurol. 19(12):45; Kay, M. et al. (2017) "Future Of rAAV Gene
Therapy: Platform For RNAi, Gene Editing And Beyond," Human Gene
Ther. 28:361-372); Berns, K. I. et al. (2017) "AAV: An Overview of
Unanswered Questions," Human Gene Ther. 28(4):308-313). More than
150 clinical trials involving rAAV have been instituted (Buning, H.
et al. (2019) "CapsidModifications for Targeting and Improving the
Efficacy of AAV Vectors," Mol. Ther. Meth. Clin. Devel.
12:P248-P265; Clement, N. et al. (2016) "Manufacturing Of
Recombinant Adeno Associated Viral Vectors For Clinical Trials,"
Meth. Clin. Develop. 3:16002:1-7). The most commonly used AAV
serotype for such recombinantly-modified AAV is AAV2, which is
capable of infecting cells of the central nervous system, kidney,
retinal pigment epithelium and photoreceptor cells. AAV serotype is
AAV9, which infects muscle cells, also has been widely used (Duan,
D. (2016) "Systemic Delivery Of Adeno-Associated Viral Vectors,"
Curr. Opin. Virol. 21:16-25). AAV serotypes are described in U.S.
Pat. Nos. 10,301,650; 10,266,846; 10,265,417; 10,214,785;
10,214,566; 10,202,657; 10,046,016; 9,884,071; 9,856,539;
9,737,618; 9,677,089; 9,458,517; 9,457,103; 9,441,244; 9,193,956;
8,846,389; 8,507,267; 7,906,111; 7,479,554; 7,186,552; 7,105,345;
6,984,517; 6,962,815; and 6,733,757.
[0013] III. Methods of rAAV Production
[0014] rAAV containing a desired transgene expression cassette are
typically produced by human cells (such as HEK293) grown in
suspension. Since, as described above, rAAV are defective viruses,
additional functions must be provided in order to replicate and
package rAAV.
[0015] rAAV can be produced by transiently transfecting cells with
an rAAV plasmid vector and a second plasmid vector that comprises
an AAV helper function-providing polynucleotide that provides the
Rep52 and Rep78 genes that are required for vector transcription
control and replication, and for the packaging of viral genomes
into the viral capsule (Rep40 and Rep68 are not required for rAAV
production) and the cap genes that were excised from the AAV in
order to produce the rAAV. The second plasmid vector may
additionally comprise a non-AAV helper function-providing
polynucleotide that encodes the viral transcription and translation
factors (E1a, E1b, E2a, VA and E4) required for AAV proliferation,
so as to comprise, in concert with the rAAV, a double plasmid
transfection system (Grimm, D. et al. (1998) "Novel Tools For
Production And Purification Of Recombinant Adeno-Associated Virus
Vectors," Hum. Gene Ther. 9:2745-2760; Penaud-Budloo, M. et al.
(2018) "Pharmacology of Recombinant Adeno-associated Virus
Production," Molec. Ther. Meth. Clin. Develop. 8:166-180).
[0016] However, it has become increasingly common to clone the AAV
helper function-providing polynucleotide (which provides the
required rep and cap genes) into an AAV helper plasmid, and to
clone the non-AAV helper function-providing polynucleotide (which
provides the genes that encode the viral transcription and
translation factors) on a different plasmid (e.g., an "Ad helper
plasmid"), so that such plasmids, in concert with an rAAV plasmid
vector, comprise a triple plasmid transfection system (FIG. 2). Use
of the triple plasmid transfection system has the advantage of
permitting one to easily switch one cap gene for another, thereby
facilitating changes in the rAAV' s serotype. The use of helper
plasmids, rather than helper viruses, permits rAAV to be produced
without additionally producing particles of the helper virus
(Francois, A. et al. (2018) "Accurate Titration of Infectious AAV
Particles Requires Measurement of Biologically Active Vector
Genomes and Suitable Controls," Molec. Ther. Meth. Clin. Develop.
10:223-236; Matsushita, T. et al. (1998) "Adeno-Associated Virus
Vectors Can Be Efficiently Produced Without Helper Virus," Gene
Ther. 5:938-945).
[0017] The transient transfection of plasmid DNAs comprising the
rAAV plasmid vector, the AAV rep and cap genes, and the
trans-acting AAD helper genes into HEK293 cells by calcium
phosphate coprecipitation has become the standard method to produce
rAAV in the research laboratory (Grimm, D. et al. (1998) "Novel
Tools For Production And Purification Of Recombinant
Adeno-Associated Virus Vectors," Hum. Gene Ther. 9:2745-2760).
However, the use of such a calcium phosphate-mediated transfection
process with suspension-cultured transfected mammalian cells
requires media exchanges, and is thus not considered ideal for the
large-scale rAAV production that is required in order to produce
therapeutic doses of rAAV (Lock, M. et al. (2010) "Rapid, Simple,
and Versatile Manufacturing of Recombinant Adeno-Associated Viral
Vectors at Scale," Hum. Gene Ther. 21:1259-1271). For this reason,
polyethylenimine (PEI), has been used as a transfection reagent and
has been found to provide yields of virus that are similar to those
obtained using calcium phosphate-mediated transfection (Durocher,
Y. et al. (2007) "Scalable Serum-Free Production Of Recombinant
Adeno-Associated Virus Type 2 By Transfection Of 293 Suspension
Cells," J. Virol. Meth. 144:32-40).
[0018] rAAV may alternatively be produced in insect cells (e.g.,
sf9 cells) using baculoviral vectors (see, e.g., U.S. Pat. Nos.
9,879,282; 9,879,279; 8,945,918; 8,163,543; 7,271,002 and
6,723,551), or in HSV-infected baby hamster kidney (BHK) cells
(e.g., BHK21) (Francois, A. et al. (2018) "Accurate Titration of
Infectious AAV Particles Requires Measurement of Biologically
Active Vector Genomes and Suitable Controls," Molec. Ther. Meth.
Clin. Develop. 10:223-236). Methods of rAAV production are reviewed
in Grieger, J.C. et al. (2012) "Adeno-Associated Virus Vectorology,
Manufacturing, and Clinical Applications," Meth. Enzymol.
507:229-254, and in Penaud-Budloo, M. et al. (2018) "Pharmacology
of Recombinant Adeno-associated Virus Production," Molec. Ther.
Meth. Clin. Develop. 8:166-180.
[0019] IV. Methods of rAAV Purification and Recovery
[0020] After production, rAAV are typically collected and purified
by one or more overnight CsCl gradient centrifugations (Zolotukhin,
S. et al. (1999) "Recombinant Adeno Associated Virus Purification
Using Novel Methods Improves Infectious Titer And Yield," Gene
Ther. 6:973-985), followed by desalting to form a purified rAAV
production stock. Titers of 10.sup.12-10.sup.13 infectious rAAV
capsids/mL are obtainable.
[0021] Because rAAV infection does not cause a cytopathic effect,
plaque assays cannot be used to determine the infectious titer of
an rAAV preparation. Infectious titer is thus typically measured as
the median tissue culture infective dose (TCID50). In this method,
a HeLa-derived AAV2 rep- and cap-expressing cell line is grown in a
96-well plate and infected with replicate 10-fold serial dilutions
of the rAAV preparation, in the presence of adenovirus of serotype
5. After infection, vector genome replication is determined by
quantitative PCR (qPCR) (Zen, Z. et al. (2004) "Infectious Titer
Assay For Adeno-Associated Virus Vectors With Sensitivity
Sufficient To Detect Single Infectious Events," Hum. Gene Ther.
15:709-715). Alternatively, the infectious titer of an rAAV
preparation can be measured using the infectious center assay
(ICA). This assay uses HeLa rep-cap cells and Ad, but, after
incubation, involves transferring the cells to a membrane. A
labeled probe that is complementary to a portion of the employed
transgene is used to detect infectious centers (representing
individual infected cells) via hybridization. Although more widely
used, the TCID50 assay has been reported to lead to a higher
background than the ICA and to overestimate vector infectivity
relative to the ICA (Francois, A. et al. (2018) "Accurate Titration
of Infectious AAV Particles Requires Measurement of Biologically
Active Vector Genomes and Suitable Controls," Molec. Ther. Meth.
Clin. Develop. 10:223-236). Methods of producing and purifying rAAV
are described inter alia in U.S. Pat. Nos. 10,294,452; 10,161,011;
10,017,746; 9,598,703; 7,625,570; 7,439,065; 7,419,817; 7,208,315;
6,995,006; 6,989,264; 6,846,665 and 6,841,357.
[0022] Despite all such prior advances, a need remains to develop
methods capable of addressing problems that presently limit the
applicability of rAAV to gene therapy (Grieger, J. C. et al. (2012)
"Adeno-Associated Virus Vectorology, Manufacturing, and Clinical
Applications," Meth. Enzymol. 507:229-254; Kotterman, M. A. et al.
(2014) "Engineering Adeno-Associated Viruses For Clinical Gene
Therapy," Nat. Rev. Genet. 15(7):445-451; Kwon, I. et al. (2007)
"Designer Gene Delivery Vectors: Molecular Engineering and
Evolution of Adeno-Associated Viral Vectors for Enhanced Gene
Transfer," Pharm. Res. 25(3):489-499; Naso, M. F. et al. (2017)
"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy,"
BioDrugs 31:317-334).
[0023] The present invention is directed to improved methods for
increasing the efficiency of AAV and rAAV packaging through
regulation of the expression of the AAV rep and cap genes.
SUMMARY OF THE INVENTION
[0024] The present invention is directed to recombinantly-modified
adeno-associated virus (AAV) helper vectors that are capable of
increasing the packaging efficiency of recombinantly-modified
adeno-associated virus (rAAV) and their use to improve the
packaging efficiency of such rAAV. The present invention is
particularly directed to recombinantly-modified adeno-associated
virus (AAV) helper vectors that have been further modified to
replace (or augment) the P5 and/or P40 promoter sequences that are
natively associated with the Rep proteins encoded by such rAAV with
AAV P5 and/or P40 promoters that are associated with the Rep
proteins of an rAAV of different serotype. The use of such
substitute or additional promoter sequences causes increased
production of recombinantly-modified adeno-associated virus.
[0025] In detail, the invention provides a recombinantly-modified
adeno-associated virus (AAV) helper vector that comprises an AAV
helper function-providing polynucleotide, and especially an AAV
helper function-providing polynucleotide that is a plasmid vector,
wherein the polynucleotide comprises a non-native AAV serotype P5
or P40 promoter sequence.
[0026] The invention particularly includes the embodiment of such
recombinantly-modified adeno-associated virus (AAV) helper vector
wherein the AAV helper function-providing polynucleotide vector
comprises a non-native AAV serotype P5 promoter sequence and/or a
non-native AAV serotype P40 promoter sequence.
[0027] The invention also particularly includes the embodiment of
such recombinantly-modified adeno-associated virus (AAV) helper
vector wherein the non-native AAV serotype P5 or P40 promoter
sequence replaces a native AAV serotype promoter sequence.
[0028] The invention also particularly includes the embodiment of
such recombinantly-modified adeno-associated virus (AAV) helper
vector wherein the vector additionally comprises a non-AAV helper
function-providing polynucleotide.
[0029] The invention additionally provides a method for increasing
the production titer of a recombinantly-modified adeno-associated
virus (rAAV) that comprises a transgene cassette, wherein the
method comprises culturing cells that have been transfected with:
[0030] (1) the rAAV; [0031] (2) the above-described
recombinantly-modified adeno-associated virus (AAV) helper vector
that additionally comprises a non-AAV helper function-providing
polynucleotide; wherein the culturing is conducted in a culture
medium under conditions sufficient to permit the production of the
rAAV, and wherein the presence of the non-native AAV serotype P5 or
P40 promoter sequence causes the cells to produce the rAAV at an
increased production titer relative to that which would be attained
if the AAV helper function-providing polynucleotide contained
native serotype P5 and P40 promoters.
[0032] The invention additionally provides a method for increasing
the production titer of recombinantly-modified adeno-associated
virus (rAAV) that comprises a transgene cassette, wherein the
method comprises culturing cells that have been transfected with:
[0033] (1) the rAAV; [0034] (2) any of the above-described
recombinantly-modified adeno-associated virus (AAV) helper vectors;
and [0035] (3) an additional vector, especially a plasmid vector,
that comprises a non-AAV helper function-providing polynucleotide;
wherein the culturing is conducted in a culture medium under
conditions sufficient to permit the production of the rAAV, and
wherein the presence of the non-native AAV serotype P5 or P40
promoter sequence causes the cells to produce the rAAV at an
increased production titer relative to that which would be attained
if the AAV helper function-providing polynucleotide contained
native serotype P5 and P40 promoters.
[0036] The invention particularly includes the embodiment of such
methods, wherein the transgene cassette encodes a protein, or
comprises a transcribed nucleic acid, that is therapeutic for a
genetic or heritable disease or condition.
[0037] The invention also particularly includes the embodiment of
such methods, wherein: [0038] (A) the AAV helper function-providing
polynucleotide of the vector encodes an AAV1 Cap protein, and the
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a
hybrid of one or more of the serotypes; [0039] (B) the AAV helper
function-providing polynucleotide of the vector encodes an AAV2 Cap
protein, and the non-native AAV serotype promoter sequence is a
promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5,
AAV6, AAV7 or AAV8, or a hybrid of one or more of the serotypes;
[0040] (C) the AAV helper function-providing polynucleotide of the
vector encodes an AAV3 Cap protein, and the non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of
the serotypes; [0041] (D) the AAV helper function-providing
polynucleotide of the vector encodes an AAV4 Cap protein, and the
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV3, AAV5, AAV6, AAV7 or AAV8, or a
hybrid of one or more of the serotypes; [0042] (E) the AAV helper
function-providing polynucleotide of the vector encodes an AAV5 Cap
protein, and the non-native AAV serotype promoter sequence is a
promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV6,
AAV7 or AAV8, or a hybrid of one or more of the serotypes; [0043]
(F) the AAV helper function-providing polynucleotide of the vector
encodes an AAV6 Cap protein, and the non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV5, AAV7 or AAV8, or a hybrid of one or more of
the serotypes; [0044] (G) the AAV helper function-providing
polynucleotide of the vector encodes an AAV7 Cap protein, and the
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6 or AAV8, or a
hybrid of one or more of the serotypes; [0045] (H) the AAV helper
function-providing polynucleotide of the vector encodes an AAV8 Cap
protein, and the non-native AAV serotype promoter sequence is a
promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5,
AAV6 or AAV7, or a hybrid of one or more of the serotypes.
[0046] The invention also particularly includes the embodiment of
such methods, wherein the cells are human embryonic kidney cells,
baby hamster kidney cells or sf9 insect cells.
[0047] The invention additionally provides a pharmaceutical
composition that comprises the recombinantly-modified
adeno-associated virus (rAAV) produced by any of the above-listed
methods, and a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
[0048] FIG. 1 provides a schematic genetic map of the wild-type
(Wt) AAV genome.
[0049] FIG. 2 provides a schematic of the structural domain of the
wild-type AAV2 genome (1), a recombinant AAV (rAAV) (2),
complementing "AAV helper plasmid" (3) and an adenovirus helper
plasmid ("Ad helper plasmid") (4). The wild-type (Wt) AAV2 (1) is
composed of AAV-specific palindromic inverted terminal repeated
sequences (ITR), a 5' half containing genes that encode the Rep
proteins and a 3' half containing genes that encode the Cap
proteins. The rAAV (2) is formed by replacing the Rep- and
Cap-encoding genes of the wild-type (Wt) AAV2 (1) with a transgene
cassette that comprises a promoter (Pro), the exogenous transgene
of interest, and a polyadenylation site (pA). In order to produce
the rAAV (2), a complementing "AAV helper" plasmid vector (3) and
an adenovirus helper plasmid vector (Ad helper plasmid) (4) are
provided. The complementing AAV helper plasmid (3) provides Rep and
Cap proteins. The Ad helper plasmid (4) provides adenovirus
proteins E1a, E1b, Eta, VA and E4.
[0050] FIG. 3 shows a map of the AAV helper plasmid vector pAAV-RC1
(SEQ ID NO:1).
[0051] FIG. 4 shows a map of the AAV helper plasmid vector pAAV-RC2
(SEQ ID NO:2).
[0052] FIG. 5 shows a map of the AAV helper plasmid vector pAAV-RC5
(SEQ ID NO:3).
[0053] FIG. 6 shows a map of the AAV helper plasmid vector pAAV-RC6
(SEQ ID NO:4).
[0054] FIG. 7 shows a map of the AAV helper plasmid vector pAAV-RC7
(SEQ ID NO:5).
[0055] FIG. 8 shows a map of the non-AAV helper plasmid vector
pHelper-Kan (SEQ ID NO:6).
[0056] FIG. 9 shows a map of the rAAV plasmid vector pAV-CMV-EGFP
(SEQ ID NO:7).
[0057] FIG. 10 shows a map of the rAAV plasmid vector pAV-TBG-EGFP
(SEQ ID NO:8).
[0058] FIG. 11 shows the overall structure and approach followed
for the development of the exemplary AAV helper constructs
described herein. The parent construct (pAAV-RC2; Parent-RC)
comprises AAV2 serotype promoter sequences for the P5 and P19
promoters (solid black boxes) that direct expression of the native
AAV2 rep gene (white boxed gene), which encodes the Rep proteins,
as well as the AAV2 serotype promoter sequence of the P40 promoter
(solid black box) that directs expression of the native AAV2 cap
gene (gray boxed gene), which encodes the Cap proteins.
[0059] P5-RC constructs are derivatives of parental plasmid AAV RC
that have been modified to direct expression of the AAV rep gene
using a non-native P5 promoter (i.e., an AAV P5 promoter that is
not natively present within the AAV rep gene of the vector
(downward striped box)) in lieu of the native AAV serotype P5
promoter (solid black box); P5-RC constructs direct expression of
the AAV rep and cap genes using the native AAV serotype P19 and P40
promoter sequences (solid black boxes) of the parent vector. P40-RC
constructs are derivatives of parental plasmid AAV RC that have
been modified to direct expression of the AAV cap gene using a
non-native P40 promoter (i.e., an AAV P40 promoter that is not
natively present within the AAV rep gene (upward striped box)) of
the vector in lieu of the native AAV serotype P40 promoter (solid
black box); P40-RC constructs direct expression of the AAV rep gene
using the native AAV serotype P5 and P19 promoter sequences (solid
black boxes) of the parent vector. P5/P40-RC constructs are
derivatives of parental plasmid AAV RC that have been modified to
direct expression of the AAV rep gene using a non-native P5
promoter (i.e., an AAV P5 promoter that is not natively present
within the AAV rep gene of the vector (downward striped box)) in
lieu of the native AAV serotype P5 promoter (solid black box).
P5/P40-RC constructs have additionally been modified to direct
expression to direct expression of the AAV cap gene using a
non-native P40 promoter (i.e., an AAV P40 promoter that is not
natively present within the AAV rep gene (upward striped box)) of
the vector in lieu of the native AAV serotype P40 promoter (solid
black box). P40-RC constructs direct expression of the AAV rep gene
using the native AAV serotype P19 promoter sequences (solid black
boxes) of the parent vector. The sequences of the promoter regions
are shown in Table 1.
[0060] FIGS. 12A-12B show the production titers of rAAV obtained by
modifying a parental RC2 vector to comprise a non-native P5
promoter sequence (FIG. 11; FIG. 12A; downward striped rectangle)
in lieu of the AAV2 P5 promoter that is natively associated with
the rep gene of such vector. The P19 and P40 promoters are both
native AAV2 serotype promoter sequences (solid black rectangles).
FIG. 12B shows the production titers of rAAV obtained using such
AAV helper plasmid vectors. The following constructs were employed:
Parent-RC2, P5(2)-RC2, P5(1)-RC2, P5(3)-RC2, P5(4)-RC2, P5(5)-RC2,
P5(7)-RC2, and P5(8)-RC2. The sequences of the promoter regions are
shown in Table 1. The production titers of rAAV were obtained using
a triple plasmid transfection system with an rAAV, and an Ad helper
plasmid that provided the required adenoviral functions.
[0061] FIGS. 13A-13B show the production titers of rAAV obtained by
modifying a parental RC2 vector to comprise a non-native P40
promoter sequence (FIG. 11; FIG. 13A; upward striped rectangle) in
lieu of the AAV2 serotype P40 promoter of the parental vector. The
P5 and P19 promoters are both native AAV2 serotype promoter
sequences (solid black rectangle). FIG. 13B shows the production
titers of rAAV obtained using such AAV helper plasmid vectors. The
following constructs were employed: Parent-RC2, P40(1)-RC2,
P40(3)-RC2, P40(4)-RC2, P40(5)-RC2, P40(6)-RC2, P40(7)-RC2, and
P40(8)-RC2. The sequences of the promoter regions are shown in
Table 1. The production titers of rAAV were obtained using a triple
plasmid transfection system with an rAAV, and an Ad helper plasmid
that provided the required adenoviral functions.
[0062] FIGS. 14A-14B show the production titers of rAAV obtained by
modifying a parental RC2 vector to comprise a non-native P5
promoter sequence and/or a non-native P40 promoter sequence (FIG.
11; FIG. 14A; P5, downward striped rectangle; P40, upward striped
rectangle) in lieu of the AAV2 serotype P5 and P40 promoters of the
parental vector. The P19 promoter is a native AAV2 serotype
promoter sequences (solid black rectangle). The following
constructs were employed: Parent-RC2, P5(2)-RC2, P5(3)-RC2,
P5(5)-RC2, P40(1)-RC2, P5(2)/P40(1)-RC2, P5(3)/P40(1)-RC2, and
P5(5)/P40(1)-RC2. The sequences of the promoter regions are shown
in Table 1. FIG. 14B shows the production titers of rAAV obtained
using such AAV helper plasmid vectors. The production titers of
rAAV were obtained using a triple plasmid transfection system with
an rAAV, and an Ad helper plasmid that provided the required
adenoviral functions.
[0063] FIGS. 15A-15C show the production titers of rAAV obtained by
modifying a parental RC6 vector to comprise a non-native P5
promoter sequence (FIG. 11; FIG. 15A; downward striped rectangle)
in lieu of the AAV2 serotype P5 promoter that is natively
associated with the rep gene of such vector. The P19 and P40
promoters are both native AAV2 serotype promoter sequences (solid
black rectangles). The following constructs were employed:
Parent-RC6, P5(1)-RC6, P5(2)-RC6, P5(3)-RC6, P5(7)-RC6 and
P5(8)-RC6. The sequences of the promoter regions are shown in Table
1. The production titers of rAAV were obtained (FIGS. 15B-15C)
using a triple plasmid transfection system with an rAAV, and an Ad
helper plasmid that provided the required adenoviral functions.
[0064] FIGS. 16A-16B show the production titers of rAAV obtained by
modifying a parental RC1, RC5, or RC7 vector to comprise a
non-native P5 promoter sequence (FIG. 11; FIG. 16A; downward
striped rectangle) in lieu of the AAV2 serotype P5 promoter that is
natively associated with the rep gene of such vectors. The P19 and
P40 promoters are both native AAV2 serotype promoter sequences
(solid black rectangles). The following constructs were employed:
Parent-RC1, Parent-RCS, Parent-RC7, P5(2)-RC1, P5(7)-RC1,
P5(8)-RC1, P5(7)-RC5, P5(2)-RC7, P5(7)-RC7 and P5(8)-RC7. The
sequences of the promoter regions are shown in Table 1. The
production titers of rAAV (FIG. 16B) were obtained using a triple
plasmid transfection system with an rAAV, and an Ad helper plasmid
that provided the required adenoviral functions.
DETAILED DESCRIPTION OF THE INVENTION:
[0065] I. The Methods of the Present Invention
[0066] The present invention is directed to recombinantly-modified
adeno-associated virus (AAV) helper vectors that are capable of
increasing the packaging efficiency of recombinantly-modified
adeno-associated virus (rAAV) and their use to improve the
packaging efficiency of such rAAV. The present invention is
particularly directed to recombinantly-modified adeno-associated
virus (AAV) helper vectors that have been further modified to
replace (or augment) the P5 and/or P40 promoter sequences that are
natively associated with the Rep proteins encoded by such rAAV with
AAV P5 and/or P40 promoters that are associated with the Rep
proteins of an rAAV of different serotype. The use of such
substitute or additional promoter sequences causes increased
production of recombinantly-modified adeno-associated virus.
[0067] The present invention is based in part on the recognition
that high levels of Rep and Cap proteins increase the amount of
rAAV genomes particles produced and, consequently, the efficiency
of rAAV packaging, and thus result in high production titers of
rAAV stocks. It has been unexpectedly found that by replacing the
AAV P5 and/or P40 promoters that direct the expression of the Cap
proteins with different AAV P5 and/or P40 promoters, or by adding
such different AAV P5 and/or P40 promoters in addition to those
initially present, causes the desired high levels of rAAV to be
attained. AAV Rep proteins are described in U.S. Pat. Nos.
10,214,730; 7,122,348; 6,821,511; 6,753,419; 9,441,206; and
7,115,391.
[0068] As discussed above, AAV and rAAV are characterized based on
their serotype, which is determined by their capsid proteins
(Colella, P. et al. (2018) "Emerging Issues in AAV-Mediated In Vivo
Gene Therapy," Molec. Ther. Meth. Clin. Develop. 8:87-104;
Hocquemiller, M. et al. (2016) "Adeno-Associated Virus-Based Gene
Therapy for CNS Diseases," Hum. Gene Ther. 27(7):478-496; Lisowski,
L. et al. (2015) "Adeno-Associated Virus Serotypes For Gene
Therapeutics," 24:59-67; U.S. Pat. Nos. 10,301,650; 10,266,846;
10,265,417; 10,214,785; 10,214,566; 10,202,657; 10,046,016;
9,884,071; 9,856,539; 9,737,618; 9,677,089; 9,458,517; 9,457,103;
9,441,244; 9,193,956; 8,846,389; 8,507,267; 7,906,111; 7,479,554;
7,186,552; 7,105,345; 6,984,517; 6,962,815; and 6,733,757). By
forming AAV and rAAV in the presence of AAV helper
function-providing polynucleotides that encode two or more capsid
proteins of different serotype, one can produce AAV and rAAV having
"hybrid" serotypes. Such AAV and rAAV exhibit the combined trophism
of AAV and rAAV having each of such capsid proteins.
[0069] The Rep proteins of the different AAV serotypes differ,
however, since such proteins are not structural proteins, the
differences do not contribute to the observed serotype of an
AAV.
[0070] As used herein, the term "AAV" is intended to denote
adeno-associated virus, and may be used to refer to the virus
itself or derivatives thereof. The term covers all subtypes and
both naturally-occurring and recombinant forms. As used herein, the
term "rAAV" is intended to denote a recombinantly-modified version
of AAV that comprises a polynucleotide sequence not of AAV origin
(i.e., a polynucleotide heterologous to AAV). The rAAV may be
single-stranded or double-stranded, and may be composed of
deoxyribonucleotides or ribonucleotides. As discussed above, rAAV
typically lack certain AAV genes and thus are produced using a
double plasmid transfection system, or more preferably a triple
plasmid transfection system that comprises a plasmid vector that
comprises an AAV helper function-providing polynucleotide, a
plasmid vector that comprises a non-AAV helper function-providing
polynucleotide, and the rAAV plasmid vector (FIG. 2). In one
embodiment, the AAV helper function-providing polynucleotide of
such double or triple transfection systems may comprise more than
one rep and/or cap gene, so as to be capable of forming rAAV having
hybrid serotypes. In another embodiment, a second or additional AAV
helper function-providing polynucleotide (for example on a second
or additional plasmid vector) may be provided to permit the
formation of rAAV having hybrid serotypes.
[0071] A. Illustrative AAV Helper Function-Providing
Polynucleotides
[0072] As used herein, the term "AAV helper functions" denotes AAV
proteins (e.g., Rep and Cap) and/or polynucleotides of AAV that are
required for the replication and packaging of an rAAV. Such AAV
helper functions are provided by an "AAV helper function-providing
polynucleotide," which as such term is used herein is a virus,
plasmid vector, a non-plasmid vector, or a polynucleotide that has
been integrated into a cellular chromosome, that provides AAV
helper functions. AAV helper plasmids that may be used in
accordance with the present invention to provide AAV helper
functions include pAAV-RC (Agilent; Addgene; Cell Biolabs),
pAAV-RC1, pAAV-RC2, pAAV-RC5, pAAV-RC6, and pAAV-RC7.
[0073] 1. Plasmid pAAV-RC1
[0074] Plasmid pAAV-RC1 (SEQ ID NO:1; FIG. 3) is an AAV helper
plasmid that expresses AAV1 serotype capsid proteins that may be
used in accordance with the present invention to provide AAV helper
functions. The P5 and P40 promoters of pAAV-RC1 are AAV2 serotype
promoters (SEQ ID NO:10 and SEQ ID NO:18, respectively).
TABLE-US-00001 Coding Strand of Plasmid pAAV-RC1 (SEQ ID NO: 1):
catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg
cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg
aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca
gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct
cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca
gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc
caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg
gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca
aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga
ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt
ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa
aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa
catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga
gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat
gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga
ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac
caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca
agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac
caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca
tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat
aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc
ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct
gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac
tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt
cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga
cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata
aatgatttaa atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc
tctctgaggg cattcgcgag tggtgggact tgaaacctgg agccccgaag cccaaagcca
accagcaaaa gcaggacgac ggccggggtc tggtgcttcc tggctacaag tacctcggac
ccttcaacgg actcgacaag ggggagcccg tcaacgcggc ggacgcagcg gccctcgagc
acgacaaggc ctacgaccag cagctcaaag cgggtgacaa tccgtacctg cggtataacc
acgccgacgc cgagtttcag gagcgtctgc aagaagatac gtcttttggg ggcaacctcg
ggcgagcagt cttccaggcc aagaagcggg ttctcgaacc tctcggtctg gttgaggaag
gcgctaagac ggctcctgga aagaaacgtc cggtagagca gtcgccacaa gagccagact
cctcctcggg catcggcaag acaggccagc agcccgctaa aaagagactc aattttggtc
agactggcga ctcagagtca gtccccgatc cacaacctct cggagaacct ccagcaaccc
ccgctgctgt gggacctact acaatggctt caggcggtgg cgcaccaatg gcagacaata
acgaaggcgc cgacggagtg ggtaatgcct caggaaattg gcattgcgat tccacatggc
tgggcgacag agtcatcacc accagcaccc gcacctgggc cttgcccacc tacaataacc
acctctacaa gcaaatctcc agtgcttcaa cgggggccag caacgacaac cactacttcg
gctacagcac cccctggggg tattttgatt tcaacagatt ccactgccac ttttcaccac
gtgactggca gcgactcatc aacaacaatt ggggattccg gcccaagaga ctcaacttca
aactcttcaa catccaagtc aaggaggtca cgacgaatga tggcgtcaca accatcgcta
ataaccttac cagcacggtt caagtcttct cggactcgga gtaccagctt ccgtacgtcc
tcggctctgc gcaccagggc tgcctccctc cgttcccggc ggacgtgttc atgattccgc
aatacggcta cctgacgctc aacaatggca gccaagccgt gggacgttca tccttttact
gcctggaata tttcccttct cagatgctga gaacgggcaa caactttacc ttcagctaca
cctttgagga agtgcctttc cacagcagct acgcgcacag ccagagcctg gaccggctga
tgaatcctct catcgaccaa tacctgtatt acctgaacag aactcaaaat cagtccggaa
gtgcccaaaa caaggacttg ctgtttagcc gtgggtctcc agctggcatg tctgttcagc
ccaaaaactg gctacctgga ccctgttatc ggcagcagcg cgtttctaaa acaaaaacag
acaacaacaa cagcaatttt acctggactg gtgcttcaaa atataacctc aatgggcgtg
aatccatcat caaccctggc actgctatgg cctcacacaa agacgacgaa gacaagttct
ttcccatgag cggtgtcatg atttttggaa aagagagcgc cggagcttca aacactgcat
tggacaatgt catgattaca gacgaagagg aaattaaagc cactaaccct gtggccaccg
aaagatttgg gaccgtggca gtcaatttcc agagcagcag cacagaccct gcgaccggag
atgtgcatgc tatgggagca ttacctggca tggtgtggca agatagagac gtgtacctgc
agggtcccat ttgggccaaa attcctcaca cagatggaca ctttcacccg tctcctctta
tgggcggctt tggactcaag aacccgcctc ctcagatcct catcaaaaac acgcctgttc
ctgcgaatcc tccggcggag ttttcagcta caaagtttgc ttcattcatc acccaatact
ccacaggaca agtgagtgtg gaaattgaat gggagctgca gaaagaaaac agcaagcgct
ggaatcccga agtgcagtac acatccaatt atgcaaaatc tgccaacgtt gattttactg
tggacaacaa tggactttat actgagcctc gccccattgg cacccgttac cttacccgtc
ccctgtaagg cgcgccaccg gttgcttgtt aatcaataaa ccgtttaatt cgtttcagtt
gaactttggt ctctgcgtat ttctttctta tctagtttcc atgctctagg atccactagt
aacggccgcc agtgtgctgg aattcggctt tgtagttaat gattaacccg ccatgctact
tatctacgta gccatgctct agaggtcctg tattagaggt cacgtgagtg ttttgcgaca
ttttgcgaca ccatgtggtc acgctgggta tttaagcccg agtgagcacg cagggtctcc
attttgaagc gggaggtttg aacgcgcagc cgccaagccg aattctgcag atatccaaac
actggcggcc gctcgactag agcggccgcc accgcggtgg agctccagct tttgttccct
ttagtgaggg ttaattgcgc gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa
ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg
gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca
gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg
tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg
gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg
ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa
ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg
acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc
tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc
ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc
ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg
ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc
actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga
gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg gtatctgcgc
tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac
caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg
atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc
acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa
ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta
ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt
tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag
tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag caataaacca
gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc
tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt
tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag
ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt
tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat
ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt
gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc
ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat
cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag
ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt
ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg
gaaatgttga
atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg
agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc gcgcacattt
ccccgaaaag tgccacctaa attgtaagcg ttaatatttt gttaaaattc gcgttaaatt
tttgttaaat cagctcattt tttaaccaat aggccgaaat cggcaaaatc ccttataaat
caaaagaata gaccgagata gggttgagtg ttgttccagt ttggaacaag agtccactat
taaagaacgt ggactccaac gtcaaagggc gaaaaaccgt ctatcagggc gatggcccac
tacgtgaacc atcaccctaa tcaagttttt tggggtcgag gtgccgtaaa gcactaaatc
ggaaccctaa agggagcccc cgatttagag cttgacgggg aaagccggcg aacgtggcga
gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc gctggcaagt gtagcggtca
cgctgcgcgt aaccaccaca cccgccgcgc ttaatgcgcc gctacagggc gcgtcccatt
cgccattcag gctgcgcaac tgttgggaag ggcgatcggt gcgggcctct tcgctattac
gccagctggc gaaaggggga tgtgctgcaa ggcgattaag ttgggtaacg ccagggtttt
cccagtcacg acgttgtaaa acgacggcca gtgagcgcgc gtaatacgac tcactatagg
gcgaattggg taccgggccc cccctcgagg tcgacggtat cgggggagct cgcagggtct
ccattttgaa gcgggaggtt tgaacgcgca gccgccatgc cggggtttta cgagattgtg
attaaggtcc ccagcgacct tgacgagcat ctgcccggca tttctgacag ctttgtgaac
tgggtggccg agaaggaatg ggagttgccg ccagattctg acatggatct gaatctgatt
gagcaggcac ccctgaccgt ggccgagaag ctgcagcgcg actttctgac ggaatggcgc
cgtgtgagta aggccccgga ggctcttttc tttgtgcaat ttgagaaggg agagagctac
ttccacatgc acgtgctcgt ggaaaccacc ggggtgaaat c
[0075] In SEQ ID NO:1, residues 1-1561 of pAAV-RC1 encode the Rep
protein, Rep78 (with residues 95-221 corresponding to the AAV2 P19
promoter and residues 1075-1254 corresponding to the AAV2 P40
promoter (SEQ ID NO:18)); residues 1578-3788 encode the AAV1 VP1
capsid protein; residues 7127-7431 encode a portion of the Rep68
protein; residues 3984-4114 correspond to AAV2 P5 promoter
sequences (SEQ ID NO:10); residues 4237-4253 are M13 Rev sequences;
residues 4261-4277 are Lac operator sequences; 4285-4315 are Lac
promoter sequences; residues 4578-5302 correspond to pMB ori
sequences, residues 5398-6258 encode an ampicillin resistance
determinant; and residues 6259-6357 are bla promoter sequences
(FIG. 3).
[0076] 2. Plasmid pAAV-RC2
[0077] Plasmid pAAV-RC2 (SEQ ID NO:2; FIG. 4) is an AAV helper
plasmid that expresses AAV2 serotype capsid proteins that may be
used in accordance with the present invention to provide AAV helper
functions. The P5 and P40 promoters of pAAV-RC2 are AAV2 serotype
promoters (SEQ ID NO:10 and SEQ ID NO:18, respectively).
TABLE-US-00002 Coding Strand of Plasmid pAAV-RC2 (SEQ ID NO: 2):
ccgggccccc cctcgaggtc gacggtatcg ggggagctcg cagggtctcc attttgaagc
gggaggtttg aacgcgcagc cgccatgccg gggttttacg agattgtgat taaggtcccc
agcgaccttg acgagcatct gcccggcatt tctgacagct ttgtgaactg ggtggccgag
aaggaatggg agttgccgcc agattctgac atggatctga atctgattga gcaggcaccc
ctgaccgtgg ccgagaagct gcagcgcgac tttctgacgg aatggcgccg tgtgagtaag
gccccggagg ctcttttctt tgtgcaattt gagaagggag agagctactt ccacatgcac
gtgctcgtgg aaaccaccgg ggtgaaatcc atggttttgg gacgtttcct gagtcagatt
cgcgaaaaac tgattcagag aatttaccgc gggatcgagc cgactttgcc aaactggttc
gcggtcacaa agaccagaaa tggcgccgga ggcgggaaca aggtggtgga tgagtgctac
atccccaatt acttgctccc caaaacccag cctgagctcc agtgggcgtg gactaatatg
gaacagtatt taagcgcctg tttgaatctc acggagcgta aacggttggt ggcgcagcat
ctgacgcacg tgtcgcagac gcaggagcag aacaaagaga atcagaatcc caattctgat
gcgccggtga tcagatcaaa aacttcagcc aggtacatgg agctggtcgg gtggctcgtg
gacaagggga ttacctcgga gaagcagtgg atccaggagg accaggcctc atacatctcc
ttcaatgcgg cctccaactc gcggtcccaa atcaaggctg ccttggacaa tgcgggaaag
attatgagcc tgactaaaac cgcccccgac tacctggtgg gccagcagcc cgtggaggac
atttccagca atcggattta taaaattttg gaactaaacg ggtacgatcc ccaatatgcg
gcttccgtct ttctgggatg ggccacgaaa aagttcggca agaggaacac catctggctg
tttgggcctg caactaccgg gaagaccaac atcgcggagg ccatagccca cactgtgccc
ttctacgggt gcgtaaactg gaccaatgag aactttccct tcaacgactg tgtcgacaag
atggtgatct ggtgggagga ggggaagatg accgccaagg tcgtggagtc ggccaaagcc
attctcggag gaagcaaggt gcgcgtggac cagaaatgca agtcctcggc ccagatagac
ccgactcccg tgatcgtcac ctccaacacc aacatgtgcg ccgtgattga cgggaactca
acgaccttcg aacaccagca gccgttgcaa gaccggatgt tcaaatttga actcacccgc
cgtctggatc atgactttgg gaaggtcacc aagcaggaag tcaaagactt tttccggtgg
gcaaaggatc acgtggttga ggtggagcat gaattctacg tcaaaaaggg tggagccaag
aaaagacccg cccccagtga cgcagatata agtgagccca aacgggtgcg cgagtcagtt
gcgcagccat cgacgtcaga cgcggaagct tcgatcaact acgcagacag gtaccaaaac
aaatgttctc gtcacgtggg catgaatctg atgctgtttc cctgcagaca atgcgagaga
atgaatcaga attcaaatat ctgcttcact cacggacaga aagactgttt agagtgcttt
cccgtgtcag aatctcaacc cgtttctgtc gtcaaaaagg cgtatcagaa actgtgctac
attcatcata tcatgggaaa ggtgccagac gcttgcactg cctgcgatct ggtcaatgtg
gatttggatg actgcatctt tgaacaataa atgatttaaa tcaggtatgg ctgccgatgg
ttatcttcca gattggctcg aggacactct ctctgaagga ataagacagt ggtggaagct
caaacctggc ccaccaccac caaagcccgc agagcggcat aaggacgaca gcaggggtct
tgtgcttcct gggtacaagt acctcggacc cttcaacgga ctcgacaagg gagagccggt
caacgaggca gacgccgcgg ccctcgagca cgacaaagcc tacgaccggc agctcgacag
cggagacaac ccgtacctca agtacaacca cgccgacgcg gagtttcagg agcgccttaa
agaagatacg tcttttgggg gcaacctcgg acgagcagtc ttccaggcga aaaagagggt
tcttgaacct ctgggcctgg ttgaggaacc tgttaagacg gctccgggaa aaaagaggcc
ggtagagcac tctcctgtgg agccagactc ctcctcggga accggaaagg cgggccagca
gcctgcaaga aaaagattga attttggtca gactggagac gcagactcag tacctgaccc
ccagcctctc ggacagccac cagcagcccc ctctggtctg ggaactaata cgatggctac
aggcagtggc gcaccaatgg cagacaataa cgagggcgcc gacggagtgg gtaattcctc
gggaaattgg cattgcgatt ccacatggat gggcgacaga gtcatcacca ccagcacccg
aacctgggcc ctgcccacct acaacaacca cctctacaaa caaatttcca gccaatcagg
agcctcgaac gacaatcact actttggcta cagcacccct tgggggtatt ttgacttcaa
cagattccac tgccactttt caccacgtga ctggcaaaga ctcatcaaca acaactgggg
attccgaccc aagagactca acttcaagct ctttaacatt caagtcaaag aggtcacgca
gaatgacggt acgacgacga ttgccaataa ccttaccagc acggttcagg tgtttactga
ctcggagtac cagctcccgt acgtcctcgg ctcggcgcat caaggatgcc tcccgccgtt
cccagcagac gtcttcatgg tgccacagta tggatacctc accctgaaca acgggagtca
ggcagtagga cgctcttcat tttactgcct ggagtacttt ccttctcaga tgctgcgtac
cggaaacaac tttaccttca gctacacttt tgaggacgtt cctttccaca gcagctacgc
tcacagccag agtctggacc gtctcatgaa tcctctcatc gaccagtacc tgtattactt
gagcagaaca aacactccaa gtggaaccac cacgcagtca aggcttcagt tttctcaggc
cggagcgagt gacattcggg accagtctag gaactggctt cctggaccct gttaccgcca
gcagcgagta tcaaagacat ctgcggataa caacaacagt gaatactcgt ggactggagc
taccaagtac cacctcaatg gcagagactc tctggtgaat ccgggcccgg ccatggcaag
ccacaaggac gatgaagaaa agttttttcc tcagagcggg gttctcatct ttgggaagca
aggctcagag aaaacaaatg tggacattga aaaggtcatg attacagacg aagaggaaat
caggacaacc aatcccgtgg ctacggagca gtatggttct gtatctacca acctccagag
aggcaacaga caagcagcta ccgcagatgt caacacacaa ggcgttcttc caggcatggt
ctggcaggac agagatgtgt accttcaggg gcccatctgg gcaaagattc cacacacgga
cggacatttt cacccctctc ccctcatggg tggattcgga cttaaacacc ctcctccaca
gattctcatc aagaacaccc cggtacctgc gaatccttcg accaccttca gtgcggcaaa
gtttgcttcc ttcatcacac agtactccac gggacaggtc agcgtggaga tcgagtggga
gctgcagaag gaaaacagca aacgctggaa tcccgaaatt cagtacactt ccaactacaa
caagtctgtt aatgtggact ttactgtgga cactaatggc gtgtattcag agcctcgccc
cattggcacc agatacctga ctcgtaatct gtaattgctt gttaatcaat aaaccgttta
attcgtttca gttgaacttt ggtctctgcg tatttctttc ttatctagtt tccatgctct
aggatccact agtaacggcc gccagtgtgc tggaattcgg ctttgtagtt aatgattaac
ccgccatgct acttatctac gtagccatgc tctagaggtc ctgtattaga ggtcacgtga
gtgttttgcg acattttgcg acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc
acgcagggtc tccattttga agcgggaggt ttgaacgcgc agccgccaag ccgaattctg
cagatatcca aacactggcg gccgctcgac tagagcggcc gccaccgcgg tggagctcca
gcttttgttc cctttagtga gggttaattg cgcgcttggc gtaatcatgg tcatagctgt
ttcctgtgtg aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa
agtgtaaagc ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac
tgcccgcttt ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg
cggggagagg cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc
gctcggtcgt tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat
ccacagaatc aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca
ggaaccgtaa aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc
atcacaaaaa tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc
aggcgtttcc ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg
gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta
ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg
ttcagcccga ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac
acgacttatc gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag
gcggtgctac agagttcttg aagtggtggc ctaactacgg ctacactaga agaacagtat
ttggtatctg cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat
ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc
gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt
ggaacgaaaa ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct
agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt
ggtctgacag ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc
gttcatccat agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac
catctggccc cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat
cagcaataaa ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg
cctccatcca gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata
gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt gtcacgctcg tcgtttggta
tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt
gcaaaaaagc ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag
tgttatcact
catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc
tgtgactggt gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg
ctcttgcccg gcgtcaatac gggataatac cgcgccacat agcagaactt taaaagtgct
catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc
cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac
acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca tttatcaggg
ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt
tccgcgcaca tttccccgaa aagtgccacc taaattgtaa gcgttaatat tttgttaaaa
ttcgcgttaa atttttgtta aatcagctca ttttttaacc aataggccga aatcggcaaa
atcccttata aatcaaaaga atagaccgag atagggttga gtgttgttcc agtttggaac
aagagtccac tattaaagaa cgtggactcc aacgtcaaag ggcgaaaaac cgtctatcag
ggcgatggcc cactacgtga accatcaccc taatcaagtt ttttggggtc gaggtgccgt
aaagcactaa atcggaaccc taaagggagc ccccgattta gagcttgacg gggaaagccg
gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag cgggcgctag ggcgctggca
agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg cgcttaatgc gccgctacag
ggcgcgtccc attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc
tcttcgctat tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta
acgccagggt tttcccagtc acgacgttgt aaaacgacgg ccagtgagcg cgcgtaatac
gactcactat agggcgaatt gggta
[0078] In SEQ ID NO:2, residues 85-1950 of pAAV-RC2 encode the Rep
protein, Rep78 (with residues 484-663 corresponding to the AAV2 P19
promoter, residues 1464-1643 corresponding to the AAV2 P40 promoter
(SEQ ID NO:18) and residues 1668-1676 being a donor site); residues
1967-4174 encode the AAV2 VP1 capsid protein; residues 1992-2016
encode a portion of the Rep68 protein; residues 4175-4256 encode a
polyA sequence; residues 4357-4487 correspond to the AAV2 P5
promoter sequences of SEQ ID NO:10); residues 4610-4626 are M13 Rev
sequences; residues 4634-4650 are Lac operator sequences; 4658-4688
are Lac promoter sequences; residues 4951-5675 correspond to pMB
ori sequences, residues 5771-6631 encode an ampicillin resistance
determinant; and residues 6632-6730 are bla promoter sequences
(FIG. 4).
[0079] 3. Plasmid pAAV-RC5
[0080] Plasmid pAAV-RC5 (SEQ ID NO:3; FIG. 5) is an AAV helper
plasmid that expresses AAV5 serotype capsid proteins that may be
used in accordance with the present invention to provide AAV helper
functions. The P5 and P40 promoters of pAAV-RC5 are AAV2 serotype
promoters (SEQ ID NO:10 and SEQ ID NO:18, respectively).
TABLE-US-00003 Coding Strand of Plasmid pAAV-RC5 (SEQ ID NO: 3):
catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg
cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg
aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca
gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct
cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca
gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc
caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg
gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca
aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga
ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt
ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa
aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa
catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga
gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat
gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga
ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac
caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca
agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac
caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca
tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat
aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc
ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct
gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac
tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt
cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga
cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata
aatgatttaa atcaggtatg tcttttgttg atcaccctcc agattggttg gaagaagttg
gtgaaggtct tcgcgagttt ttgggccttg aagcgggccc accgaaacca aaacccaatc
agcagcatca agatcaagcc cgtggtcttg tgctgcctgg ttataactat ctcggacccg
gaaacggtct cgatcgagga gagcctgtca acagggcaga cgaggtcgcg cgagagcacg
acatctcgta caacgagcag cttgaggcgg gagacaaccc ctacctcaag tacaaccacg
cggacgccga gtttcaggag aagctcgccg acgacacatc cttcggggga aacctcggaa
aggcagtctt tcaggccaag aaaagggttc tcgaaccttt tggcctggtt gaagagggtg
ctaagacggc ccctaccgga aagcggatag acgaccactt tccaaaaaga aagaaggctc
ggaccgaaga ggactccaag ccttccacct cgtcagacgc cgaagctgga cccagcggat
cccagcagct gcaaatccca gcccaaccag cctcaagttt gggagctgat acaatgtctg
cgggaggtgg cggcccattg ggcgacaata accaaggtgc cgatggagtg ggcaatgcct
cgggagattg gcattgcgat tccacgtgga tgggggacag agtcgtcacc aagtccaccc
gaacctgggt gctgcccagc tacaacaacc accagtaccg agagatcaaa agcggctccg
tcgacggaag caacgccaac gcctactttg gatacagcac cccctggggg tactttgact
ttaaccgctt ccacagccac tggagccccc gagactggca aagactcatc aacaactact
ggggcttcag accccggtcc ctcagagtca aaatcttcaa cattcaagtc aaagaggtca
cggtgcagga ctccaccacc accatcgcca acaacctcac ctccaccgtc caagtgttta
cggacgacga ctaccagctg ccctacgtcg tcggcaacgg gaccgaggga tgcctgccgg
ccttccctcc gcaggtcttt acgctgccgc agtacggtta cgcgacgctg aaccgcgaca
acacagaaaa tcccaccgag aggagcagct tcttctgcct agagtacttt cccagcaaga
tgctgagaac gggcaacaac tttgagttta cctacaactt tgaggaggtg cccttccact
ccagcttcgc tcccagtcag aacctgttca agctggccaa cccgctggtg gaccagtact
tgtaccgctt cgtgagcaca aataacactg gcggagtcca gttcaacaag aacctggccg
ggagatacgc caacacctac aaaaactggt tcccggggcc catgggccga acccagggct
ggaacctggg ctccggggtc aaccgcgcca gtgtcagcgc cttcgccacg accaatagga
tggagctcga gggcgcgagt taccaggtgc ccccgcagcc gaacggcatg accaacaacc
tccagggcag caacacctat gccctggaga acactatgat cttcaacagc cagccggcga
acccgggcac caccgccacg tacctcgagg gcaacatgct catcaccagc gagagcgaga
cgcagccggt gaaccgcgtg gcgtacaacg tcggcgggca gatggccacc aacaaccaga
gctccaccac tgcccccgcg accggcacgt acaacctcca ggaaatcgtg cccggcagcg
tgtggatgga gagggacgtg tacctccaag gacccatctg ggccaagatc ccagagacgg
gggcgcactt tcacccctct ccggccatgg gcggattcgg actcaaacac ccaccgccca
tgatgctcat caagaacacg cctgtgcccg gaaatatcac cagcttctcg gacgtgcccg
tcagcagctt catcacccag tacagcaccg ggcaggtcac cgtggagatg gagtgggagc
tcaagaagga aaactccaag aggtggaacc cagagatcca gtacacaaac aactacaacg
acccccagtt tgtggacttt gccccggaca gcaccgggga atacagaacc accagaccta
tcggaacccg ataccttacc cgaccccttt aaggcgcgcc accggttgct tgttaatcaa
taaaccgttt aattcgtttc agttgaactt tggtctctgc gtatttcttt cttatctagt
ttccatgctc taggatccac tagtaacggc cgccagtgtg ctggaattcg gctttgtagt
taatgattaa cccgccatgc tacttatcta cgtagccatg ctctagaggt cctgtattag
aggtcacgtg agtgttttgc gacattttgc gacaccatgt ggtcacgctg ggtatttaag
cccgagtgag cacgcagggt ctccattttg aagcgggagg tttgaacgcg cagccgccaa
gccgaattct gcagatatcc aaacactggc ggccgctcga ctagagcggc cgccaccgcg
gtggagctcc agcttttgtt ccctttagtg agggttaatt gcgcgcttgg cgtaatcatg
gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc
cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc
gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat
cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac
tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt
aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca
gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc
ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact
ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct
gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag
ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca
cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa
cccggtaaga cacgacttat cgccactggc agcagccact
ggtaacagga ttagcagagc gaggtatgta ggcggtgcta cagagttctt gaagtggtgg
cctaactacg gctacactag aagaacagta tttggtatct gcgctctgct gaagccagtt
accttcggaa aaagagttgg tagctcttga tccggcaaac aaaccaccgc tggtagcggt
ggtttttttg tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct
ttgatctttt ctacggggtc tgacgctcag tggaacgaaa actcacgtta agggattttg
gtcatgagat tatcaaaaag gatcttcacc tagatccttt taaattaaaa atgaagtttt
aaatcaatct aaagtatata tgagtaaact tggtctgaca gttaccaatg cttaatcagt
gaggcaccta tctcagcgat ctgtctattt cgttcatcca tagttgcctg actccccgtc
gtgtagataa ctacgatacg ggagggctta ccatctggcc ccagtgctgc aatgataccg
cgagacccac gctcaccggc tccagattta tcagcaataa accagccagc cggaagggcc
gagcgcagaa gtggtcctgc aactttatcc gcctccatcc agtctattaa ttgttgccgg
gaagctagag taagtagttc gccagttaat agtttgcgca acgttgttgc cattgctaca
ggcatcgtgg tgtcacgctc gtcgtttggt atggcttcat tcagctccgg ttcccaacga
tcaaggcgag ttacatgatc ccccatgttg tgcaaaaaag cggttagctc cttcggtcct
ccgatcgttg tcagaagtaa gttggccgca gtgttatcac tcatggttat ggcagcactg
cataattctc ttactgtcat gccatccgta agatgctttt ctgtgactgg tgagtactca
accaagtcat tctgagaata gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata
cgggataata ccgcgccaca tagcagaact ttaaaagtgc tcatcattgg aaaacgttct
tcggggcgaa aactctcaag gatcttaccg ctgttgagat ccagttcgat gtaacccact
cgtgcaccca actgatcttc agcatctttt actttcacca gcgtttctgg gtgagcaaaa
acaggaaggc aaaatgccgc aaaaaaggga ataagggcga cacggaaatg ttgaatactc
atactcttcc tttttcaata ttattgaagc atttatcagg gttattgtct catgagcgga
tacatatttg aatgtattta gaaaaataaa caaatagggg ttccgcgcac atttccccga
aaagtgccac ctaaattgta agcgttaata ttttgttaaa attcgcgtta aatttttgtt
aaatcagctc attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag
aatagaccga gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga
acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg
aaccatcacc ctaatcaagt tttttggggt cgaggtgccg taaagcacta aatcggaacc
ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg
aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc
gcgtaaccac cacacccgcc gcgcttaatg cgccgctaca gggcgcgtcc cattcgccat
tcaggctgcg caactgttgg gaagggcgat cggtgcgggc ctcttcgcta ttacgccagc
tggcgaaagg gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt
cacgacgttg taaaacgacg gccagtgagc gcgcgtaata cgactcacta tagggcgaat
tgggtaccgg gccccccctc gaggtcgacg gtatcggggg agctcgcagg gtctccattt
tgaagcggga ggtttgaacg cgcagccgcc atgccggggt tttacgagat tgtgattaag
gtccccagcg accttgacga gcatctgccc ggcatttctg acagctttgt gaactgggtg
gccgagaagg aatgggagtt gccgccagat tctgacatgg atctgaatct gattgagcag
gcacccctga ccgtggccga gaagctgcag cgcgactttc tgacggaatg gcgccgtgtg
agtaaggccc cggaggctct tttctttgtg caatttgaga agggagagag ctacttccac
atgcacgtgc tcgtggaaac caccggggtg aaatc
[0081] In SEQ ID NO:3, residues 1-1561 of pAAV-RC5 encode the Rep
protein, Rep78 (with residues 91-221 corresponding to the AAV2 P19
promoter, and residues 1075-1254 corresponding to the P40 promoter
(SEQ ID NO:18)); residues 1578-3749 encode the AAV5 VP1 capsid
protein; residues 7091-7395 encode a portion of the Rep68 protein;
residues 3948-4078 correspond to the AAV2 P5 promoter sequences of
SEQ ID NO:10); residues 4201-4217 are M13 Rev sequences; residues
4225-4241 are Lac operator sequences; 4249-4279 are Lac promoter
sequences; residues 4542-5266 correspond to pMB ori sequences,
residues 5362-6222 encode an ampicillin resistance determinant; and
residues 6223-6321 are bla promoter sequences (FIG. 5).
[0082] 4. Plasmid pAAV-RC6
[0083] Plasmid pAAV-RC6 (SEQ ID NO:4; FIG. 6) is an AAV helper
plasmid that expresses AAV6 serotype capsid proteins that may be
used in accordance with the present invention to provide AAV helper
functions. The P5 and P40 promoters of pAAV-RC6 are AAV2 serotype
promoters (SEQ ID NO:10 and SEQ ID NO:18, respectively).
TABLE-US-00004 Coding Strand of Plasmid pAAV-RC6 (SEQ ID NO: 4):
catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg
cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg
aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca
gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct
cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca
gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc
caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg
gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca
aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga
ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt
ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa
aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa
catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga
gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat
gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga
ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac
caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca
agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac
caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca
tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat
aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc
ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct
gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac
tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt
cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga
cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata
aatgatttaa atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc
tctctgaggg cattcgcgag tggtgggact tgaaacctgg agccccgaaa cccaaagcca
accagcaaaa gcaggacgac ggccggggtc tggtgcttcc tggctacaag tacctcggac
ccttcaacgg actcgacaag ggggagcccg tcaacgcggc ggatgcagcg gccctcgagc
acgacaaggc ctacgaccag cagctcaaag cgggtgacaa tccgtacctg cggtataacc
acgccgacgc cgagtttcag gagcgtctgc aagaagatac gtcttttggg ggcaacctcg
ggcgagcagt cttccaggcc aagaagaggg ttctcgaacc ttttggtctg gttgaggaag
gtgctaagac ggctcctgga aagaaacgtc cggtagagca gtcgccacaa gagccagact
cctcctcggg cattggcaag acaggccagc agcccgctaa aaagagactc aattttggtc
agactggcga ctcagagtca gtccccgacc cacaacctct cggagaacct ccagcaaccc
ccgctgctgt gggacctact acaatggctt caggcggtgg cgcaccaatg gcagacaata
acgaaggcgc cgacggagtg ggtaatgcct caggaaattg gcattgcgat tccacatggc
tgggcgacag agtcatcacc accagcaccc gaacatgggc cttgcccacc tataacaacc
acctctacaa gcaaatctcc agtgcttcaa cgggggccag caacgacaac cactacttcg
gctacagcac cccctggggg tattttgatt tcaacagatt ccactgccat ttctcaccac
gtgactggca gcgactcatc aacaacaatt ggggattccg gcccaagaga ctcaacttca
agctcttcaa catccaagtc aaggaggtca cgacgaatga tggcgtcacg accatcgcta
ataaccttac cagcacggtt caagtcttct cggactcgga gtaccagttg ccgtacgtcc
tcggctctgc gcaccagggc tgcctccctc cgttcccggc ggacgtgttc atgattccgc
agtacggcta cctaacgctc aacaatggca gccaggcagt gggacggtca tccttttact
gcctggaata tttcccatcg cagatgctga gaacgggcaa taactttacc ttcagctaca
ccttcgagga cgtgcctttc cacagcagct acgcgcacag ccagagcctg gaccggctga
tgaatcctct catcgaccag tacctgtatt acctgaacag aactcagaat cagtccggaa
gtgcccaaaa caaggacttg ctgtttagcc gggggtctcc agctggcatg tctgttcagc
ccaaaaactg gctacctgga ccctgttacc ggcagcagcg cgtttctaaa acaaaaacag
acaacaacaa cagcaacttt acctggactg gtgcttcaaa atataacctt aatgggcgtg
aatctataat caaccctggc actgctatgg cctcacacaa agacgacaaa gacaagttct
ttcccatgag cggtgtcatg atttttggaa aggagagcgc cggagcttca aacactgcat
tggacaatgt catgatcaca gacgaagagg aaatcaaagc cactaacccc gtggccaccg
aaagatttgg gactgtggca gtcaatctcc agagcagcag cacagaccct gcgaccggag
atgtgcatgt tatgggagcc ttacctggaa tggtgtggca agacagagac gtatacctgc
agggtcctat ttgggccaaa attcctcaca cggatggaca ctttcacccg tctcctctca
tgggcggctt tggacttaag cacccgcctc ctcagatcct catcaaaaac acgcctgttc
ctgcgaatcc tccggcagag ttttcggcta caaagtttgc ttcattcatc acccagtatt
ccacaggaca agtgagcgtg gagattgaat gggagctgca gaaagaaaac agcaaacgct
ggaatcccga agtgcagtat acatctaact atgcaaaatc tgccaacgtt gatttcactg
tggacaacaa tggactttat actgagcctc gccccattgg cacccgttac ctcacccgtc
ccctgtaagg cgcgccaccg gttgcttgtt aatcaataaa ccgtttaatt cgtttcagtt
gaactttggt ctctgcgtat ttctttctta tctagtttcc atgctctagg atccactagt
aacggccgcc agtgtgctgg aattcggctt tgtagttaat gattaacccg ccatgctact
tatctacgta gccatgctct agaggtcctg tattagaggt cacgtgagtg ttttgcgaca
ttttgcgaca ccatgtggtc acgctgggta tttaagcccg agtgagcacg cagggtctcc
attttgaagc gggaggtttg aacgcgcagc cgccaagccg aattctgcag atatccaaac
actggcggcc gctcgactag agcggccgcc accgcggtgg agctccagct tttgttccct
ttagtgaggg ttaattgcgc gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa
ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg
gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca
gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg
tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg
gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg
ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa
ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg
acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc
tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc
ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc
ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg
ctgcgcctta tccggtaact atcgtcttga gtccaacccg
gtaagacacg acttatcgcc actggcagca gccactggta acaggattag cagagcgagg
tatgtaggcg gtgctacaga gttcttgaag tggtggccta actacggcta cactagaaga
acagtatttg gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc
tcttgatccg gcaaacaaac caccgctggt agcggtggtt tttttgtttg caagcagcag
attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac
gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc
ttcacctaga tccttttaaa ttaaaaatga agttttaaat caatctaaag tatatatgag
taaacttggt ctgacagtta ccaatgctta atcagtgagg cacctatctc agcgatctgt
ctatttcgtt catccatagt tgcctgactc cccgtcgtgt agataactac gatacgggag
ggcttaccat ctggccccag tgctgcaatg ataccgcgag acccacgctc accggctcca
gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg tcctgcaact
ttatccgcct ccatccagtc tattaattgt tgccgggaag ctagagtaag tagttcgcca
gttaatagtt tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg
tttggtatgg cttcattcag ctccggttcc caacgatcaa ggcgagttac atgatccccc
atgttgtgca aaaaagcggt tagctccttc ggtcctccga tcgttgtcag aagtaagttg
gccgcagtgt tatcactcat ggttatggca gcactgcata attctcttac tgtcatgcca
tccgtaagat gcttttctgt gactggtgag tactcaacca agtcattctg agaatagtgt
atgcggcgac cgagttgctc ttgcccggcg tcaatacggg ataataccgc gccacatagc
agaactttaa aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc
ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca
tcttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa
aagggaataa gggcgacacg gaaatgttga atactcatac tcttcctttt tcaatattat
tgaagcattt atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa
aataaacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctaa attgtaagcg
ttaatatttt gttaaaattc gcgttaaatt tttgttaaat cagctcattt tttaaccaat
aggccgaaat cggcaaaatc ccttataaat caaaagaata gaccgagata gggttgagtg
ttgttccagt ttggaacaag agtccactat taaagaacgt ggactccaac gtcaaagggc
gaaaaaccgt ctatcagggc gatggcccac tacgtgaacc atcaccctaa tcaagttttt
tggggtcgag gtgccgtaaa gcactaaatc ggaaccctaa agggagcccc cgatttagag
cttgacgggg aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg
gcgctagggc gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc
ttaatgcgcc gctacagggc gcgtcccatt cgccattcag gctgcgcaac tgttgggaag
ggcgatcggt gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgcaa
ggcgattaag ttgggtaacg ccagggtttt cccagtcacg acgttgtaaa acgacggcca
gtgagcgcgc gtaatacgac tcactatagg gcgaattggg taccgggccc cccctcgagg
tcgacggtat cgggggagct cgcagggtct ccattttgaa gcgggaggtt tgaacgcgca
gccgccatgc cggggtttta cgagattgtg attaaggtcc ccagcgacct tgacgagcat
ctgcccggca tttctgacag ctttgtgaac tgggtggccg agaaggaatg ggagttgccg
ccagattctg acatggatct gaatctgatt gagcaggcac ccctgaccgt ggccgagaag
ctgcagcgcg actttctgac ggaatggcgc cgtgtgagta aggccccgga ggctcttttc
tttgtgcaat ttgagaaggg agagagctac ttccacatgc acgtgctcgt ggaaaccacc
ggggtgaaat c
[0084] In SEQ ID NO:4, residues 1-1561 of pAAV-RC6 encode the Rep
protein, Rep78 (with residues 91-221 corresponding to the AAV2 P19
promoter, and residues 1075-1254 corresponding to the P40 promoter
(SEQ ID NO:18)); residues 1578-3788 encode the AAV6 VP1 capsid
protein; residues 736-1281 encode a portion of the Rep68 protein;
residues 3984-4114 correspond to the AAV2 P5 promoter sequences of
SEQ ID NO:10); residues 4237-4253 are M13 Rev sequences; residues
4261-4277 are Lac operator sequences; 4285-4315 are Lac promoter
sequences; residues 4578-5302 correspond to pMB ori sequences,
residues 5398-6258 encode an ampicillin resistance determinant; and
residues 6259-6357 are bla promoter sequences (FIG. 6).
[0085] 5. Plasmid pAAV-RC7
[0086] Plasmid pAAV-RC7 (SEQ ID NO:5; FIG. 7) is an AAV helper
plasmid that expresses AAV6 serotype capsid proteins that may be
used in accordance with the present invention to provide AAV helper
functions. The P5 and P40 promoters of pAAV-RC7 are AAV2 serotype
promoters (SEQ ID NO:10 and SEQ ID NO:18, respectively).
TABLE-US-00005 Coding Strand of Plasmid pAAV-RC7 (SEQ ID NO: 5):
catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg
cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg
aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca
gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct gtttgaatct
cacggagcgt aaacggttgg tggcgcagca tctgacgcac gtgtcgcaga cgcaggagca
gaacaaagag aatcagaatc ccaattctga tgcgccggtg atcagatcaa aaacttcagc
caggtacatg gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg
gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca
aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa ccgcccccga
ctacctggtg ggccagcagc ccgtggagga catttccagc aatcggattt ataaaatttt
ggaactaaac gggtacgatc cccaatatgc ggcttccgtc tttctgggat gggccacgaa
aaagttcggc aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa
catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga
gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg aggggaagat
gaccgccaag gtcgtggagt cggccaaagc cattctcgga ggaagcaagg tgcgcgtgga
ccagaaatgc aagtcctcgg cccagataga cccgactccc gtgatcgtca cctccaacac
caacatgtgc gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca
agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac
caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg aggtggagca
tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc gcccccagtg acgcagatat
aagtgagccc aaacgggtgc gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc
ttcgatcaac tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct
gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac
tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac ccgtttctgt
cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat atcatgggaa aggtgccaga
cgcttgcact gcctgcgatc tggtcaatgt ggatttggat gactgcatct ttgaacaata
aatgatttaa atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc
tctctgaggg cattcgcgag tggtgggacc tgaaacctgg agccccgaaa cccaaagcca
accagcaaaa gcaggacaac ggccggggtc tggtgcttcc tggctacaag tacctcggac
ccttcaacgg actcgacaag ggggagcccg tcaacgcggc ggacgcagcg gccctcgagc
acgacaaggc ctacgaccag cagctcaaag cgggtgacaa tccgtacctg cggtataacc
acgccgacgc cgagtttcag gagcgtctgc aagaagatac gtcatttggg ggcaacctcg
ggcgagcagt cttccaggcc aagaagcggg ttctcgaacc tctcggtctg gttgaggaag
gcgctaagac ggctcctgca aagaagagac cggtagagcc gtcacctcag cgttcccccg
actcctccac gggcatcggc aagaaaggcc agcagcccgc cagaaagaga ctcaatttcg
gtcagactgg cgactcagag tcagtccccg accctcaacc tctcggagaa cctccagcag
cgccctctag tgtgggatct ggtacagtgg ctgcaggcgg tggcgcacca atggcagaca
ataacgaagg tgccgacgga gtgggtaatg cctcaggaaa ttggcattgc gattccacat
ggctgggcga cagagtcatt accaccagca cccgaacctg ggccctgccc acctacaaca
accacctcta caagcaaatc tccagtgaaa ctgcaggtag taccaacgac aacacctact
tcggctacag caccccctgg gggtattttg actttaacag attccactgc cacttctcac
cacgtgactg gcagcgactc atcaacaaca actggggatt ccggcccaag aagctgcggt
tcaagctctt caacatccag gtcaaggagg tcacgacgaa tgacggcgtt acgaccatcg
ctaataacct taccagcacg attcaggtat tctcggactc ggaataccag ctgccgtacg
tcctcggctc tgcgcaccag ggctgcctgc ctccgttccc ggcggacgtc ttcatgattc
ctcagtacgg ctacctgact ctcaacaatg gcagtcagtc tgtgggacgt tcctccttct
actgcctgga gtacttcccc tctcagatgc tgagaacggg caacaacttt gagttcagct
acagcttcga ggacgtgcct ttccacagca gctacgcaca cagccagagc ctggaccggc
tgatgaatcc cctcatcgac cagtacttgt actacctggc cagaacacag agtaacccag
gaggcacagc tggcaatcgg gaactgcagt tttaccaggg cgggccttca actatggccg
aacaagccaa gaattggtta cctggacctt gcttccggca acaaagagtc tccaaaacgc
tggatcaaaa caacaacagc aactttgctt ggactggtgc caccaaatat cacctgaacg
gcagaaactc gttggttaat cccggcgtcg ccatggcaac tcacaaggac gacgaggacc
gctttttccc atccagcgga gtcctgattt ttggaaaaac tggagcaact aacaaaacta
cattggaaaa tgtgttaatg acaaatgaag aagaaattcg tcctactaat cctgtagcca
cggaagaata cgggatagtc agcagcaact tacaagcggc taatactgca gcccagacac
aagttgtcaa caaccaggga gccttacctg gcatggtctg gcagaaccgg gacgtgtacc
tgcagggtcc catctgggcc aagattcctc acacggatgg caactttcac ccgtctcctt
tgatgggcgg ctttggactt aaacatccgc ctcctcagat cctgatcaag aacactcccg
ttcccgctaa tcctccggag gtgtttactc ctgccaagtt tgcttcgttc atcacacagt
acagcaccgg acaagtcagc gtggaaatcg agtgggagct gcagaaggaa aacagcaagc
gctggaaccc ggagattcag tacacctcca actttgaaaa gcagactggt gtggactttg
ccgttgacag ccagggtgtt tactctgagc ctcgccctat tggcactcgt tacctcaccc
gtaatctgta aggcgcgcca ccggttgctt gttaatcaat aaaccgttta attcgtttca
gttgaacttt ggtctctgcg tatttctttc ttatctagtt tccatgctct aggatccact
agtaacggcc gccagtgtgc tggaattcgg ctttgtagtt aatgattaac ccgccatgct
acttatctac gtagccatgc tctagaggtc ctgtattaga ggtcacgtga gtgttttgcg
acattttgcg acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc acgcagggtc
tccattttga agcgggaggt ttgaacgcgc agccgccaag ccgaattctg cagatatcca
aacactggcg gccgctcgac tagagcggcc gccaccgcgg tggagctcca gcttttgttc
cctttagtga gggttaattg cgcgcttggc gtaatcatgg tcatagctgt ttcctgtgtg
aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc
ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg
cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt
tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc
aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa
aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc
ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc
cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag
ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga
ccgctgcgcc ttatccggta actatcgtct tgagtccaac
ccggtaagac acgacttatc gccactggca gcagccactg gtaacaggat tagcagagcg
aggtatgtag gcggtgctac agagttcttg aagtggtggc ctaactacgg ctacactaga
agaacagtat ttggtatctg cgctctgctg aagccagtta ccttcggaaa aagagttggt
agctcttgat ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag
cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct
gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg tcatgagatt atcaaaaagg
atcttcacct agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat
gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc
tgtctatttc gttcatccat agttgcctga ctccccgtcg tgtagataac tacgatacgg
gagggcttac catctggccc cagtgctgca atgataccgc gagacccacg ctcaccggct
ccagatttat cagcaataaa ccagccagcc ggaagggccg agcgcagaag tggtcctgca
actttatccg cctccatcca gtctattaat tgttgccggg aagctagagt aagtagttcg
ccagttaata gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt gtcacgctcg
tcgtttggta tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc
cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag
ttggccgcag tgttatcact catggttatg gcagcactgc ataattctct tactgtcatg
ccatccgtaa gatgcttttc tgtgactggt gagtactcaa ccaagtcatt ctgagaatag
tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac gggataatac cgcgccacat
agcagaactt taaaagtgct catcattgga aaacgttctt cggggcgaaa actctcaagg
atcttaccgc tgttgagatc cagttcgatg taacccactc gtgcacccaa ctgatcttca
gcatctttta ctttcaccag cgtttctggg tgagcaaaaa caggaaggca aaatgccgca
aaaaagggaa taagggcgac acggaaatgt tgaatactca tactcttcct ttttcaatat
tattgaagca tttatcaggg ttattgtctc atgagcggat acatatttga atgtatttag
aaaaataaac aaataggggt tccgcgcaca tttccccgaa aagtgccacc taaattgtaa
gcgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc
aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga
gtgttgttcc agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag
ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcaccc taatcaagtt
ttttggggtc gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta
gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag
cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg
cgcttaatgc gccgctacag ggcgcgtccc attcgccatt caggctgcgc aactgttggg
aagggcgatc ggtgcgggcc tcttcgctat tacgccagct ggcgaaaggg ggatgtgctg
caaggcgatt aagttgggta acgccagggt tttcccagtc acgacgttgt aaaacgacgg
ccagtgagcg cgcgtaatac gactcactat agggcgaatt gggtaccggg ccccccctcg
aggtcgacgg tatcggggga gctcgcaggg tctccatttt gaagcgggag gtttgaacgc
gcagccgcca tgccggggtt ttacgagatt gtgattaagg tccccagcga ccttgacgag
catctgcccg gcatttctga cagctttgtg aactgggtgg ccgagaagga atgggagttg
ccgccagatt ctgacatgga tctgaatctg attgagcagg cacccctgac cgtggccgag
aagctgcagc gcgactttct gacggaatgg cgccgtgtga gtaaggcccc ggaggctctt
ttctttgtgc aatttgagaa gggagagagc tacttccaca tgcacgtgct cgtggaaacc
accggggtga aatc
[0087] In SEQ ID NO:5, residues 1-1561 of pAAV-RC7 encode the Rep
protein, Rep78 (with residues 91-221 corresponding to the AAV2 P19
promoter, and residues 1075-1254 corresponding to the P40 promoter
(SEQ ID NO:18)); residues 1578-3791 encode the AAV7 VP1 capsid
protein; residues 736-1281 encode a portion of the Rep68 protein;
residues 3987-4117 correspond to the AAV2 P5 promoter sequences of
SEQ ID NO:10); residues 4240-4256 are M13 Rev sequences; residues
4264-4280 are Lac operator sequences; 4288-4318 are Lac promoter
sequences; residues 4581-5305 correspond to pMB ori sequences,
residues 5401-6261 encode an ampicillin resistance determinant; and
residues 6262-6360 are bla promoter sequences (FIG. 7).
[0088] B. Illustrative Non-AAV Helper Function-Providing
Polynucleotides
[0089] As used herein, the term "non-AAV helper functions" denotes
proteins of Ad, CMV, HSV or other non-AAD viruses (e.g., E1a, E1b,
E2a, VA and E4) and/or polynucleotides of Ad, CMV, HSV or other
non-AAD viruses that are required for the replication and packaging
of an rAAV. Such non-AAV helper functions are provided by a
"non-AAV helper function-providing polynucleotide," which as such
term is used herein is a virus, plasmid vector, a non-plasmid
vector, or a polynucleotide that has been integrated into a
cellular chromosome, that provides non-AAV helper functions. The
vector, pHelper, and derivatives thereof (such as those
commercially available from Cell Biolabs, Inc., Invitrogen,
Stratagene and other sources), are suitable non-AAV helper
function-providing polynucleotide (see, e.g., Matsushita, T. et al.
(1998) "Adeno-Associated Virus Vectors Can Be Efficiently Produced
Without Helper Virus," Gene Ther. 5:938-945; Sharma, A. et al.
(2010) "Transduction Efficiency Of AAV 2/6, 2/8 And 2/9 Vectors For
Delivering Genes In Human Corneal Fibroblasts," Brain Res. Bull.
81(2-3):273-278).
[0090] Plasmid pHelper-Kan (SEQ ID NO:6; FIG. 8) is a non-AAV
helper function-providing polynucleotide that may be used in
accordance with the present invention to provide non-AAV helper
functions.
TABLE-US-00006 Coding Strand of Plasmid pHelper-Kan (SEQ ID NO: 6):
ggtacccaac tccatgctta acagtcccca ggtacagccc accctgcgtc gcaaccagga
acagctctac agcttcctgg agcgccactc gccctacttc cgcagccaca gtgcgcagat
taggagcgcc acttcttttt gtcacttgaa aaacatgtaa aaataatgta ctaggagaca
ctttcaataa aggcaaatgt ttttatttgt acactctcgg gtgattattt accccccacc
cttgccgtct gcgccgttta aaaatcaaag gggttctgcc gcgcatcgct atgcgccact
ggcagggaca cgttgcgata ctggtgttta gtgctccact taaactcagg cacaaccatc
cgcggcagct cggtgaagtt ttcactccac aggctgcgca ccatcaccaa cgcgtttagc
aggtcgggcg ccgatatctt gaagtcgcag ttggggcctc cgccctgcgc gcgcgagttg
cgatacacag ggttgcagca ctggaacact atcagcgccg ggtggtgcac gctggccagc
acgctcttgt cggagatcag atccgcgtcc aggtcctccg cgttgctcag ggcgaacgga
gtcaactttg gtagctgcct tcccaaaaag ggtgcatgcc caggctttga gttgcactcg
caccgtagtg gcatcagaag gtgaccgtgc ccggtctggg cgttaggata cagcgcctgc
atgaaagcct tgatctgctt aaaagccacc tgagcctttg cgccttcaga gaagaacatg
ccgcaagact tgccggaaaa ctgattggcc ggacaggccg cgtcatgcac gcagcacctt
gcgtcggtgt tggagatctg caccacattt cggccccacc ggttcttcac gatcttggcc
ttgctagact gctccttcag cgcgcgctgc ccgttttcgc tcgtcacatc catttcaatc
acgtgctcct tatttatcat aatgctcccg tgtagacact taagctcgcc ttcgatctca
gcgcagcggt gcagccacaa cgcgcagccc gtgggctcgt ggtgcttgta ggttacctct
gcaaacgact gcaggtacgc ctgcaggaat cgccccatca tcgtcacaaa ggtcttgttg
ctggtgaagg tcagctgcaa cccgcggtgc tcctcgttta gccaggtctt gcatacggcc
gccagagctt ccacttggtc aggcagtagc ttgaagtttg cctttagatc gttatccacg
tggtacttgt ccatcaacgc gcgcgcagcc tccatgccct tctcccacgc agacacgatc
ggcaggctca gcgggtttat caccgtgctt tcactttccg cttcactgga ctcttccttt
tcctcttgcg tccgcatacc ccgcgccact gggtcgtctt cattcagccg ccgcaccgtg
cgcttacctc ccttgccgtg cttgattagc accggtgggt tgctgaaacc caccatttgt
agcgccacat cttctctttc ttcctcgctg tccacgatca cctctgggga tggcgggcgc
tcgggcttgg gagaggggcg cttctttttc tttttggacg caatggccaa atccgccgtc
gaggtcgatg gccgcgggct gggtgtgcgc ggcaccagcg catcttgtga cgagtcttct
tcgtcctcgg actcgagacg ccgcctcagc cgcttttttg ggggcgcgcg gggaggcggc
ggcgacggcg acggggacga cacgtcctcc atggttggtg gacgtcgcgc cgcaccgcgt
ccgcgctcgg gggtggtttc gcgctgctcc tcttcccgac tggccatttc cttctcctat
aggcagaaaa agatcatgga gtcagtcgag aaggaggaca gcctaaccgc cccctttgag
ttcgccacca ccgcctccac cgatgccgcc aacgcgccta ccaccttccc cgtcgaggca
cccccgcttg aggaggagga agtgattatc gagcaggacc caggttttgt aagcgaagac
gacgaggatc gctcagtacc aacagaggat aaaaagcaag accaggacga cgcagaggca
aacgaggaac aagtcgggcg gggggaccaa aggcatggcg actacctaga tgtgggagac
gacgtgctgt tgaagcatct gcagcgccag tgcgccatta tctgcgacgc gttgcaagag
cgcagcgatg tgcccctcgc catagcggat gtcagccttg cctacgaacg ccacctgttc
tcaccgcgcg taccccccaa acgccaagaa aacggcacat gcgagcccaa cccgcgcctc
aacttctacc ccgtatttgc cgtgccagag gtgcttgcca cctatcacat ctttttccaa
aactgcaaga tacccctatc ctgccgtgcc aaccgcagcc gagcggacaa gcagctggcc
ttgcggcagg gcgctgtcat acctgatatc gcctcgctcg acgaagtgcc aaaaatcttt
gagggtcttg gacgcgacga gaaacgcgcg gcaaacgctc tgcaacaaga aaacagcgaa
aatgaaagtc actgtggagt gctggtggaa cttgagggtg acaacgcgcg cctagccgtg
ctgaaacgca gcatcgaggt cacccacttt gcctacccgg cacttaacct accccccaag
gttatgagca cagtcatgag cgagctgatc gtgcgccgtg cacgacccct ggagagggat
gcaaacttgc aagaacaaac cgaggagggc ctacccgcag ttggcgatga gcagctggcg
cgctggcttg agacgcgcga gcctgccgac ttggaggagc gacgcaagct aatgatggcc
gcagtgcttg ttaccgtgga gcttgagtgc atgcagcggt tctttgctga cccggagatg
cagcgcaagc tagaggaaac gttgcactac acctttcgcc agggctacgt gcgccaggcc
tgcaaaattt ccaacgtgga gctctgcaac ctggtctcct accttggaat tttgcacgaa
aaccgcctcg ggcaaaacgt gcttcattcc acgctcaagg gcgaggcgcg ccgcgactac
gtccgcgact gcgtttactt atttctgtgc tacacctggc aaacggccat gggcgtgtgg
cagcaatgcc tggaggagcg caacctaaag gagctgcaga agctgctaaa gcaaaacttg
aaggacctat ggacggcctt caacgagcgc tccgtggccg cgcacctggc ggacattatc
ttccccgaac gcctgcttaa aaccctgcaa cagggtctgc cagacttcac cagtcaaagc
atgttgcaaa actttaggaa ctttatccta gagcgttcag gaattctgcc cgccacctgc
tgtgcgcttc ctagcgactt tgtgcccatt aagtaccgtg aatgccctcc gccgctttgg
ggtcactgct accttctgca gctagccaac taccttgcct accactccga catcatggaa
gacgtgagcg gtgacggcct actggagtgt cactgtcgct gcaacctatg caccccgcac
cgctccctgg tctgcaattc gcaactgctt agcgaaagtc aaattatcgg tacctttgag
ctgcagggtc cctcgcctga cgaaaagtcc gcggctccgg ggttgaaact cactccgggg
ctgtggacgt cggcttacct tcgcaaattt gtacctgagg actaccacgc ccacgagatt
aggttctacg aagaccaatc ccgcccgcca aatgcggagc ttaccgcctg cgtcattacc
cagggccaca tccttggcca attgcaagcc atcaacaaag cccgccaaga gtttctgcta
cgaaagggac ggggggttta cctggacccc cagtccggcg aggagctcaa cccaatcccc
ccgccgccgc agccctatca gcagccgcgg gcccttgctt cccaggatgg cacccaaaaa
gaagctgcag ctgccgccgc cgccacccac ggacgaggag gaatactggg acagtcaggc
agaggaggtt ttggacgagg aggaggagat gatggaagac tgggacagcc tagacgaagc
ttccgaggcc gaagaggtgt cagacgaaac accgtcaccc tcggtcgcat tcccctcgcc
ggcgccccag aaattggcaa ccgttcccag catcgctaca acctccgctc ctcaggcgcc
gccggcactg cctgttcgcc gacccaaccg tagatgggac accactggaa ccagggccgg
taagtctaag cagccgccgc cgttagccca agagcaacaa cagcgccaag gctaccgctc
gtggcgcggg cacaagaacg ccatagttgc ttgcttgcaa gactgtgggg gcaacatctc
cttcgcccgc cgctttcttc tctaccatca cggcgtggcc ttcccccgta acatcctgca
ttactaccgt catctctaca gcccctactg caccggcggc agcggcagcg gcagcaacag
cagcggtcac acagaagcaa aggcgaccgg atagcaagac tctgacaaag cccaagaaat
ccacagcggc ggcagcagca ggaggaggag cgctgcgtct ggcgcccaac gaacccgtat
cgacccgcga gcttagaaat aggatttttc ccactctgta tgctatattt caacaaagca
ggggccaaga acaagagctg aaaataaaaa acaggtctct gcgctccctc acccgcagct
gcctgtatca caaaagcgaa gatcagcttc ggcgcacgct ggaagacgcg gaggctctct
tcagcaaata ctgcgcgctg actcttaagg actagtttcg cgccctttct caaatttaag
cgcgaaaact acgtcatctc cagcggccac acccggcgcc
agcacctgtc gtcagcgcca ttatgagcaa ggaaattccc acgccctaca tgtggagtta
ccagccacaa atgggacttg cggctggagc tgcccaagac tactcaaccc gaataaacta
catgagcgcg ggaccccaca tgatatcccg ggtcaacgga atccgcgccc accgaaaccg
aattctcctc gaacaggcgg ctattaccac cacacctcgt aataacctta atccccgtag
ttggcccgct gccctggtgt accaggaaag tcccgctccc accactgtgg tacttcccag
agacgcccag gccgaagttc agatgactaa ctcaggggcg cagcttgcgg gcggctttcg
tcacagggtg cggtcgcccg ggcgttttag ggcggagtaa cttgcatgta ttgggaattg
tagttttttt aaaatgggaa gtgacgtatc gtgggaaaac ggaagtgaag atttgaggaa
gttgtgggtt ttttggcttt cgtttctggg cgtaggttcg cgtgcggttt tctgggtgtt
ttttgtggac tttaaccgtt acgtcatttt ttagtcctat atatactcgc tctgtacttg
gcccttttta cactgtgact gattgagctg gtgccgtgtc gagtggtgtt ttttaatagg
tttttttact ggtaaggctg actgttatgg ctgccgctgt ggaagcgctg tatgttgttc
tggagcggga gggtgctatt ttgcctaggc aggagggttt ttcaggtgtt tatgtgtttt
tctctcctat taattttgtt atacctccta tgggggctgt aatgttgtct ctacgcctgc
gggtatgtat tcccccgggc tatttcggtc gctttttagc actgaccgat gttaaccaac
ctgatgtgtt taccgagtct tacattatga ctccggacat gaccgaggaa ctgtcggtgg
tgctttttaa tcacggtgac cagttttttt acggtcacgc cggcatggcc gtagtccgtc
ttatgcttat aagggttgtt tttcctgttg taagacaggc ttctaatgtt taaatgtttt
tttttttgtt attttatttt gtgtttaatg caggaacccg cagacatgtt tgagagaaaa
atggtgtctt tttctgtggt ggttccggaa cttacctgcc tttatctgca tgagcatgac
tacgatgtgc ttgctttttt gcgcgaggct ttgcctgatt ttttgagcag caccttgcat
tttatatcgc cgcccatgca acaagcttac ataggggcta cgctggttag catagctccg
agtatgcgtg tcataatcag tgtgggttct tttgtcatgg ttcctggcgg ggaagtggcc
gcgctggtcc gtgcagacct gcacgattat gttcagctgg ccctgcgaag ggacctacgg
gatcgcggta tttttgttaa tgttccgctt ttgaatctta tacaggtctg tgaggaacct
gaatttttgc aatcatgatt cgctgcttga ggctgaaggt ggagggcgct ctggagcaga
tttttacaat ggccggactt aatattcggg atttgcttag agacatattg ataaggtggc
gagatgaaaa ttatttgggc atggttgaag gtgctggaat gtttatagag gagattcacc
ctgaagggtt tagcctttac gtccacttgg acgtgagggc agtttgcctt ttggaagcca
ttgtgcaaca tcttacaaat gccattatct gttctttggc tgtagagttt gaccacgcca
ccggagggga gcgcgttcac ttaatagatc ttcattttga ggttttggat aatcttttgg
aataaaaaaa aaaaaacatg gttcttccag ctcttcccgc tcctcccgtg tgtgactcgc
agaacgaatg tgtaggttgg ctgggtgtgg cttattctgc ggtggtggat gttatcaggg
cagcggcgca tgaaggagtt tacatagaac ccgaagccag ggggcgcctg gatgctttga
gagagtggat atactacaac tactacacag agcgagctaa gcgacgagac cggagacgca
gatctgtttg tcacgcccgc acctggtttt gcttcaggaa atatgactac gtccggcgtt
ccatttggca tgacactacg accaacacga tctcggttgt ctcggcgcac tccgtacagt
agggatcgcc tacctccttt tgagacagag acccgcgcta ccatactgga ggatcatccg
ctgctgcccg aatgtaacac tttgacaatg cacaacgtga gttacgtgcg aggtcttccc
tgcagtgtgg gatttacgct gattcaggaa tgggttgttc cctgggatat ggttctgacg
cgggaggagc ttgtaatcct gaggaagtgt atgcacgtgt gcctgtgttg tgccaacatt
gatatcatga cgagcatgat gatccatggt tacgagtcct gggctctcca ctgtcattgt
tccagtcccg gttccctgca gtgcatagcc ggcgggcagg ttttggccag ctggtttagg
atggtggtgg atggcgccat gtttaatcag aggtttatat ggtaccggga ggtggtgaat
tacaacatgc caaaagaggt aatgtttatg tccagcgtgt ttatgagggg tcgccactta
atctacctgc gcttgtggta tgatggccac gtgggttctg tggtccccgc catgagcttt
ggatacagcg ccttgcactg tgggattttg aacaatattg tggtgctgtg ctgcagttac
tgtgctgatt taagtgagat cagggtgcgc tgctgtgccc ggaggacaag gcgtctcatg
ctgcgggcgg tgcgaatcat cgctgaggag accactgcca tgttgtattc ctgcaggacg
gagcggcggc ggcagcagtt tattcgcgcg ctgctgcagc accaccgccc tatcctgatg
cacgattatg actctacccc catgtaggcg tggacttccc cttcgccgcc cgttgagcaa
ccgcaagttg gacagcagcc tgtggctcag cagctggaca gcgacatgaa cttaagcgag
ctgcccgggg agtttattaa tatcactgat gagcgtttgg ctcgacagga aaccgtgtgg
aatataacac ctaagaatat gtctgttacc catgatatga tgctttttaa ggccagccgg
ggagaaagga ctgtgtactc tgtgtgttgg gagggaggtg gcaggttgaa tactagggtt
ctgtgagttt gattaaggta cggtgatcaa tataagctat gtggtggtgg ggctatacta
ctgaatgaaa aatgacttga aattttctgc aattgaaaaa taaacacgtt gaaacataac
atgcaacagg ttcacgattc tttattcctg ggcaatgtag gagaaggtgt aagagttggt
agcaaaagtt tcagtggtgt attttccact ttcccaggac catgtaaaag acatagagta
agtgcttacc tcgctagttt ctgtggattc actagaatcg atgtaggatg ttgcccctcc
tgacgcggta ggagaagggg agggtgccct gcatgtctgc cgctgctctt gctcttgccg
ctgctgagga ggggggcgca tctgccgcag caccggatgc atctgggaaa agcaaaaaag
gggctcgtcc ctgtttccgg aggaatttgc aagcggggtc ttgcatgacg gggaggcaaa
cccccgttcg ccgcagtccg gccggcccga gactcgaacc gggggtcctg cgactcaacc
cttggaaaat aaccctccgg ctacagggag cgagccactt aatgctttcg ctttccagcc
taaccgctta cgccgcgcgc ggccagtggc caaaaaagct agcgcagcag ccgccgcgcc
tggaaggaag ccaaaaggag cgctcccccg ttgtctgacg tcgcacacct gggttcgaca
cgcgggcggt aaccgcatgg atcacggcgg acggccggat ccggggttcg aaccccggtc
gtccgccatg atacccttgc gaatttatcc accagaccac ggaagagtgc ccgcttacag
gctctccttt tgcacggtct agagcgtcaa cgactgcgca cgcctcaccg gccagagcgt
cccgaccatg gagcactttt tgccgctgcg caacatctgg aaccgcgtcc gcgactttcc
gcgcgcctcc accaccgccg ccggcatcac ctggatgtcc aggtacatct acggattacg
tcgacgttta aaccatatga tcagctcact caaaggcggt aatacggtta tccacagaat
caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta
aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa
atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc
cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt
ccgcctttct cccttcggga agcgtggcgc tttctcatag ctcacgctgt aggtatctca
gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg
accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat
cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta
cagagttctt gaagtggtgg cctaactacg gctacactag aagaacagta tttggtatct
gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac
aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg
cgcagaaaaa
aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa
actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc tagatccttt
taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact tggtctgaca
gtcagaagaa ctcgtcaaga aggcgataga aggcgatgcg ctgcgaatcg ggagcggcga
taccgtaaag cacgaggaag cggtcagccc attcgccgcc aagctcttca gcaatatcac
gggtagccaa cgctatgtcc tgatagcggt ccgccacacc cagccggcca cagtcgatga
atccagaaaa gcggccattt tccaccatga tattcggcaa gcaggcatcg ccatgggtca
cgacgagatc ctcgccgtcg ggcatgctcg ccttgagcct ggcgaacagt tcggctggcg
cgagcccctg atgctcttcg tccagatcat cctgatcgac aagaccggct tccatccgag
tacgtgctcg ctcgatgcga tgtttcgctt ggtggtcgaa tgggcaggta gccggatcaa
gcgtatgcag ccgccgcatt gcatcagcca tgatggatac tttctcggca ggagcaaggt
gagatgacag gagatcctgc cccggcactt cgcccaatag cagccagtcc cttcccgctt
cagtgacaac gtcgagtaca gctgcgcaag gaacgcccgt cgtggccagc cacgatagcc
gcgctgcctc gtcttgcagt tcattcaggg caccggacag gtcggtcttg acaaaaagaa
ccgggcgccc ctgcgctgac agccggaaca cggcggcatc agagcagccg attgtctgtt
gtgcccagtc atagccgaat agcctctcca cccaagcggc cggagaacct gcgtgcaatc
catcttgttc aatcatactc ttcctttttc aatattattg aagcatttat cagggttatt
gtctcatgag cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc
gcacatttcc ccgaaaagtg ccacctaaat tgtaagcgtt aatattttgt taaaattcgc
gttaaatttt tgttaaatca gctcattttt taaccaatag gccgaaatcg gcaaaatccc
ttataaatca aaagaataga ccgagatagg gttgagtgtt gttccagttt ggaacaagag
tccactatta aagaacgtgg actccaacgt caaagggcga aaaaccgtct atcagggcga
tggcccacta cgtgaaccat caccctaatc aagttttttg gggtcgaggt gccgtaaagc
actaaatcgg aaccctaaag ggagcccccg atttagagct tgacggggaa agccggcgaa
cgtggcgaga aaggaaggga agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt
agcggtcacg ctgcgcgtaa ccaccacacc cgccgcgctt aatgcgccgc tacagggcgc
gatggatcc
[0091] In SEQ ID NO:6, residues 1-5343 of pHelper-Kan are derived
from adenovirus, and include a polynucleotide encoding the E2A
protein (residues 258-1847); residues 5344-8535 are derived from
adenovirus, and include a polynucleotide encoding the E4orf6
protein; residues 9423-10011 correspond to ori sequences; residues
10182-10976 encode a kanamycin resistance determinant expressed by
a bla promoter sequence (residues 10977-11081); residues
11107-11561 correspond to f1 ori sequences (FIG. 8).
[0092] C. Illustrative rAAV Plasmid Vectors
[0093] As discussed above, AAV helper function-providing
polynucleotides and non-AAV helper function-providing
polynucleotides are typically employed in concert with an rAAV
plasmid vector to comprise a triple plasmid transfection system.
Multiple commercially available rAAV plasmid vectors (e.g.,
pAV-CMV-EGFP, pGOI, etc. (Cell Biolabs, Inc., Invitrogen and
Stratagene)) may be used in accordance with the present invention.
An illustrative rAAV plasmid vector that may be used in accordance
with the present invention is pAV-CMV-EGFP (SEQ ID NO:7; FIG. 9)
which comprises a 5' ITR, a U6 promoter, CMV enhancer and promoter
sequences, a polynucleotide encoding the enhanced green fluorescent
protein (EGFP) (Gambotto, A. et al. (2000) "Immunogenicity Of
Enhanced Green Fluorescent Protein (EGFP) In BALB/C Mice:
Identification Of An H2-Kd-Restricted CTL Epitope," Gene Ther.
7(23):2036-2040; Tsien, R. Y. (1998) "The Green Fluorescent
Protein," Annu. Rev. Biochem. 67:509-544; Cinelli, R. A. et al.
(2000) "The Enhanced Green Fluorescent Protein As A Tool For The
Analysis Of Protein Dynamics And Localization: Local Fluorescence
Study At The Single-Molecule Level," Photochem. Photobiol.
71(6):771-776; Chopra A. (2008) "Recombinant Adenovirus With
Enhanced Green Fluorescent Protein," In: MOLECULAR IMAGING AND
CONTRAST AGENT DATABASE (MICAD), National Center for Biotechnology
Information, Bethesda Md.), FLAG-tag and 6.times.His-tag sites for
facilitating recovery or localization of expressed proteins, an
SV40 poly(A) site and a 3' ITR.
TABLE-US-00007 Coding Strand of Plasmid pAV-CMV-EGFP (SEQ ID NO:
7): cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg
ggcgaccttt ggtcgcccgg ccctccagtg agcgagcgcg cagagaggga gtggccaact
ccatcactag gggttcctgc ggccgcacgc gtctagttat taatagtaat cgaattcgtg
ttactcataa ctagtaaggt cgggcaggaa gagggcctat ttcccatgat tccttcatat
ttgcatatac gatacaaggc tgttagagag ataattagaa ttaatttgac tgtaaacaca
aagatattag tacaaaatac gtgacgtaga aagtaataat ttcttgggta gtttgcagtt
ttaaaattat gttttaaaat ggactatcat atgcttaccg taacttgaaa gtatttcgat
ttcttgggtt tatatatctt gtggaaagga cgcgggatcc actggaccag gcagcagcgt
cagaagactt ttttggaaaa gcttgactag taatactgta atagtaatca attacggggt
cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc
ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag
taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc
acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg
gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc
agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca
atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca
atgggagttt gttttgcacc aaaatcaacg ggactttcca aaatgtcgta acaactccgc
cccattgacg caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctgg
tttagtgaac cgtcagatcc gctagagatc cggtaccgag gagatctgcc gccgcgatcg
ccggcgcgcc agatctcacg cttaactagc tagcggaccg acgcgtacgc ggccgctcga
gatggtgagc aagggcgagg agctgttcac cggggtggtg cccatcctgg tcgagctgga
cggcgacgta aacggccaca agttcagcgt gtccggcgag ggcgagggcg atgccaccta
cggcaagctg accctgaagt tcatctgcac caccggcaag ctgcccgtgc cctggcccac
cctcgtgacc accctgacct acggcgtgca gtgcttcagc cgctaccccg accacatgaa
gcagcacgac ttcttcaagt ccgccatgcc cgaaggctac gtccaggagc gcaccatctt
cttcaaggac gacggcaact acaagacccg cgccgaggtg aagttcgagg gcgacaccct
ggtgaaccgc atcgagctga agggcatcga cttcaaggag gacggcaaca tcctggggca
caagctggag tacaactaca acagccacaa cgtctatatc atggccgaca agcagaagaa
cggcatcaag gtgaacttca agatccgcca caacatcgag gacggcagcg tgcagctcgc
cgaccactac cagcagaaca cccccatcgg cgacggcccc gtgctgctgc ccgacaacca
ctacctgagc acccagtccg ccctgagcaa agaccccaac gagaagcgcg atcacatggt
cctgctggag ttcgtgaccg ccgccgggat cactctcggc atggacgagc tgtacaagta
agtcgaggat tataaggatg acgacgataa attcgtcgag caccaccacc accaccacta
ataaggttta tccgatccac cggatctaga taagatatcc gatccaccgg atctagataa
ctgatcataa tcagccatac cacatttgta gaggttttac ttgctttaaa aaacctccca
cacctccccc tgaacctgaa acataaaatg aatgcaattg ttgttgttaa cttgtttatt
gcagcttata atggttacaa ataaagcaat agcatcacaa atttcacaaa taaagcattt
ttttcactgc attctagttg tggtttgtcc aaactcatca atgtatctta acgcggtaac
cacgtgcgga ccgagcggcc gcaggaaccc ctagtgatgg agttggccac tccctctctg
cgcgctcgct cgctcactga ggccgggcga ccaaaggtcg cccgacgccc gggctttgcc
cgggcggcct cagtgagcga gcgagcgcgc agctgcctgc aggggcgcct gatgcggtat
tttctcctta cgcatctgtg cggtatttca caccgcatac gtcaaagcaa ccatagtacg
cgccctgtag cggcgcatta agcgcggcgg gtgtggtggt tacgcgcagc gtgaccgcta
cacctgccag cgccttagcg cccgctcctt tcgctttctt cccttccttt ctcgccacgt
tcgccggctt tccccgtcaa gctctaaatc gggggctccc tttagggttc cgatttagtg
ctttacggca cctcgacccc aaaaaacttg atttgggtga tggttcacgt agtgggccat
cgccctgata gacggttttt cgccctttga cgttggagtc cacgttcttt aatagtggac
tcttgttcca aactggaaca acactcaacc ctatctcggg ctattctttt gatttataag
ggattttgcc gatttcggcc tattggttaa aaaatgagct gatttaacaa aaatttaacg
cgaattttaa caaaatatta acgtttacaa ttttatggtg cactctcagt acaatctgct
ctgatgccgc atagttaagc cagccccgac acccgccaac acccgctgac gcgccctgac
gggcttgtct gctcccggca tccgcttaca gacaagctgt gaccgtctcc gggagctgca
tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag acgaaagggc ctcgtgatac
gcctattttt ataggttaat gtcatgataa taatggtttc ttagacgtca ggtggcactt
ttcggggaaa tgtgcgcgga acccctattt gtttattttt ctaaatacat tcaaatatgt
atccgctcat gagacaataa ccctgataaa tgcttcaata atattgaaaa aggaagagta
tgagtattca acatttccgt gtcgccctta ttcccttttt tgcggcattt tgccttcctg
tttttgctca cccagaaacg ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac
gagtgggtta catcgaactg gatctcaaca gcggtaagat ccttgagagt tttcgccccg
aagaacgttt tccaatgatg agcactttta aagttctgct atgtggcgcg gtattatccc
gtattgacgc cgggcaagag caactcggtc gccgcataca ctattctcag aatgacttgg
ttgagtactc accagtcaca gaaaagcatc ttacggatgg catgacagta agagaattat
gcagtgctgc cataaccatg agtgataaca ctgcggccaa cttacttctg acaacgatcg
gaggaccgaa ggagctaacc gcttttttgc acaacatggg ggatcatgta actcgccttg
atcgttggga accggagctg aatgaagcca taccaaacga cgagcgtgac accacgatgc
ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg cgaactactt actctagctt
cccggcaaca attaatagac tggatggagg cggataaagt tgcaggacca cttctgcgct
cggcccttcc ggctggctgg tttattgctg ataaatctgg agccggtgag cgtgggtctc
gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta gttatctaca
cgacggggag tcaggcaact atggatgaac gaaatagaca gatcgctgag ataggtgcct
cactgattaa gcattggtaa ctgtcagacc aagtttactc atatatactt tagattgatt
taaaacttca tttttaattt aaaaggatct aggtgaagat cctttttgat aatctcatga
ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc agaccccgta gaaaagatca
aaggatcttc ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa acaaaaaaac
caccgctacc agcggtggtt tgtttgccgg atcaagagct accaactctt tttccgaagg
taactggctt cagcagagcg cagataccaa atactgtcct tctagtgtag ccgtagttag
gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta atcctgttac
cagtggctgc tgccagtggc gataagtcgt gtcttaccgg gttggactca agacgatagt
taccggataa ggcgcagcgg tcgggctgaa cggggggttc gtgcacacag cccagcttgg
agcgaacgac ctacaccgaa ctgagatacc tacagcgtga gctatgagaa agcgccacgc
ttcccgaagg gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga acaggagagc
gcacgaggga gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc gggtttcgcc
acctctgact tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc
ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg ctggcctttt
gctcacatgt
[0094] In SEQ ID NO:7, residues 1-128 of pAV-CMV-EGFP correspond to
the 5' ITR; residues 201-441 are U6 promoter sequences; residues
562-865 are human cytomegalovirus (CMV) immediate early enhancer
sequences; residues 866-1068 comprise the CMV immediate early
promoter; residues 1192-1911 comprise a mammalian codon-optimized
polynucleotide that encodes the EGFP; residues 1918-1941 encode the
FLAG-tag; residues 1951-1968 encode the 6.times.His-tag; residues
2139-2260 encode the SV40 poly(A) sequence; residues 2293-2433
correspond to the 3' ITR; residues 2508-22963 correspond to F1 ori
sequences; residues 3350-4210 encode an ampicillin resistance
determinant and its signal sequence (residues 3350-3418) expressed
by a bla promoter sequence (residues 3245-3349); residues 4381-4969
correspond to an ori sequence (FIG. 9).
[0095] A second illustrative rAAV plasmid vector that may be used
in accordance with the present invention is pAV-TBG-EGFP (SEQ ID
NO:8; FIG. 10) which comprises a 5' ITR, a thyroid hormone-binding
globulin (TBG) promoter, a polynucleotide encoding the enhanced
green fluorescent protein (EGFP), FLAG-tag and 6.times.His-tag
sites for facilitating recovery or localization of expressed
proteins, an SV40 poly(A) site and a 3' ITR.
TABLE-US-00008 Coding Strand of Plasmid pAV-TBG-EGFP (SEQ ID NO:
8): cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg
ggcgaccttt ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa
ctccatcact aggggttcct gcggccggtc gcgtctagta ctagtaggtt aatttttaaa
aagcagtcaa aagtccaagt ggcccttggc agcatttact ctctctgttt gctctggtta
ataatctcag gagcacaaac attccagatc caggttaatt tttaaaaagc agtcaaaagt
ccaagtggcc cttggcagca tttactctct ctgtttgctc tggttaataa tctcaggagc
acaaacattc cagatccggc gcgccagggc tggaagctac ctttgacatc atttcctctg
cgaatgcatg tataatttct acagaaccta ttagaaagga tcacccagcc tctgcttttg
tacaactttc ccttaaaaaa ctgccaattc cactgctgtt tggcccaata gtgagaactt
tttcctgctg cctcttggtg cttttgccta tggcccctat tctgcctgct gaagacactc
ttgccagcat ggacttaaac ccctccagct ctgacaatcc tctttctctt ttgttttaca
tgaagggtct ggcagccaaa gcaatcactc aaagttcaaa ccttatcatt ttttgctttg
ttcctcttgg ccttggtttt gtacatcagc tttgaaaata ccatcccagg gttaatgctg
gggttaattt ataactaaga gtgctctagt tttgcaatac aggacatgct ataaaaatgg
aaagatgttg ctttctgaga gacaggtacc gaggagatct gccgccgcga tcgccaccat
ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgccc atcctggtcg agctggacgg
cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg ccacttacgg
caagctgacc ctgaagttca tctgcaccac cggcaagctg cccgtgccct ggcccaccct
cgtgaccacc ctgacctacg gcgtgcagtg cttcagccgc taccccgacc acatgaagca
gcacgacttc ttcaagtccg ccatgcccga aggctacgtc caggagcgca ccatcttctt
caaggacgac ggcaactaca agacccgcgc cgaggtgaag ttcgagggcg acaccctggt
gaaccgcatc gagctgaagg gcatcgactt caaggaggac ggcaacatcc tggggcacaa
gctggagtac aactacaaca gccacaacgt ctatatcatg gccgacaagc agaagaacgg
catcaaggtg aacttcaaga tccgccacaa catcgaggac ggcagcgtgc agctcgccga
ccactaccag cagaacaccc ccatcggcga cggccccgtg ctgctgcccg acaaccacta
cctgagcacc cagtccgccc tgagcaaaga ccccaacgag aagcgcgatc acatggtcct
gctggagttc gtgaccgccg ccgggatcac tctcggcatg gacgagctgt acaagtagac
gcgtacgcgg ccgctcgagg attataagga tgacgacgat aaattcgtcg agcaccacca
ccaccaccac taataaggtt tatccgatcc accggatcta gataagatat ccgatccacc
ggatctagat aactgatcat aatcagccat accacatttg tagaggtttt acttgcttta
aaaaacctcc cacacctccc cctgaacctg aaacataaaa tgaatgcaat tgttgttgtt
aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac aaatttcaca
aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct
taacgcggta accacgtgcg gacccaacgg ccgcaggaac ccctagtgat ggagttggcc
actccctctc tgcgcgctcg ctcgctcact gaggccgggc gaccaaaggt cgcccgacgc
ccgggctttg cccgggcggc ctcagtgagc gagcgagcgc gcagctgcct gcaggggcgc
ctgatgcggt attttctcct tacgcatctg tgcggtattt cacaccgcat acgtcaaagc
aaccatagta cgcgccctgt agcggcacat taagcgcggc gggtgtggtg gttacgcgca
gcgtgaccgc tacacctgcc agcgccttag cgcccgctcc tttcgctttc ttcccttcct
ttctcgccac gttcgccggc tttccccgtc aagctctaaa tcgggggctc cctttagggt
tccgatttag tgctttacgg cacctcgacc ccaaaaaact tgatttgggt gatggttcac
gtagtgggcc atcgccctga tagacggttt ttcgcccttt gacgttggag tccacgttct
ttaatagtgg actcttgttc caaactggaa caacactcaa ctctatctcg ggctattctt
ttgatttata agggattttg ccgatttcgg tctattggtt aaaaaatgag ctgatttaac
aaaaatttaa cgcgaatttt aacaaaatat taacgtttac aattttatgg tgcactctca
gtacaatctg ctctgatgcc gcatagttaa gccagccccg acacccgcca acacccgctg
acgcgccctg acgggcttgt ctgctcccgg catccgctta cagacaagct gtgaccgtct
ccgggagctg catgtgtcag aggttttcac cgtcatcacc gaaacgcgcg agacgaaagg
gcctcgtgat acgcctattt ttataggtta atgtcatgat aataatggtt tcttagacgt
caggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttattt ttctaaatac
attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa
aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt tttgcggcat
tttgccttcc tgtttttgct cacccagaaa cgctggtgaa agtaaaagat gctgaagatc
agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga
gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg
cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc
agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat ggcatgacag
taagagaatt atgcagtgct gccataacca tgagtgataa cactgcggcc aacttacttc
tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg
taactcgcct tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg
acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcgaactac
ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac
cacttctgcg ctcggccctt ccggctggct ggtttattgc tgataaatct ggagccggtg
agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaagccc tcccgtatcg
tagttatcta cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg
agataggtgc ctcactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac
tttagattga tttaaaactt catttttaat ttaaaaggat ctaggtgaag atcctttttg
ataatctcat gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg tcagaccccg
tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc
aaacaaaaaa accaccgcta ccagcggtgg tttgtttgcc ggatcaagag ctaccaactc
tttttccgaa ggtaactggc ttcagcagag cgcagatacc aaatactgtt cttctagtgt
agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac ctcgctctgc
taatcctgtt accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact
caagacgata gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac
agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag
aaagcgccac gcttcccgaa gggagaaagg cggacaggta tccggtaagc ggcagggtcg
gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt tatagtcctg
tcgggtttcg ccacctctga cttgagcgtc gatttttgtg atgctcgtca ggggggcgga
gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt tgctggcctt
ttgctcacat gt
[0096] In SEQ ID NO:8, residues 1-130 of pAV-TBG-EGFP correspond to
the 5' ITR; residues 150-854 are TBG promoter sequences, with
residues 415-824 comprising the TBG promoter; residues 886-1608
encode the EGFP; residues 1630-1653 encode the FLAG-tag; residues
1663-1680 encode the 6xHis-tag; residues 1851-1972 encode the
poly(A) sequence; residues 2005-2145 corresponds to the 3' ITR;
residues 2220-2675 correspond to F1 ori sequences; residues
3062-3922 encode an ampicillin resistance determinant and its
signal sequence (residues 3062-3130) expressed by a bla promoter
sequence (residues 2957-3061); residues 4093-4681 correspond to an
ori sequence (FIG. 10).
[0097] As used herein, the term "native AAV serotype promoter
sequence" is intended to denote a promoter sequence that natively
controls the transcription of an AAV rep gene or is natively
present within such rep gene. For example: [0098] AAV1 P5 promoter
sequences natively control the transcription of the rep gene of
AAV1 and AAV1 P40 promoter sequences are natively found within the
rep gene of AAV1. Thus, the AAV1 P5 promoter sequences and the AAV1
P40 promoter sequences are native AAV serotype promoter sequences
of the rep gene of AAV1; [0099] AAV2 P5 promoter sequences natively
control the transcription of the rep gene of AAV2 and the AAV2 P40
promoter sequences are natively found within the rep gene of AAV2.
Thus, the AAV2 P5 promoter sequences and the AAV2 P40 promoter
sequences are native AAV serotype promoter sequences of the rep
gene of AAV2; [0100] AAV5 P5 promoter sequences natively control
the transcription of the rep gene of AAV5 and the AAVS P40 promoter
sequences are natively found within the rep gene of AAV5. Thus, the
AAVS P5 promoter sequences and the AAV5 P40 promoter sequences are
native AAV serotype promoter sequences of the rep gene of AAV5;
[0101] AAV6 P5 promoter sequences natively control the
transcription of the rep gene of AAV6 and the AAV6 P40 promoter
sequences are natively found within the rep gene of AAV6. Thus, the
AAV6 P5 promoter sequences and the AAV6 P40 promoter sequences are
native AAV serotype promoter sequences of the rep gene of AAV6; and
[0102] AAV7 P5 promoter sequences natively control the
transcription of the rep gene of AAV7 and the AAV7 P40 promoter
sequences are natively found within the rep gene of AAV7. Thus, the
AAV7 P5 promoter sequences and the AAV7 P40 promoter sequences are
native AAV serotype promoter sequences of the rep gene of AAV7;
[0103] Native AAV P5 and P40 promoter sequences for AAV serotypes
1-8 are shown in Table 1. Such sequences, or subsequences thereof
that are capable of mediating transcription, may be used in
accordance with the methods of the present invention.
TABLE-US-00009 TABLE 1 AAV Native SEQ ID Pro- Sero- NO moter type
Sequence SEQ ID P5 AAV1 ggtcctgtat tagctgtcac gtgagtgctt NO: 9
ttgcgacatt ttgcgacacc acgtggccat ttagggtata tatggccgag tgagcgagca
ggatctccat tttgaccgcg aaatttgaac gagcagcagc c SEQ ID P5 AAV2
ggtcctgtat tagaggtcac gtgagtgttt NO: 10 tgcgacattt tgcgacacca
tgtggtcacg ctgggtattt aagcccgagt gagcacgcag ggtctccatt ttgaagcggg
aggtttgaac gcgcagccgc c SEQ ID P5 AAV3 ccagctgcgt cagcagtcag
gtgacccttt NO: 11 tgcgacagtt tgcgacacca cgtggccgct gagggtatat
attctcgagt gagcgaacca ggagctccat tttgaccgcg aaatttgaac gagcagcagc c
SEQ ID P5 AAV4 ggtccctgta ttagcagtca cgtgagtgtc NO: 12 gtatttcgcg
gagcgtagcg gagcgcatac caagctgcca cgtcacagcc acgtggtccg tttgcgacag
tttgcgacac catgtggtca ggagggtata taaccgcgag tgagccagcg aggagctcca
ttttgcccgc gaattttgaa cgagcagcag cc SEQ ID P5 AAV5 atgtgatgtg
ttttatccaa taggaagaaa NO: 13 gcgcgcgtat gagttctcgc gagacttccg
gggtataaaa gaccgagtga acgagcccgc cgccattctt tgctctggac tgctagagga
ccctcgctgc c SEQ ID P5 AAV6 ggtcctgtat tagaggtcac gtgagtgttt NO: 14
tgcgacattt tgcgacacca tgtggtcacg ctgggtattt aagcccgagt gagcacgcag
ggtctccatt ttgaagcggg aggtttgaac gcgcagcgcc SEQ ID P5 AAV7
ggtcctgtat tagctgtcac gtgagtgctt NO: 15 ttgcgacatt ttgcgacacc
acgtggccat ttgaggtata tatggccgag tgagcgagca ggatctccat tttgaccgcg
aaatttgaac gagcagcagc c SEQ ID P5 AAV8 ggtcctgtat tagctgtcac
gtgagtgctt NO: 16 ttgcggcatt ttgcgacacc acgtggccat ttgaggtata
tatggccgag tgagcgagca ggatctccat tttgaccgcg aaatttgaac gagcagcagc c
SEQ ID P40 AAV1 ggtgacaaag caggaagtca aagagttctt NO: 17 ccgctgggcg
caggatcacg tgaccgaggt ggcgcatgag ttctacgtca gaaagggtgg agccaacaaa
agacccgccc ccgatgacgc ggataaaagc gagcccaagc gggcctgccc ctcagtcgcg
gatccatcga cgtcagacgc SEQ ID P40 AAV2 ggtcaccaag caggaagtca
aagacttttt NO: 18 ccggtgggca aaggatcacg tggttgaggt ggagcatgaa
ttctacgtca aaaagggtgg agccaagaaa agacccgccc ccagtgacgc agatataagt
gagcccaaac gggtgcgcga gtcagttgcg cagccatcga cgtcagacgc SEQ ID P40
AAV3 ggtcaccaaa caggaagtaa aggacttttt NO: 19 ccggtgggct tccgatcacg
tgactgacgt ggctcatgag ttctacgtca gaaagggtgg agctaagaaa cgccccgcct
ccaatgacgc ggatgtaagc gagccaaaac gggagtgcac gtcacttgcg cagccgacaa
cgtcagacgc SEQ ID P40 AAV4 ggtcaccaag caggaagtca aagacttttt NO: 20
ccggtgggcg tcagatcacg tgaccgaggt gactcacgag ttttacgtca gaaagggtgg
agctagaaag aggcccgccc ccaatgacgc agatataagt gagcccaagc gggcctgtcc
gtcagttgcg cagccatcga cgtcagacgc SEQ ID P40 AAV5 gattactaag
caggaagtca aggacttttt NO: 21 tgcttgggca aaggtcaatc aggtgccggt
gactcacgag tttaaagttc ccagggaatt ggcgggaact aaaggggcgg agaaatctct
aaaacgccca ctgggtgacg tcaccaatac tagctataaa agtctggaga agcgggcctg
gagcatgagg ctctcatttg ttcccgagac gcctcgcagt tcagacg SEQ ID P40 AAV6
ggtgacaaag caggaagtca aagagttctt NO: 22 ccgctgggcg caggatcacg
tgaccgaggt ggcgcatgag ttctacgtca gaaagggtgg agccaacaag agacccgccc
ccgatgacgc ggataaaagc gagcccaagc gggcctgccc ctcagtcgcg gatccatcga
cgtcagacgc SEQ ID P40 AAV7 ggtgacgaag caggaagtca aagagttctt NO: 23
ccgctgggcc agtgatcacg tgaccgaggt ggcgcatgag ttctacgtca gaaagggcgg
agccagcaaa agacccgccc ccgatgacgc ggatataagc gagcccaagc gggcctgccc
ctcagtcgcg gatccatcga cgtcagacgc SEQ ID P40 AAV8 ggtgacaaag
caggaagtca aagagttctt NO: 24 ccgctgggcc agtgatcacg tgaccgaggt
ggcgcatgag ttttacgtca gaaagggcgg agccagcaaa agacccgccc ccgatgacgc
ggataaaagc gagcccaagc gggcctgccc ctcagtcgcg gatccatcga
cgtcagacgc
[0104] In contrast, the term "non-native AAV serotype promoter
sequence" is intended to denote a promoter sequence that does not
natively control a rep gene of an AAV and is not natively found
within such rep gene. Illustrative, non-limiting examples of
non-native AAV serotype promoter sequences include: the AAV1 P5
promoter when used to direct the expression of an AAV2, AAV5, AAV6,
or AAV7 rep gene; the AAV2 P5 promoter when used to direct the
expression of an AAV1, AAV5, AAV6, or AAV7 rep gene; the AAV5 P5
promoter when used to direct the expression of an AAV1, AAV2, AAV6,
or AAV7 rep gene; the AAV6 P5 promoter when used to direct the
expression of an AAV1, AAV2, AAV5, or AAV7 rep gene; the AAV7 P5
promoter when used to direct the expression of an AAV1, AAV2, AAV5,
or AAV6 rep gene; the AAV1 P40 promoter, when present within an
AAV2, AAV5, AAV6, or AAV7 rep gene; the AAV2 P40 promoter, when
present within an AAV1, AAV5, AAV6, or AAV7 rep gene; the AAV5 P40
promoter, when present within an AAV1, AAV2, AAV6, or AAV7 rep
gene; the AAV6 P40 promoter, when present within an AAV1, AAV2,
AAV5, or AAV7 rep gene; the AAV7 P40 promoter, when present within
an AAV1, AAV2, AAV5, or AAV6 rep gene, etc.
[0105] In one embodiment, one or more of such AAV serotype promoter
sequences can be genetically engineered into recombinant AAV helper
plasmids that are designed to provide the Rep and Cap proteins to
replace or augment the existing P5 or P40 promoters of such
plasmids. Such modification is preferably accomplished using
well-known methods of recombinant DNA technology.
[0106] The identity of the serotype of promoter sequences is
indicated herein by denoting the involved promoter (e.g., P5, P40,
etc.), the serotype of the rep gene with which it is natively
associated, and the name of the vector. Thus, for example, a
pAAV-RC2 plasmid that comprises a P5 promoter sequence that is
natively associated with AAV2 is denoted as P5(2)-RC2; a pAAV-RC2
plasmid that comprises a P5 promoter sequence that is natively
associated with AAV3 is denoted as P5(3)-RC2; a pAAV-RC5 plasmid
that comprises a P40 promoter sequence that is natively associated
with AAV7 is denoted as P40(7)-RCS; a pAAV-RC2 plasmid that
comprises a P5 promoter sequence that is natively associated with
AAV3 and a P40 promoter sequence that is natively associated with
AAV8 is denoted as P5(3)/P40(8)-RC2; etc.
[0107] In one embodiment, the introduced AAV serotype promoter
sequence will replace an initially present AAV serotype promoter
sequence. In other embodiments, the introduced AAV serotype
promoter sequence will be present in addition to such initially
present AAV serotype promoter sequence, and will be positioned 5'
to, or 3' to, such initially present AAV serotype promoter
sequence. The introduced nucleotide sequence may be positioned
adjacent to, or apart from, such initially present AAV serotype
promoter sequence.
[0108] The substitution or addition of one or more of such AAV
serotype promoter sequences invention increases rAAV production
titers. As used herein, the term "production titer" is intended to
denote the amount of concentration of infectious rAAV in a
preparation. Such amounts or concentrations are preferably
determined by titering the AAV or rAAV in such preparation. The
production titers of the rAAV preparations of the present invention
are preferably titered after subjecting producing cells (e.g.,
HEK293 transformed with an rAAV plasmid vector, an AAV helper
vector providing Rep and Cap proteins, and an Ad helper vector
providing required adenovirus transcription and translation
factors) to three rounds of freeze/thawing, followed by sonication
to release the rAAV particles. The preparation is then centrifuged.
The employed AAV helper vector is localized to the supernatant. An
aliquot of the preparation is treated with proteinase K, and the
number of AAV genomes is determined. An aliquot of the preparation
is infected into HeLa-32C2 cells (which express AAV2 Rep and Cap
proteins), and infectious titer is measured using the infectious
center assay (ICA) (Francois, A. et al. (2018) "Accurate Titration
of Infectious AAV Particles Requires Measurement of Biologically
Active Vector Genomes and Suitable Controls," Molec. Ther. Meth.
Clin. Develop. 10:223-236) or more preferably, as the median tissue
culture infective dose (TCID50) (Zen, Z. et al. (2004) "Infectious
Titer Assay For Adeno Associated Virus Vectors With Sensitivity
Sufficient To Detect Single Infectious Events," Hum. Gene Ther.
15:709-715).
[0109] As used herein, an rAAV production titer is said to be
"increased" by the methods of the present invention if the
production titer obtained from the use of the methods of the
present invention is at least 10% greater, more preferably at least
20% greater, still more preferably at least 30% greater, still more
preferably at least 40% greater, still more preferably at least 50%
greater, still more preferably at least 60% greater, still more
preferably at least 70% greater, still more preferably at least 80%
greater, still more preferably at least 90% greater, still more
preferably at least 2-fold greater, still more preferably at least
110% greater, still more preferably at least 120% greater, still
more preferably at least 130% greater, still more preferably at
least 140% greater, still more preferably at least 2.5-fold
greater, still more preferably at least 160% greater, still more
preferably at least 170% greater, still more preferably at least
180% greater, still more preferably at least 190% greater, and
still more preferably at least 3-fold greater than the titer
obtained from a similarly conducted production in which the
additionally provided ions were not provided.
[0110] The rAAV whose production titer may be increased using the
methods of the present invention may comprise any transgene
cassette that permits the rAAV to be packaged into an rAAV plasmid
vector that may be encapsidated within an AAV capsid particle.
Without limitation, such transgene cassette(s) may be of human,
primate (including chimpanzee, gibbon, gorilla, orangutan, etc.),
cercopithecine (including baboon, cynomolgus monkey, velvet monkey,
etc.), canine, glirine (including rat, mouse, hamster, guinea pig,
etc.) , feline, ovine, caprine, or equine origin.
[0111] In preferred embodiments, such an rAAV or rAAV plasmid
vector will encode a protein (e.g., an enzyme, hormone, antibody,
receptor, ligand, etc.), or comprise a transcribed nucleic acid,
that is relevant to a genetic or heritable disease or condition,
such that it may be used in gene therapy to treat such disease or
condition.
[0112] The methods of the present invention may be used to increase
the production titer of rAAV and rAAV plasmid vectors in cells that
have been additionally transfected with: [0113] (1) an AAD helper
vector possessing a non-native AAV serotype promoter sequence and
capable of expressing proteins or RNA molecules that are not
natively provided by such rAAV or rAAV plasmid vectors, but are
required for their production. As discussed above, such proteins or
RNA molecules include the genes encoding the Rep52 and Rep78
proteins that are required for vector transcription control and
replication, and for the packaging of viral genomes into the viral
capsule, and cap genes that encode VP capsid proteins required to
form infectious particles; and [0114] (2) an Ad helper vector that
can provide the non-AAV helper proteins (e.g., E1a, E1b, E2a, VA
and E4) or RNA molecules that are not provided by such rAAV or rAAV
plasmid vectors, but are required for their production.
[0115] In one embodiment for producing the rAAV of the present
invention, all of such genes and RNA molecules are provided on the
same helper virus (or more preferably, helper vector) so as to
comprise, in concert with an rAAV, a double plasmid transfection
system. More preferably, however, for producing the rAAV of the
present invention, the AAV helper function-providing polynucleotide
that provides the required rep and cap genes and such non-native
AAV serotype promoter sequences are provided on a vector that is
separate from the vector that comprises the non-AAV helper
function-providing polynucleotide, so that such vectors or
plasmids, in concert with the rAAV, comprise a triple plasmid
transfection system.
[0116] The invention thus derives in part from the recognition that
the production of rAAV may be increased by causing the expression
of Rep and Cap proteins to be directed by promoter sequences that
are not native promoter sequences. Thus, by modifying a particular
rAAV to replace its native P5 and/or P40 AAV serotype promoter
sequence(s) with a non-native P5 and/or P40 AAV serotype promoter
sequence (or by incorporating a non-native P5 and/or P40 AAV
serotype promoter sequence into such rAAV), the methods of the
present invention may be employed to increase the production titer
of rAAV belonging to any serotype, including the AAV1, AAV2, AAV5,
AAV6, AAV7, AAV8, AAV9 and AAV10 serotypes, and including hybrid
serotypes (e.g., AAV2/5 and rAAV2/5, which is a hybrid of AAV
serotypes 2 and 5 and thus has the trophism of both such
serotypes).
[0117] The methods of the present invention may be employed to
increase the production titers of rAAV that are to be produced
using "helper" RNA or proteins provided by an adenovirus, a herpes
simplex virus, a cytomegalovirus, a vaccinia virus or a
papillomavirus.
[0118] The methods of the present invention may be employed to
increase the production titers of rAAV produced by cells in
adherent monolayer culture or in suspension culture, and may be
used with any method capable of producing rAAV. Preferably,
however, rAAV is produced by transfecting baby hamster kidney (BHK)
cells, or more preferably, human embryonic kidney (HEK) cells grown
in tissue culture with the plasmid vectors described above. The BHK
cell line BHK-21 (ATCC CCL-10), which lacks endogenous retroviruses
is a preferred BHK cell line. The HEK cell line HEK293 (ATCC
CRL-1573) and its derivatives, such as HEK293T (ATCC CRL-3216,
which is a highly transfectable derivative of the HEK293 cell line
into which the temperature-sensitive gene for SV40 T-antigen was
inserted) or HEK293T/17 (ATCC.RTM. CRL-11268, which was selected
for its ease of transfection) are particularly preferred. The
HEK293T/17 SF cell line (ATCC ACS-4500) is a derivative of the
293T/17 cell line (ATCC CRL-11268), adapted to serum-free medium
and suspension, and may be employed if desired.
[0119] The preferred base medium of the present invention for
culturing such cells is Eagle's Minimum Essential Medium (ATCC
Catalog No. 30-2003) or Dulbecco's Modified Eagle's Medium (DMEM;
Mediatech, Manassas, Va.). Fetal bovine serum (e.g., FBS; HyClone
Laboratories, South Logan, Utah) is added to a final concentration
of 10% in order to make the complete growth medium. Eagle's Minimum
Essential Medium and Dulbecco's Modified Eagle's Medium are complex
media that contain amino acids, vitamins, and optionally glucose,
in addition to various inorganic salts. The media differ in that
Dulbecco's modified Eagle's medium contains approximately four
times as much of the vitamins and amino acids present in the
original formula of Eagle's Minimum Essential Medium, and two to
four times as much glucose. Additionally, it contains iron in the
form of ferric sulfate and phenol red for pH indication (Yao, T et
al. (2017) "Animal-Cell Culture Media: History, Characteristics,
And Current Issues," Reproduc. Med. Biol. 16(2): 99-117).
[0120] Cells to be used for such transfection are preferably
passaged twice weekly to maintain them in exponential growth phase.
For small-scale transfections, an aliquot of, for example,
1.times.10.sup.6 HEK293 or BHK cells per well on a multi-well
plate, or 1.5.times.10.sup.7 HEK293 cells per 15-cm dish, may be
employed. For large-scale production HEK293 or BHK cells may be
collected from multiple confluent 15-cm plates, and split into two
10-layer cell stacks (Corning, Corning, N.Y.) containing 1 liter of
complete culturing medium. In one embodiment, such cells are grown
for 4 days in such medium before transfection. The day before
transfection, the two cell stacks may be trypsinized and the cells
(e.g., approximately 6.times.10.sup.8 cells) may be resuspended in
200 ml of medium. Preferably, the cells are allowed to attach for
24 hours before transfection. Confluency of the cell stacks may be
monitored using a Diaphot inverted microscope (Nikon, Melville,
N.Y.) from which the phase-contrast hardware had been removed in
order to accommodate the cell stack on the microscope stage.
[0121] In particular, the present invention thus provides a method
for increasing the production titer of a recombinantly-modified
adeno-associated virus (rAAV) that comprises a transgene cassette,
wherein the method comprises culturing cells that have been
transfected with: [0122] (1) the rAAV; [0123] (2) a
recombinantly-modified adeno-associated virus (AAV) helper vector
that comprises an AAV helper function-providing polynucleotide,
wherein such polynucleotide comprises a non-native AAV serotype P5
or P40 promoter sequence in replacement of, or in addition to, a
native AAV serotype promoter sequence; and [0124] (3) a vector that
comprises a non-AAV helper function-providing polynucleotide;
wherein the culturing is conducted in a culture medium under
conditions sufficient to permit the production of the rAAV, and
wherein the presence of the non-native AAV serotype P5 or P40
promoter sequence causes the cells to produce the rAAV at an
increased production titer relative to that which would be attained
if the AAV helper function-providing polynucleotide contained
native serotype P5 and P40 promoters.
[0125] The present invention further provides a method for
increasing the production titer of a recombinantly-modified
adeno-associated virus (rAAV) that comprises a transgene cassette,
wherein the method comprises culturing cells that have been
transfected with: [0126] (1) the rAAV; and [0127] (2) a
recombinantly-modified adeno-associated virus (AAV) helper vector
that comprises: [0128] (a) an AAV helper function-providing
polynucleotide, wherein such polynucleotide comprises a non-native
AAV serotype P5 or P40 promoter sequence in replacement of, or in
addition to, a native AAV serotype promoter sequence; and [0129]
(b) a non-AAV helper function-providing polynucleotide; wherein the
culturing is conducted in a culture medium under conditions
sufficient to permit the production of the rAAV, and wherein the
presence of the non-native AAV serotype P5 or P40 promoter sequence
causes the cells to produce the rAAV at an increased production
titer relative to that which would be attained if the AAV helper
function-providing polynucleotide contained native serotype P5 and
P40 promoters.
[0130] In preferred embodiments, the transgene cassette of such
rAAV encodes a protein, or comprises a transcribed nucleic acid,
that is therapeutic for a genetic or heritable disease or
condition.
[0131] II. Pharmaceutical Compositions of the Present Invention
[0132] The invention additionally includes pharmaceutical
compositions that comprise a pharmaceutically acceptable
preparation of rAAV produced in accordance with the methods of the
present invention, and a pharmaceutically acceptable carrier. The
rAAV of such pharmaceutical compositions comprises a transgene
cassette that encodes a protein, or comprises a transcribed nucleic
acid, that is therapeutic for a genetic or heritable disease or
condition, and is present in such pharmaceutical composition in an
amount effective to ("effective amount")
[0133] The term "pharmaceutically acceptable" means approved by a
regulatory agency of the Federal or a state government or listed in
the U.S. Pharmacopeia or other generally recognized pharmacopeia
for use in animals, and more particularly in humans. The term
"carrier" refers to a diluent, adjuvant (e.g., Freund's adjuvant
complete and incomplete), excipient, or vehicle with which the
therapeutic is administered. Such pharmaceutical carriers can be
sterile liquids, such as water and oils, including those of
petroleum, animal, vegetable or synthetic origin, such as peanut
oil, soybean oil, mineral oil, sesame oil and the like. Water is a
preferred carrier when the pharmaceutical composition is
administered intravenously. Saline solutions and aqueous dextrose
and glycerol solutions can also be employed as liquid carriers,
particularly for injectable solutions. Suitable pharmaceutical
excipients include starch, glucose, lactose, sucrose, gelatin,
malt, rice, flour, chalk, silica gel, sodium stearate, glycerol
monostearate, talc, sodium chloride, dried skim milk, glycerol,
propylene, glycol, water, ethanol and the like. The composition, if
desired, can also contain minor amounts of wetting or emulsifying
agents, or pH buffering agents. These compositions can take the
form of solutions, suspensions, emulsion, tablets, pills, capsules,
powders, sustained-release formulations and the like. Suitable
pharmaceutical excipients are described in U.S. Pat. Nos.
8,852,607; 8,192,975; 6,764,845; 6,759,050; and 7,598,070.
[0134] Generally, the ingredients of compositions of the invention
are supplied either separately or mixed together in unit dosage
form, for example, as a dry lyophilized powder or water-free
concentrate, or as an aqueous solution in a hermetically sealed
container such as a vial, an ampoule or sachette indicating the
quantity of active agent. Where the composition is to be
administered by infusion, it can be dispensed with an infusion
bottle containing sterile pharmaceutical grade water or saline.
Where the composition is administered by injection, an ampoule of
sterile water for injection or saline, or other diluent can be
provided so that the ingredients may be mixed prior to
administration.
[0135] The invention also provides a pharmaceutical pack or kit
comprising one or more containers such pharmaceutical composition.
Optionally associated with such container(s) can be a notice in the
form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceuticals or biological products,
which notice reflects approval by the agency of manufacture, use or
sale for human administration.
[0136] The rAAV of such pharmaceutical compositions is preferably
packaged in a hermetically sealed container, such as a vial, an
ampoule or sachette indicating the quantity of the molecule, and
optionally including instructions for use. In one embodiment, the
rAAV of such kit is supplied as a dry sterilized lyophilized powder
or water-free concentrate in a hermetically sealed container and
can be reconstituted, e.g., with water, saline, or other diluent to
the appropriate concentration for administration to a subject. The
lyophilized material should be stored at between 2.degree. C. and
8.degree. C. in their original container and the material should be
administered within 12 hours, preferably within 6 hours, within 5
hours, within 3 hours, or within 1 hour after being reconstituted.
In another embodiment, the rAAV of such kit is supplied as an
aqueous solution in a hermetically sealed container and can be
diluted, e.g., with water, saline, or other diluent, to the
appropriate concentration for administration to a subject. The kit
can further comprise one or more other prophylactic and/or
therapeutic agents useful for the treatment of the disease or
condition, in one or more containers; and/or the kit can further
comprise one or more cytotoxic antibodies that bind one or more
cancer antigens associated with cancer. In certain embodiments, the
other prophylactic or therapeutic agent is a chemotherapeutic. In
other embodiments, the prophylactic or therapeutic agent is a
biological or hormonal therapeutic.
[0137] III. Uses of the Invention
[0138] The methods of the present invention may be used to
facilitate the production of rAAV, and may particularly be used to
facilitate the production of rAAV that comprise transgene cassettes
that encode a protein (e.g., an enzyme, hormone, antibody,
receptor, ligand, etc.), or of rAAV that comprise a transcribed
nucleic acid, that is relevant to a genetic or heritable disease or
condition, such that it may be used in gene therapy to treat such
disease or condition. Examples of such diseases and conditions
include: achromatopsia (ACHM); alpha-1 antitrypsin (AAT)
deficiency; Alzheimer's Disease; aromatic L-amino acid
decarboxylase (AADC) deficiency; choroideremia (CHM); cancer;
Duchenne muscular dystrophy; dysferlin deficiency; follistatin gene
deficiency (BMDSIBM); hemophilia A; hemophilia B; hepatitis A;
hepatitis B; hepatitis C; Huntington's disease; idiopathic
Parkinson's disease; late-infantile neuronal ceroid lipofuscinosis
(LINCL, an infantile form of Batten disease); Leber congenital
amaurosis (LCA); Leber' s hereditary optic neuropathy (LHON); limb
girdle muscular dystrophy 1B (LGMD1B); limb girdle muscular
dystrophy 1C (LGMD1C); limb girdle muscular dystrophy 2A (LGMD2A);
limb girdle muscular dystrophy 2B (LGMD2B); limb girdle muscular
dystrophy 2I (LGMD2I); limb girdle muscular dystrophy 2L (LGMD2L);
lipoprotein lipase (LPL) deficiency; metachromatic leukodystrophy;
neurological disability; neuromotor deficit; neuroskeletal
impairment; Parkinson's disease; rheumatoid arthritis; Sanfilippo A
syndrome; spinal muscular atrophy (SMA); X-linked retinoschisis
(XLRS); .alpha.-sarcoglycan deficiency (LGMD2D); .beta.-sarcoglycan
deficiency (LGMD2E); .gamma.-sarcoglycan deficiency (LGMD2C) and
.delta.-sarcoglycan deficiency (LGMD2F).
IV. Embodiments of the Invention
[0139] The invention concerns a recombinantly-modified
adeno-associated virus (AAV) helper vector that comprises an AAV
helper function-providing polynucleotide, and uses and compositions
thereof. It is particularly directed to the following embodiments
E1-E16: [0140] E1. A recombinantly-modified adeno-associated virus
(AAV) helper vector that comprises an AAV helper function-providing
polynucleotide, wherein the polynucleotide comprises a non-native
AAV serotype P5 or P40 promoter sequence. [0141] E2. The
recombinantly-modified adeno-associated virus (AAV) helper vector
of E1, wherein the AAV helper function-providing polynucleotide
vector comprises a non-native AAV serotype P5 promoter sequence.
[0142] E3. The recombinantly-modified adeno-associated virus (AAV)
helper vector of any one of E1 or E2, wherein the AAV helper
function-providing polynucleotide vector comprises a non-native AAV
serotype P40 promoter sequence. [0143] E4. The
recombinantly-modified adeno-associated virus (AAV) helper vector
of any one of E1-E3, wherein the vector is a plasmid vector. [0144]
E5. The recombinantly-modified adeno-associated virus (AAV) helper
vector of E1, wherein the non-native AAV serotype P5 or P40
promoter sequence replaces a native AAV serotype promoter sequence.
[0145] E6. The recombinantly-modified adeno-associated virus (AAV)
helper vector of any one of E1-E5, wherein the vector additionally
comprises a non-AAV helper function-providing polynucleotide.
[0146] E7. A method for increasing the production titer of a
recombinantly-modified adeno-associated virus (rAAV) that comprises
a transgene cassette, wherein the method comprises culturing cells
that have been transfected with: [0147] (1) the rAAV; [0148] (2)
the recombinantly-modified adeno-associated virus (AAV) helper
vector of E6; [0149] wherein the culturing is conducted in a
culture medium under conditions sufficient to permit the production
of the rAAV and wherein the presence of the non-native AAV serotype
P5 or P40 promoter sequence causes the cells to produce the rAAV at
an increased production titer relative to that which would be
attained if the AAV helper function-providing polynucleotide
contained native serotype P5 and P40 promoters. [0150] E8. A method
for increasing the production titer of a recombinantly-modified
adeno-associated virus (rAAV) that comprises a transgene cassette,
wherein the method comprises culturing cells that have been
transfected with: [0151] (1) the rAAV; [0152] (2) the
recombinantly-modified adeno-associated virus (AAV) helper vector
of any one of E1-E6; and [0153] (3) an additional vector,
especially a plasmid vector, that comprises a non-AAV helper
function-providing polynucleotide; wherein the culturing is
conducted in a culture medium under conditions sufficient to permit
the production of the rAAV, and wherein the presence of the
non-native AAV serotype P5 or P40 promoter sequence causes the
cells to produce the rAAV at an increased production titer relative
to that which would be attained if the AAV helper
function-providing polynucleotide contained native serotype P5 and
P40 promoters. [0154] E9. The method of any one of E7-E8, wherein:
[0155] (A) the AAV helper function-providing polynucleotide of the
vector encodes an AAV1 Cap protein, and the non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of
the serotypes; [0156] (B) the AAV helper function-providing
polynucleotide of the vector encodes an AAV2 Cap protein, and the
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6, AAV7 or AAV8, or a
hybrid of one or more of the serotypes; 7 [0157] (C) the AAV helper
function-providing polynucleotide of the vector encodes an AAV3 Cap
protein, and the non-native AAV serotype promoter sequence is a
promoter sequence of an AAV of serotype AAV1, AAV4, AAV5, AAV6,
AAV7 or AAV8, or a hybrid of one or more of the serotypes; [0158]
(D) the AAV helper function-providing polynucleotide of the vector
encodes an AAV4 Cap protein, and the non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV5, AAV6, AAV7 or AAV8, or a hybrid of one or more of
the serotypes; [0159] (E) the AAV helper function-providing
polynucleotide of the vector encodes an AAV5 Cap protein, and the
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV3, AAV4, AAV6, AAV7 or AAV8, or a
hybrid of one or more of the serotypes; [0160] (F) the AAV helper
function-providing polynucleotide of the vector encodes an AAV6 Cap
protein, and the non-native AAV serotype promoter sequence is a
promoter sequence of an AAV of serotype AAV1, AAV3, AAV4, AAV5,
AAV7 or AAV8, or a hybrid of one or more of the serotypes; [0161]
(G) the AAV helper function-providing polynucleotide of the vector
encodes an AAV7 Cap protein, and the non-native AAV serotype
promoter sequence is a promoter sequence of an AAV of serotype
AAV1, AAV3, AAV4, AAV5, AAV6 or AAV8, or a hybrid of one or more of
the serotypes; or [0162] (H) the AAV helper function-providing
polynucleotide of the vector encodes an AAV8 Cap protein, and the
non-native AAV serotype promoter sequence is a promoter sequence of
an AAV of serotype AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7, or a
hybrid of one or more of the serotypes. [0163] E10. The method of
any one of E7-E9, wherein the cells are human embryonic kidney
cells, baby hamster kidney cells or sf9 insect cells. [0164] E11.
The method of E10, wherein the cells are HEK293 human embryonic
kidney cells. [0165] E12. The method of E10, wherein the cells are
BHK21 baby hamster kidney cells. [0166] E13. The method of any one
of E7-E12, wherein the transgene cassette encodes a protein, or
comprises a transcribed nucleic acid, that is therapeutic for a
genetic or heritable disease or condition. [0167] E14. A
preparation of the recombinantly-modified adeno-associated virus
(rAAV) produced by the method of E13. [0168] E15. A pharmaceutical
composition that comprises the recombinantly-modified
adeno-associated virus (rAAV) produced by the method of E13, and a
pharmaceutically acceptable carrier. [0169] E16. The preparation of
recombinantly-modified adeno-associated virus (rAAV) of E14, or the
pharmaceutical composition of E15, for use in the treatment of the
genetic or heritable disease or condition.
EXAMPLES
[0170] Having now generally described the invention, the same will
be more readily understood through reference to the following
examples, which are provided by way of illustration and are not
intended to be limiting of the present invention unless
specified.
Example 1
Comparison Of rAAV Production Titers By Cells Transfected With AAV
RC2 Helper Plasmid Vectors Having A Non-Native AAV Serotype P5
Promoter Sequence
[0171] In order to demonstrate the ability of non-native AAV
serotype promoter sequences to affect the production titer of rAAV,
derivatives of AAV helper plasmid AAV RC2 (having an AAV2 rep gene
and a cap gene that encodes Cap protein of the AAV2 serotype) were
constructed that comprised a non-native AAV serotype promoter
sequence (FIG. 11) in lieu of the native AAV2 serotype P5 promoter
of such plasmid (FIG. 12A; downward striped rectangle). The P19 and
P40 promoters of the constructs were not changed, and thus were
both native AAV2 serotype promoter sequences (FIG. 12A; solid black
rectangles).
[0172] The following constructs were employed; the sequences of the
promoter regions are shown in Table 1: [0173] (1)
Parent-RC2--pAAV-RC2 (SEQ ID NO:2), which contains the AAV2 rep
gene and a partial portion of the full AAV2 serotype P5 promoter
sequence (SEQ ID NO:10), and the AAV2 cap gene, whose expression is
controlled by a native AAV2 P40 promoter sequence (SEQ ID NO:18);
[0174] (2) P5(1)-RC2--a derivative of plasmid vector pAAV-RC2 in
which native AAV serotype P5 promoter sequences had been replaced
with the P5 promoter sequences of AAV serotype 1 (SEQ ID NO:9);
[0175] (3) P5(2)-RC2--a derivative of plasmid vector pAAV-RC2 in
which the partial AV2 serotype P5 promoter sequences of Parent-RC2
had been replaced with the full-length P5 promoter sequences of AAV
serotype 2 (SEQ ID NO:10); [0176] (4) P5(3)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter
sequences had been replaced with the P5 promoter sequences of AAV
serotype 3 (SEQ ID NO:11); [0177] (5) P5(4)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter
sequences had been replaced with the P5 promoter sequences of AAV
serotype 4 (SEQ ID NO:12); [0178] (6) P5(5)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter
sequences had been replaced with the P5 promoter sequences of AAV
serotype 5 (SEQ ID NO:13); [0179] (7) P5(6)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter
sequences had been replaced with the P5 promoter sequences of AAV
serotype 6 (SEQ ID NO:14); [0180] (8) P5(7)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter
sequences had been replaced with the P5 promoter sequences of AAV
serotype 7 (SEQ ID NO:15); and [0181] (9) P5(8)-RC2--a derivative
of plasmid vector pAAV-RC2 in which native AAV2 serotype P5
promoter sequences had been replaced with the P5 promoter sequences
of AAV serotype 8 (SEQ ID NO:16).
[0182] FIG. 12B shows the production titers of rAAV obtained using
such AAV helper plasmid vectors. The production titers of rAAV were
obtained using a triple plasmid transfection system with an rAAV
(pGOI; BBa K404119), and an Ad helper plasmid (pHelper) that
provided the required adenoviral functions. Plasmid pGOI is an rAAV
plasmid vector that comprises, in the 5' to 3' direction, a 5' ITR,
a CMV promoter, a .beta.-globin intron, a polynucleotide encoding
the yellow fluorescent protein mVenus (Nagai, T. et al. (2002) "A
Variant Of Yellow Fluorescent Protein With Fast And Efficient
Maturation For Cell-Biological Applications," Nat. Biotechnol.
20(1):87-90), the polyA domain of human growth hormone and a 3'
ITR. FIG. 12B reveals that the serotype of the P5 promoter affects
rAAV production titers, and indicates that replacing the native
AAV2 P5 promoter of the plasmid vector pAAV-RC2 with an AAVS
serotype P5 promoter greatly decreased rAAV production titer,
whereas replacing the native AAV2 P5 promoter of the plasmid vector
pAAV-RC2 with a P5 promoter of AAV serotype 1, 3, 5, 7 or 8 greatly
increased rAAV production titer.
Example 2
Comparison Of rAAV Production Titers By Cells Transfected With AAV
RC2 Helper Plasmid Vectors Having A Non-Native AAV Serotype P40
Promoter Sequence
[0183] In order to further demonstrate the ability of non-native
AAV serotype promoter sequences to affect the production titer of
rAAV, derivatives of AAV helper uplasmid AAV RC2 (having an AAV2
rep gene and a cap gene that encodes Cap protein of the AAV2
serotype) were constructed that comprised a non-native AAV serotype
promoter sequence (FIG. 11) in lieu of the native serotype P40
promoter of such plasmid (FIG. 13A; upward striped rectangle). The
P5 and P19 promoters of the constructs were not changed, and thus
were both native AAV2 serotype promoter sequences (FIG. 13A; solid
black rectangles).
[0184] The following constructs were employed; the sequences of the
promoter regions are shown in Table 1: [0185] (1)
Parent-RC2--pAAV-RC2 (SEQ ID NO:2), which contains the AAV2 rep
gene and a partial portion of the full AAV2 serotype P5 promoter
sequence (SEQ ID NO:10), and the AAV2 cap gene, whose expression is
controlled by a native AAV2 P40 promoter sequence (SEQ ID NO:18);
[0186] (2) P40(1)-RC2--a derivative of plasmid vector pAAV-RC2 in
which native AAV2 serotype P40 promoter sequences had been replaced
with the P40 promoter sequences of AAV serotype 1 (SEQ ID NO:17);
[0187] (3) P40(2)-RC2--a derivative of plasmid vector pAAV-RC2 in
which the AAV2 serotype P40 promoter sequences of Parent-RC2 had
been replaced with the P40 promoter sequences of AAV serotype 2
(SEQ ID NO:18); [0188] (4) P40(3)-RC2--a derivative of plasmid
vector pAAV-RC2 in which native AAV2 serotype P40 promoter
sequences had been replaced with the P40 promoter sequences of AAV
serotype 3 (SEQ ID NO:19); [0189] (5) P40(4)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter
sequences had been replaced with the P40 promoter sequences of AAV
serotype 4 (SEQ ID NO:20); [0190] (6) P40(5)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter
sequences had been replaced with the P40 promoter sequences of AAV
serotype 5 (SEQ ID NO:21); [0191] (7) P40(6)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter
sequences had been replaced with the P40 promoter sequences of AAV
serotype 6 (SEQ ID NO:22); [0192] (8) P40(7)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P40 promoter
sequences had been replaced with the P40 promoter sequences of AAV
serotype 7 (SEQ ID NO:23); and [0193] (9) P40(8)-RC2--a derivative
of plasmid vector pAAV-RC2 in which native AAV2 serotype P40
promoter sequences had been replaced with the P40 promoter
sequences of AAV serotype 8 (SEQ ID NO:24).
[0194] FIG. 13B shows the production titers of rAAV obtained using
such AAV helper plasmid vectors. Production titers of rAAV were
obtained essentially as described in Example 1. The results of the
investigation reveal that the serotype of the P40 promoter also
affects rAAV production titers, and indicate that replacing the
native AAV2 P40 promoter of the plasmid vector pAAV-RC2 with an
AAV5 serotype P40 promoter greatly decreased rAAV production titer,
whereas replacing the native AAV2 P40 promoter of the plasmid
vector pAAV-RC2 with an AAV1 serotype P40 promoter or with an AAV8
serotype P40 promoter greatly increased rAAV production titer.
Example 3
Comparison Of rAAV Production Titers By Cells Transfected With AAV
RC2 Helper Plasmid Vectors Having Non-Native AAV Serotype P5 and
P40 Promoter Sequences
[0195] In order to further demonstrate the ability of non-native
AAV serotype promoter sequences to affect the production titer of
rAAV, derivatives of AAV helper plasmid AAV RC2 (having an AAV2 rep
gene and a cap gene that encodes Cap protein of the AAV2 serotype)
were constructed that comprised non-native AAV serotype promoter
sequences (FIG. 11) in lieu of the native AAV2 serotype P5 (FIG.
14A; downward striped rectangle) and P40 (FIG. 14A; upward striped
rectangle) promoters of such plasmid. The AAV2 P19 promoter of the
constructs were not changed, and thus was the native AAV2 serotype
promoter sequence (FIG. 14A; solid black rectangle).
[0196] The following constructs were employed; the sequences of the
promoter regions are shown in Table 1: [0197] (1)
Parent-RC2--pAAV-RC2 (SEQ ID NO:2), which contains the AAV2 rep
gene and a partial portion of the full AAV2 serotype P5 promoter
sequence (SEQ ID NO:10), and the AAV2 cap gene, whose expression is
controlled by a native AAV2 P40 promoter sequence (SEQ ID NO:18);
[0198] (2) P5(2)-RC2--a derivative of plasmid vector pAAV-RC2 in
which the partial
[0199] AAV2 serotype P5 promoter sequences of Parent-RC2 had been
replaced with the full-length P5 promoter sequences of AAV serotype
2 (SEQ ID NO:10); [0200] (3) P5(3)-RC2--a derivative of plasmid
vector pAAV-RC2 in which native AAV2 serotype P5 promoter sequences
had been replaced with the P5 promoter sequence of AAV3 (SEQ ID
NO:11); [0201] (4) P5(5)-RC2--a derivative of plasmid vector
pAAV-RC2 in which native AAV2 serotype P5 promoter sequences had
been replaced with the P5 promoter sequence of AAV5 (SEQ ID NO:13);
[0202] (5) P40(1)-RC2--a derivative of plasmid vector pAAV-RC2 in
which native AAV2 serotype P40 promoter sequences had been replaced
with the P40 promoter sequence of AAV1 (SEQ ID NO:17); [0203] (6)
P5(2)/P40(1)-RC2--a derivative of plasmid vector pAAV-RC2 in which
native AAV2 serotype P5 promoter sequences had been replaced with
the P5 promoter sequence of AAV2 (SEQ ID NO:10) and in which native
P40 promoter sequences had been replaced with the P40 promoter
sequence of AAV1 (SEQ ID NO:17); [0204] (7) P5(3)/P40(1)-RC2--a
derivative of plasmid vector pAAV-RC2 in which native AAV2 serotype
P5 promoter sequences had been replaced with the P5 promoter
sequence of AAV3 (SEQ ID NO:11) and in which native P40 promoter
sequences had been replaced with the P40 promoter sequence of AAV1
(SEQ ID NO:17); and [0205] (8) P5(5)/P40(1)-RC2--a derivative of
plasmid vector pAAV-RC2 in which native AAV2 serotype P5 promoter
sequences had been replaced with the P5 promoter sequence of AAV5
(SEQ ID NO:13) and in which native P40 promoter sequences had been
replaced with the P40 promoter sequence of AAV1 (SEQ ID NO:17).
[0206] Production titers of rAAV were obtained essentially as
described in Example 1. FIG. 14B shows the production titers of
rAAV obtained using such AAV helper plasmid vectors. As shown in
FIG. 14B, the replacement of the native P5 and P40 promoters of
pAAV-RC2 with the P5 promoter sequence of AAV3 or AAV5 and the P40
promoter sequence of AAV1 synergistically increased rAAV production
titers.
Example 4
Comparison Of rAAV Production Titers By Cells Transfected With AAV
RC6 Helper Plasmid Vectors Having Non-Native AAV Serotype P5 and
P40 Promoter Sequences
[0207] In order to further demonstrate the ability of non-native
AAV serotype promoter sequences to affect the production titer of
rAAV, derivatives of AAV helper plasmid AAV RC6 (having an AAV2 rep
gene and a cap gene that encodes Cap protein of the AAV6 serotype)
were constructed that comprised non-native AAV serotype promoter
sequences (FIG. 11) in lieu of the native AAV2 serotype P5 (FIG.
15A; downward striped rectangle) and P40 (FIG. 15A; downward
striped rectangle) promoters of such plasmid. The AAV2 P19 promoter
of the constructs were not changed, and thus was the native AAV2
serotype promoter sequence (FIG. 15A; solid black rectangle).
[0208] The following constructions were employed; the sequences of
the promoter regions are shown in Table 1: [0209] (1)
Parent-RC6--pAAV-RC6 (SEQ ID NO:4), which contains the AAV2 rep
gene and its native AAV2 serotype P5 promoter sequence (SEQ ID
NO:10), and the AAV6 cap gene, whose expression is controlled by a
native AAV2 P40 promoter sequence (SEQ ID NO:18); [0210] (2)
P5(1)-RC6--a derivative of plasmid vector pAAV-RC6 in which native
AAV2 serotype P5 promoter sequences had been replaced with the P5
promoter sequence of AAV1 (SEQ ID NO:9); [0211] (3) P5(2)-RC6--a
derivative of plasmid vector pAAV-RC6 in which native AAV2 serotype
P5 promoter sequences had been replaced with the P5 promoter
sequence of AAV2 (SEQ ID NO:10); [0212] (4) P5(3)-RC6--a derivative
of plasmid vector pAAV-RC6 in which native AAV2 serotype P5
promoter sequences had been replaced with the P5 promoter sequence
of AAV3 (SEQ ID NO:11); [0213] (5) P5(7)-RC6--a derivative of
plasmid vector pAAV-RC6 in which native AAV2 serotype P5 promoter
sequences had been replaced with the P5 promoter sequence of AAV7
(SEQ ID NO:15); and [0214] (6) P5(8)-RC6--a derivative of plasmid
vector pAAV-RC6 in which native AAV2 serotype P5 promoter sequences
had been replaced with the P5 promoter sequence of AAV8 (SEQ ID
NO:16).
[0215] FIG. 15B shows the production titers of rAAV obtained using
such AAV helper plasmid vectors. Production titers of rAAV were
obtained essentially as described in Example 1.
[0216] The results of the investigation are shown in FIGS. 15B and
15C, and reveal that the production titers of rAAV obtained using
such AAV helper plasmid vectors. As shown in such Figures, the
replacement of the native P5 and P40 promoters of pAAV-RC6 with the
P5 promoter sequence of AAV serotype 1, 2, 3, 7 or 8 increased rAAV
production titers.
Example 5
Comparison Of rAAV Production Titers By Cells Transfected With AAV
RC1, AAV RC5 or AAV RC7 Helper Plasmid Vectors Having Non-Native
AAV Serotype P5 and P40 Promoter Sequences
[0217] In order to further demonstrate the ability of non-native
AAV serotype promoter sequences to affect the production titer of
rAAV, derivatives of AAV helper plasmid AAV RC1 (having an AAV2 rep
gene and a cap gene that encodes Cap protein of the AAV1 serotype),
derivatives of AAV helper plasmid AAV RCS (having an AAV2 rep gene
and a cap gene that encodes Cap protein of the AAVS serotype) and
derivatives of AAV helper plasmid AAV RC7 (having an AAV2 rep gene
and a cap gene that encodes Cap protein of the AAV7 serotype) were
constructed that comprised non-native AAV serotype promoter
sequences (FIG. 11) in lieu of the native AAV2 serotype P5 (FIG.
16A; downward striped rectangle) and/or P40 (FIG. 16A; upward
striped rectangle) promoter sequences of such plasmids.
[0218] The following constructions were employed; the sequences of
the promoter regions are shown in Table 1: [0219] (1)
Parent-RC1--pAAV-RC1 (SEQ ID NO:1), which contains the AAV2 rep
gene and its native AAV2 serotype P5 promoter sequence (SEQ ID
NO:10), and the AAV1 cap gene, whose expression is controlled by a
native AAV2 P40 promoter sequence (SEQ ID NO:18); [0220] (2)
Parent-RC5--pAAV-RC5 (SEQ ID NO:3), which contains the AAV2 rep
gene and its native AAV2 serotype P5 promoter sequence (SEQ ID
NO:10), and the AAV5 cap gene, whose expression is controlled by a
native AAV2 P40 promoter sequence (SEQ ID NO:18); [0221] (3)
Parent-RC7--pAAV-RC7 (SEQ ID NO:5), which contains the AAV2 rep
gene and its native AAV2 serotype P5 promoter sequence (SEQ ID
NO:10), and the AAV7 cap gene, whose expression is controlled by a
native AAV2 P40 promoter sequence (SEQ ID NO:18); [0222] (4)
P5(2)-RC1-- a derivative of plasmid vector pAAV-RC1 in which native
AAV1 serotype P5 promoter sequences had been replaced with the P5
promoter sequence of AAV2 (SEQ ID NO:10); [0223] (5) P5(7)-RC1-- a
derivative of plasmid vector pAAV-RC1 in which native AAV1 serotype
P5 promoter sequences had been replaced with the P5 promoter
sequence of AAV7 (SEQ ID NO:15); [0224] (6) P5(8)-RC1-- a
derivative of plasmid vector pAAV-RC1 in which native AAV1 serotype
P5 promoter sequences had been replaced with the P5 promoter
sequence of AAV8 (SEQ ID NO:16); [0225] (7) P5(7)-RC5--a derivative
of plasmid vector pAAV-RC5 in which native AAV5 serotype P5
promoter sequences had been replaced with the P5 promoter sequence
of AAV7 (SEQ ID NO:15); [0226] (8) P5(2)-RC7--a derivative of
plasmid vector pAAV-RC7 in which native AAV7 serotype P5 promoter
sequences had been replaced with the P5 promoter sequence of AAV2
(SEQ ID NO:10). [0227] (9) P5(7)-RC7--a derivative of plasmid
vector pAAV-RC7 in which native AAV7 serotype P5 promoter sequences
had been replaced with the P5 promoter sequence of AAV7 (SEQ ID
NO:15); and [0228] (10) P5(8)-RC7--a derivative of plasmid vector
pAAV-RC7 in which native AAV7 serotype P5 promoter sequences had
been replaced with the P5 promoter sequence of AAV8 (SEQ ID
NO:16).
[0229] Production titers of rAAV were obtained essentially as
described in Example 1. The results of the investigation are shown
in FIG. 16B, and reveals that the replacement of the native P5
promoter sequences of pAAV-RC1, pAAV-RCS, and pAAV-RC7 with P5
promoter sequence of AAV serotype 2, 7 or 8 increased rAAV
production titers.
[0230] All publications and patents mentioned in this specification
are herein incorporated by reference to the same extent as if each
individual publication or patent application was specifically and
individually indicated to be incorporated by reference in its
entirety. While the invention has been described in connection with
specific embodiments thereof, it will be understood that it is
capable of further modifications and this application is intended
to cover any variations, uses, or adaptations of the invention
following, in general, the principles of the invention and
including such departures from the present disclosure as come
within known or customary practice within the art to which the
invention pertains and as may be applied to the essential features
hereinbefore set forth.
Sequence CWU 1
1
2417431DNAArtificial SequenceCoding Strand of Plasmid pAAV-RC1
1catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg
60cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg
120aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc
ccaaaaccca 180gcctgagctc cagtgggcgt ggactaatat ggaacagtat
ttaagcgcct gtttgaatct 240cacggagcgt aaacggttgg tggcgcagca
tctgacgcac gtgtcgcaga cgcaggagca 300gaacaaagag aatcagaatc
ccaattctga tgcgccggtg atcagatcaa aaacttcagc 360caggtacatg
gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg
420gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact
cgcggtccca 480aatcaaggct gccttggaca atgcgggaaa gattatgagc
ctgactaaaa ccgcccccga 540ctacctggtg ggccagcagc ccgtggagga
catttccagc aatcggattt ataaaatttt 600ggaactaaac gggtacgatc
cccaatatgc ggcttccgtc tttctgggat gggccacgaa 660aaagttcggc
aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa
720catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact
ggaccaatga 780gaactttccc ttcaacgact gtgtcgacaa gatggtgatc
tggtgggagg aggggaagat 840gaccgccaag gtcgtggagt cggccaaagc
cattctcgga ggaagcaagg tgcgcgtgga 900ccagaaatgc aagtcctcgg
cccagataga cccgactccc gtgatcgtca cctccaacac 960caacatgtgc
gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca
1020agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg
ggaaggtcac 1080caagcaggaa gtcaaagact ttttccggtg ggcaaaggat
cacgtggttg aggtggagca 1140tgaattctac gtcaaaaagg gtggagccaa
gaaaagaccc gcccccagtg acgcagatat 1200aagtgagccc aaacgggtgc
gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc 1260ttcgatcaac
tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct
1320gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata
tctgcttcac 1380tcacggacag aaagactgtt tagagtgctt tcccgtgtca
gaatctcaac ccgtttctgt 1440cgtcaaaaag gcgtatcaga aactgtgcta
cattcatcat atcatgggaa aggtgccaga 1500cgcttgcact gcctgcgatc
tggtcaatgt ggatttggat gactgcatct ttgaacaata 1560aatgatttaa
atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc
1620tctctgaggg cattcgcgag tggtgggact tgaaacctgg agccccgaag
cccaaagcca 1680accagcaaaa gcaggacgac ggccggggtc tggtgcttcc
tggctacaag tacctcggac 1740ccttcaacgg actcgacaag ggggagcccg
tcaacgcggc ggacgcagcg gccctcgagc 1800acgacaaggc ctacgaccag
cagctcaaag cgggtgacaa tccgtacctg cggtataacc 1860acgccgacgc
cgagtttcag gagcgtctgc aagaagatac gtcttttggg ggcaacctcg
1920ggcgagcagt cttccaggcc aagaagcggg ttctcgaacc tctcggtctg
gttgaggaag 1980gcgctaagac ggctcctgga aagaaacgtc cggtagagca
gtcgccacaa gagccagact 2040cctcctcggg catcggcaag acaggccagc
agcccgctaa aaagagactc aattttggtc 2100agactggcga ctcagagtca
gtccccgatc cacaacctct cggagaacct ccagcaaccc 2160ccgctgctgt
gggacctact acaatggctt caggcggtgg cgcaccaatg gcagacaata
2220acgaaggcgc cgacggagtg ggtaatgcct caggaaattg gcattgcgat
tccacatggc 2280tgggcgacag agtcatcacc accagcaccc gcacctgggc
cttgcccacc tacaataacc 2340acctctacaa gcaaatctcc agtgcttcaa
cgggggccag caacgacaac cactacttcg 2400gctacagcac cccctggggg
tattttgatt tcaacagatt ccactgccac ttttcaccac 2460gtgactggca
gcgactcatc aacaacaatt ggggattccg gcccaagaga ctcaacttca
2520aactcttcaa catccaagtc aaggaggtca cgacgaatga tggcgtcaca
accatcgcta 2580ataaccttac cagcacggtt caagtcttct cggactcgga
gtaccagctt ccgtacgtcc 2640tcggctctgc gcaccagggc tgcctccctc
cgttcccggc ggacgtgttc atgattccgc 2700aatacggcta cctgacgctc
aacaatggca gccaagccgt gggacgttca tccttttact 2760gcctggaata
tttcccttct cagatgctga gaacgggcaa caactttacc ttcagctaca
2820cctttgagga agtgcctttc cacagcagct acgcgcacag ccagagcctg
gaccggctga 2880tgaatcctct catcgaccaa tacctgtatt acctgaacag
aactcaaaat cagtccggaa 2940gtgcccaaaa caaggacttg ctgtttagcc
gtgggtctcc agctggcatg tctgttcagc 3000ccaaaaactg gctacctgga
ccctgttatc ggcagcagcg cgtttctaaa acaaaaacag 3060acaacaacaa
cagcaatttt acctggactg gtgcttcaaa atataacctc aatgggcgtg
3120aatccatcat caaccctggc actgctatgg cctcacacaa agacgacgaa
gacaagttct 3180ttcccatgag cggtgtcatg atttttggaa aagagagcgc
cggagcttca aacactgcat 3240tggacaatgt catgattaca gacgaagagg
aaattaaagc cactaaccct gtggccaccg 3300aaagatttgg gaccgtggca
gtcaatttcc agagcagcag cacagaccct gcgaccggag 3360atgtgcatgc
tatgggagca ttacctggca tggtgtggca agatagagac gtgtacctgc
3420agggtcccat ttgggccaaa attcctcaca cagatggaca ctttcacccg
tctcctctta 3480tgggcggctt tggactcaag aacccgcctc ctcagatcct
catcaaaaac acgcctgttc 3540ctgcgaatcc tccggcggag ttttcagcta
caaagtttgc ttcattcatc acccaatact 3600ccacaggaca agtgagtgtg
gaaattgaat gggagctgca gaaagaaaac agcaagcgct 3660ggaatcccga
agtgcagtac acatccaatt atgcaaaatc tgccaacgtt gattttactg
3720tggacaacaa tggactttat actgagcctc gccccattgg cacccgttac
cttacccgtc 3780ccctgtaagg cgcgccaccg gttgcttgtt aatcaataaa
ccgtttaatt cgtttcagtt 3840gaactttggt ctctgcgtat ttctttctta
tctagtttcc atgctctagg atccactagt 3900aacggccgcc agtgtgctgg
aattcggctt tgtagttaat gattaacccg ccatgctact 3960tatctacgta
gccatgctct agaggtcctg tattagaggt cacgtgagtg ttttgcgaca
4020ttttgcgaca ccatgtggtc acgctgggta tttaagcccg agtgagcacg
cagggtctcc 4080attttgaagc gggaggtttg aacgcgcagc cgccaagccg
aattctgcag atatccaaac 4140actggcggcc gctcgactag agcggccgcc
accgcggtgg agctccagct tttgttccct 4200ttagtgaggg ttaattgcgc
gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa 4260ttgttatccg
ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg
4320gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc
ccgctttcca 4380gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc
caacgcgcgg ggagaggcgg 4440tttgcgtatt gggcgctctt ccgcttcctc
gctcactgac tcgctgcgct cggtcgttcg 4500gctgcggcga gcggtatcag
ctcactcaaa ggcggtaata cggttatcca cagaatcagg 4560ggataacgca
ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa
4620ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc
acaaaaatcg 4680acgctcaagt cagaggtggc gaaacccgac aggactataa
agataccagg cgtttccccc 4740tggaagctcc ctcgtgcgct ctcctgttcc
gaccctgccg cttaccggat acctgtccgc 4800ctttctccct tcgggaagcg
tggcgctttc tcatagctca cgctgtaggt atctcagttc 4860ggtgtaggtc
gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg
4920ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg
acttatcgcc 4980actggcagca gccactggta acaggattag cagagcgagg
tatgtaggcg gtgctacaga 5040gttcttgaag tggtggccta actacggcta
cactagaaga acagtatttg gtatctgcgc 5100tctgctgaag ccagttacct
tcggaaaaag agttggtagc tcttgatccg gcaaacaaac 5160caccgctggt
agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg
5220atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga
acgaaaactc 5280acgttaaggg attttggtca tgagattatc aaaaaggatc
ttcacctaga tccttttaaa 5340ttaaaaatga agttttaaat caatctaaag
tatatatgag taaacttggt ctgacagtta 5400ccaatgctta atcagtgagg
cacctatctc agcgatctgt ctatttcgtt catccatagt 5460tgcctgactc
cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag
5520tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag
caataaacca 5580gccagccgga agggccgagc gcagaagtgg tcctgcaact
ttatccgcct ccatccagtc 5640tattaattgt tgccgggaag ctagagtaag
tagttcgcca gttaatagtt tgcgcaacgt 5700tgttgccatt gctacaggca
tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag 5760ctccggttcc
caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt
5820tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt
tatcactcat 5880ggttatggca gcactgcata attctcttac tgtcatgcca
tccgtaagat gcttttctgt 5940gactggtgag tactcaacca agtcattctg
agaatagtgt atgcggcgac cgagttgctc 6000ttgcccggcg tcaatacggg
ataataccgc gccacatagc agaactttaa aagtgctcat 6060cattggaaaa
cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag
6120ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt
tcaccagcgt 6180ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa
aagggaataa gggcgacacg 6240gaaatgttga atactcatac tcttcctttt
tcaatattat tgaagcattt atcagggtta 6300ttgtctcatg agcggataca
tatttgaatg tatttagaaa aataaacaaa taggggttcc 6360gcgcacattt
ccccgaaaag tgccacctaa attgtaagcg ttaatatttt gttaaaattc
6420gcgttaaatt tttgttaaat cagctcattt tttaaccaat aggccgaaat
cggcaaaatc 6480ccttataaat caaaagaata gaccgagata gggttgagtg
ttgttccagt ttggaacaag 6540agtccactat taaagaacgt ggactccaac
gtcaaagggc gaaaaaccgt ctatcagggc 6600gatggcccac tacgtgaacc
atcaccctaa tcaagttttt tggggtcgag gtgccgtaaa 6660gcactaaatc
ggaaccctaa agggagcccc cgatttagag cttgacgggg aaagccggcg
6720aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc
gctggcaagt 6780gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc
ttaatgcgcc gctacagggc 6840gcgtcccatt cgccattcag gctgcgcaac
tgttgggaag ggcgatcggt gcgggcctct 6900tcgctattac gccagctggc
gaaaggggga tgtgctgcaa ggcgattaag ttgggtaacg 6960ccagggtttt
cccagtcacg acgttgtaaa acgacggcca gtgagcgcgc gtaatacgac
7020tcactatagg gcgaattggg taccgggccc cccctcgagg tcgacggtat
cgggggagct 7080cgcagggtct ccattttgaa gcgggaggtt tgaacgcgca
gccgccatgc cggggtttta 7140cgagattgtg attaaggtcc ccagcgacct
tgacgagcat ctgcccggca tttctgacag 7200ctttgtgaac tgggtggccg
agaaggaatg ggagttgccg ccagattctg acatggatct 7260gaatctgatt
gagcaggcac ccctgaccgt ggccgagaag ctgcagcgcg actttctgac
7320ggaatggcgc cgtgtgagta aggccccgga ggctcttttc tttgtgcaat
ttgagaaggg 7380agagagctac ttccacatgc acgtgctcgt ggaaaccacc
ggggtgaaat c 743127415DNAArtificial SequenceCoding Strand of
Plasmid pAAV-RC2 2ccgggccccc cctcgaggtc gacggtatcg ggggagctcg
cagggtctcc attttgaagc 60gggaggtttg aacgcgcagc cgccatgccg gggttttacg
agattgtgat taaggtcccc 120agcgaccttg acgagcatct gcccggcatt
tctgacagct ttgtgaactg ggtggccgag 180aaggaatggg agttgccgcc
agattctgac atggatctga atctgattga gcaggcaccc 240ctgaccgtgg
ccgagaagct gcagcgcgac tttctgacgg aatggcgccg tgtgagtaag
300gccccggagg ctcttttctt tgtgcaattt gagaagggag agagctactt
ccacatgcac 360gtgctcgtgg aaaccaccgg ggtgaaatcc atggttttgg
gacgtttcct gagtcagatt 420cgcgaaaaac tgattcagag aatttaccgc
gggatcgagc cgactttgcc aaactggttc 480gcggtcacaa agaccagaaa
tggcgccgga ggcgggaaca aggtggtgga tgagtgctac 540atccccaatt
acttgctccc caaaacccag cctgagctcc agtgggcgtg gactaatatg
600gaacagtatt taagcgcctg tttgaatctc acggagcgta aacggttggt
ggcgcagcat 660ctgacgcacg tgtcgcagac gcaggagcag aacaaagaga
atcagaatcc caattctgat 720gcgccggtga tcagatcaaa aacttcagcc
aggtacatgg agctggtcgg gtggctcgtg 780gacaagggga ttacctcgga
gaagcagtgg atccaggagg accaggcctc atacatctcc 840ttcaatgcgg
cctccaactc gcggtcccaa atcaaggctg ccttggacaa tgcgggaaag
900attatgagcc tgactaaaac cgcccccgac tacctggtgg gccagcagcc
cgtggaggac 960atttccagca atcggattta taaaattttg gaactaaacg
ggtacgatcc ccaatatgcg 1020gcttccgtct ttctgggatg ggccacgaaa
aagttcggca agaggaacac catctggctg 1080tttgggcctg caactaccgg
gaagaccaac atcgcggagg ccatagccca cactgtgccc 1140ttctacgggt
gcgtaaactg gaccaatgag aactttccct tcaacgactg tgtcgacaag
1200atggtgatct ggtgggagga ggggaagatg accgccaagg tcgtggagtc
ggccaaagcc 1260attctcggag gaagcaaggt gcgcgtggac cagaaatgca
agtcctcggc ccagatagac 1320ccgactcccg tgatcgtcac ctccaacacc
aacatgtgcg ccgtgattga cgggaactca 1380acgaccttcg aacaccagca
gccgttgcaa gaccggatgt tcaaatttga actcacccgc 1440cgtctggatc
atgactttgg gaaggtcacc aagcaggaag tcaaagactt tttccggtgg
1500gcaaaggatc acgtggttga ggtggagcat gaattctacg tcaaaaaggg
tggagccaag 1560aaaagacccg cccccagtga cgcagatata agtgagccca
aacgggtgcg cgagtcagtt 1620gcgcagccat cgacgtcaga cgcggaagct
tcgatcaact acgcagacag gtaccaaaac 1680aaatgttctc gtcacgtggg
catgaatctg atgctgtttc cctgcagaca atgcgagaga 1740atgaatcaga
attcaaatat ctgcttcact cacggacaga aagactgttt agagtgcttt
1800cccgtgtcag aatctcaacc cgtttctgtc gtcaaaaagg cgtatcagaa
actgtgctac 1860attcatcata tcatgggaaa ggtgccagac gcttgcactg
cctgcgatct ggtcaatgtg 1920gatttggatg actgcatctt tgaacaataa
atgatttaaa tcaggtatgg ctgccgatgg 1980ttatcttcca gattggctcg
aggacactct ctctgaagga ataagacagt ggtggaagct 2040caaacctggc
ccaccaccac caaagcccgc agagcggcat aaggacgaca gcaggggtct
2100tgtgcttcct gggtacaagt acctcggacc cttcaacgga ctcgacaagg
gagagccggt 2160caacgaggca gacgccgcgg ccctcgagca cgacaaagcc
tacgaccggc agctcgacag 2220cggagacaac ccgtacctca agtacaacca
cgccgacgcg gagtttcagg agcgccttaa 2280agaagatacg tcttttgggg
gcaacctcgg acgagcagtc ttccaggcga aaaagagggt 2340tcttgaacct
ctgggcctgg ttgaggaacc tgttaagacg gctccgggaa aaaagaggcc
2400ggtagagcac tctcctgtgg agccagactc ctcctcggga accggaaagg
cgggccagca 2460gcctgcaaga aaaagattga attttggtca gactggagac
gcagactcag tacctgaccc 2520ccagcctctc ggacagccac cagcagcccc
ctctggtctg ggaactaata cgatggctac 2580aggcagtggc gcaccaatgg
cagacaataa cgagggcgcc gacggagtgg gtaattcctc 2640gggaaattgg
cattgcgatt ccacatggat gggcgacaga gtcatcacca ccagcacccg
2700aacctgggcc ctgcccacct acaacaacca cctctacaaa caaatttcca
gccaatcagg 2760agcctcgaac gacaatcact actttggcta cagcacccct
tgggggtatt ttgacttcaa 2820cagattccac tgccactttt caccacgtga
ctggcaaaga ctcatcaaca acaactgggg 2880attccgaccc aagagactca
acttcaagct ctttaacatt caagtcaaag aggtcacgca 2940gaatgacggt
acgacgacga ttgccaataa ccttaccagc acggttcagg tgtttactga
3000ctcggagtac cagctcccgt acgtcctcgg ctcggcgcat caaggatgcc
tcccgccgtt 3060cccagcagac gtcttcatgg tgccacagta tggatacctc
accctgaaca acgggagtca 3120ggcagtagga cgctcttcat tttactgcct
ggagtacttt ccttctcaga tgctgcgtac 3180cggaaacaac tttaccttca
gctacacttt tgaggacgtt cctttccaca gcagctacgc 3240tcacagccag
agtctggacc gtctcatgaa tcctctcatc gaccagtacc tgtattactt
3300gagcagaaca aacactccaa gtggaaccac cacgcagtca aggcttcagt
tttctcaggc 3360cggagcgagt gacattcggg accagtctag gaactggctt
cctggaccct gttaccgcca 3420gcagcgagta tcaaagacat ctgcggataa
caacaacagt gaatactcgt ggactggagc 3480taccaagtac cacctcaatg
gcagagactc tctggtgaat ccgggcccgg ccatggcaag 3540ccacaaggac
gatgaagaaa agttttttcc tcagagcggg gttctcatct ttgggaagca
3600aggctcagag aaaacaaatg tggacattga aaaggtcatg attacagacg
aagaggaaat 3660caggacaacc aatcccgtgg ctacggagca gtatggttct
gtatctacca acctccagag 3720aggcaacaga caagcagcta ccgcagatgt
caacacacaa ggcgttcttc caggcatggt 3780ctggcaggac agagatgtgt
accttcaggg gcccatctgg gcaaagattc cacacacgga 3840cggacatttt
cacccctctc ccctcatggg tggattcgga cttaaacacc ctcctccaca
3900gattctcatc aagaacaccc cggtacctgc gaatccttcg accaccttca
gtgcggcaaa 3960gtttgcttcc ttcatcacac agtactccac gggacaggtc
agcgtggaga tcgagtggga 4020gctgcagaag gaaaacagca aacgctggaa
tcccgaaatt cagtacactt ccaactacaa 4080caagtctgtt aatgtggact
ttactgtgga cactaatggc gtgtattcag agcctcgccc 4140cattggcacc
agatacctga ctcgtaatct gtaattgctt gttaatcaat aaaccgttta
4200attcgtttca gttgaacttt ggtctctgcg tatttctttc ttatctagtt
tccatgctct 4260aggatccact agtaacggcc gccagtgtgc tggaattcgg
ctttgtagtt aatgattaac 4320ccgccatgct acttatctac gtagccatgc
tctagaggtc ctgtattaga ggtcacgtga 4380gtgttttgcg acattttgcg
acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc 4440acgcagggtc
tccattttga agcgggaggt ttgaacgcgc agccgccaag ccgaattctg
4500cagatatcca aacactggcg gccgctcgac tagagcggcc gccaccgcgg
tggagctcca 4560gcttttgttc cctttagtga gggttaattg cgcgcttggc
gtaatcatgg tcatagctgt 4620ttcctgtgtg aaattgttat ccgctcacaa
ttccacacaa catacgagcc ggaagcataa 4680agtgtaaagc ctggggtgcc
taatgagtga gctaactcac attaattgcg ttgcgctcac 4740tgcccgcttt
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg
4800cggggagagg cggtttgcgt attgggcgct cttccgcttc ctcgctcact
gactcgctgc 4860gctcggtcgt tcggctgcgg cgagcggtat cagctcactc
aaaggcggta atacggttat 4920ccacagaatc aggggataac gcaggaaaga
acatgtgagc aaaaggccag caaaaggcca 4980ggaaccgtaa aaaggccgcg
ttgctggcgt ttttccatag gctccgcccc cctgacgagc 5040atcacaaaaa
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc
5100aggcgtttcc ccctggaagc tccctcgtgc gctctcctgt tccgaccctg
ccgcttaccg 5160gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct
ttctcatagc tcacgctgta 5220ggtatctcag ttcggtgtag gtcgttcgct
ccaagctggg ctgtgtgcac gaaccccccg 5280ttcagcccga ccgctgcgcc
ttatccggta actatcgtct tgagtccaac ccggtaagac 5340acgacttatc
gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag
5400gcggtgctac agagttcttg aagtggtggc ctaactacgg ctacactaga
agaacagtat 5460ttggtatctg cgctctgctg aagccagtta ccttcggaaa
aagagttggt agctcttgat 5520ccggcaaaca aaccaccgct ggtagcggtg
gtttttttgt ttgcaagcag cagattacgc 5580gcagaaaaaa aggatctcaa
gaagatcctt tgatcttttc tacggggtct gacgctcagt 5640ggaacgaaaa
ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct
5700agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat
gagtaaactt 5760ggtctgacag ttaccaatgc ttaatcagtg aggcacctat
ctcagcgatc tgtctatttc 5820gttcatccat agttgcctga ctccccgtcg
tgtagataac tacgatacgg gagggcttac 5880catctggccc cagtgctgca
atgataccgc gagacccacg ctcaccggct ccagatttat 5940cagcaataaa
ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg
6000cctccatcca gtctattaat tgttgccggg aagctagagt aagtagttcg
ccagttaata 6060gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt
gtcacgctcg tcgtttggta 6120tggcttcatt cagctccggt tcccaacgat
caaggcgagt tacatgatcc cccatgttgt 6180gcaaaaaagc ggttagctcc
ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag 6240tgttatcact
catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa
6300gatgcttttc tgtgactggt gagtactcaa ccaagtcatt ctgagaatag
tgtatgcggc 6360gaccgagttg ctcttgcccg gcgtcaatac gggataatac
cgcgccacat agcagaactt 6420taaaagtgct catcattgga aaacgttctt
cggggcgaaa actctcaagg atcttaccgc 6480tgttgagatc cagttcgatg
taacccactc gtgcacccaa ctgatcttca gcatctttta 6540ctttcaccag
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa
6600taagggcgac acggaaatgt tgaatactca tactcttcct ttttcaatat
tattgaagca 6660tttatcaggg ttattgtctc atgagcggat acatatttga
atgtatttag aaaaataaac 6720aaataggggt tccgcgcaca tttccccgaa
aagtgccacc taaattgtaa gcgttaatat 6780tttgttaaaa ttcgcgttaa
atttttgtta aatcagctca ttttttaacc aataggccga 6840aatcggcaaa
atcccttata aatcaaaaga atagaccgag atagggttga gtgttgttcc
6900agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag
ggcgaaaaac 6960cgtctatcag ggcgatggcc cactacgtga accatcaccc
taatcaagtt ttttggggtc 7020gaggtgccgt aaagcactaa atcggaaccc
taaagggagc ccccgattta gagcttgacg 7080gggaaagccg gcgaacgtgg
cgagaaagga agggaagaaa gcgaaaggag cgggcgctag 7140ggcgctggca
agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg cgcttaatgc
7200gccgctacag ggcgcgtccc attcgccatt caggctgcgc aactgttggg
aagggcgatc 7260ggtgcgggcc tcttcgctat tacgccagct ggcgaaaggg
ggatgtgctg caaggcgatt 7320aagttgggta acgccagggt tttcccagtc
acgacgttgt aaaacgacgg ccagtgagcg 7380cgcgtaatac gactcactat
agggcgaatt gggta 741537395DNAArtificial SequenceCoding Strand of
Plasmid pAAV-RC5
3catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg
60cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg
120aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc
ccaaaaccca 180gcctgagctc cagtgggcgt ggactaatat ggaacagtat
ttaagcgcct gtttgaatct 240cacggagcgt aaacggttgg tggcgcagca
tctgacgcac gtgtcgcaga cgcaggagca 300gaacaaagag aatcagaatc
ccaattctga tgcgccggtg atcagatcaa aaacttcagc 360caggtacatg
gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg
420gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact
cgcggtccca 480aatcaaggct gccttggaca atgcgggaaa gattatgagc
ctgactaaaa ccgcccccga 540ctacctggtg ggccagcagc ccgtggagga
catttccagc aatcggattt ataaaatttt 600ggaactaaac gggtacgatc
cccaatatgc ggcttccgtc tttctgggat gggccacgaa 660aaagttcggc
aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa
720catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact
ggaccaatga 780gaactttccc ttcaacgact gtgtcgacaa gatggtgatc
tggtgggagg aggggaagat 840gaccgccaag gtcgtggagt cggccaaagc
cattctcgga ggaagcaagg tgcgcgtgga 900ccagaaatgc aagtcctcgg
cccagataga cccgactccc gtgatcgtca cctccaacac 960caacatgtgc
gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca
1020agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg
ggaaggtcac 1080caagcaggaa gtcaaagact ttttccggtg ggcaaaggat
cacgtggttg aggtggagca 1140tgaattctac gtcaaaaagg gtggagccaa
gaaaagaccc gcccccagtg acgcagatat 1200aagtgagccc aaacgggtgc
gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc 1260ttcgatcaac
tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct
1320gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata
tctgcttcac 1380tcacggacag aaagactgtt tagagtgctt tcccgtgtca
gaatctcaac ccgtttctgt 1440cgtcaaaaag gcgtatcaga aactgtgcta
cattcatcat atcatgggaa aggtgccaga 1500cgcttgcact gcctgcgatc
tggtcaatgt ggatttggat gactgcatct ttgaacaata 1560aatgatttaa
atcaggtatg tcttttgttg atcaccctcc agattggttg gaagaagttg
1620gtgaaggtct tcgcgagttt ttgggccttg aagcgggccc accgaaacca
aaacccaatc 1680agcagcatca agatcaagcc cgtggtcttg tgctgcctgg
ttataactat ctcggacccg 1740gaaacggtct cgatcgagga gagcctgtca
acagggcaga cgaggtcgcg cgagagcacg 1800acatctcgta caacgagcag
cttgaggcgg gagacaaccc ctacctcaag tacaaccacg 1860cggacgccga
gtttcaggag aagctcgccg acgacacatc cttcggggga aacctcggaa
1920aggcagtctt tcaggccaag aaaagggttc tcgaaccttt tggcctggtt
gaagagggtg 1980ctaagacggc ccctaccgga aagcggatag acgaccactt
tccaaaaaga aagaaggctc 2040ggaccgaaga ggactccaag ccttccacct
cgtcagacgc cgaagctgga cccagcggat 2100cccagcagct gcaaatccca
gcccaaccag cctcaagttt gggagctgat acaatgtctg 2160cgggaggtgg
cggcccattg ggcgacaata accaaggtgc cgatggagtg ggcaatgcct
2220cgggagattg gcattgcgat tccacgtgga tgggggacag agtcgtcacc
aagtccaccc 2280gaacctgggt gctgcccagc tacaacaacc accagtaccg
agagatcaaa agcggctccg 2340tcgacggaag caacgccaac gcctactttg
gatacagcac cccctggggg tactttgact 2400ttaaccgctt ccacagccac
tggagccccc gagactggca aagactcatc aacaactact 2460ggggcttcag
accccggtcc ctcagagtca aaatcttcaa cattcaagtc aaagaggtca
2520cggtgcagga ctccaccacc accatcgcca acaacctcac ctccaccgtc
caagtgttta 2580cggacgacga ctaccagctg ccctacgtcg tcggcaacgg
gaccgaggga tgcctgccgg 2640ccttccctcc gcaggtcttt acgctgccgc
agtacggtta cgcgacgctg aaccgcgaca 2700acacagaaaa tcccaccgag
aggagcagct tcttctgcct agagtacttt cccagcaaga 2760tgctgagaac
gggcaacaac tttgagttta cctacaactt tgaggaggtg cccttccact
2820ccagcttcgc tcccagtcag aacctgttca agctggccaa cccgctggtg
gaccagtact 2880tgtaccgctt cgtgagcaca aataacactg gcggagtcca
gttcaacaag aacctggccg 2940ggagatacgc caacacctac aaaaactggt
tcccggggcc catgggccga acccagggct 3000ggaacctggg ctccggggtc
aaccgcgcca gtgtcagcgc cttcgccacg accaatagga 3060tggagctcga
gggcgcgagt taccaggtgc ccccgcagcc gaacggcatg accaacaacc
3120tccagggcag caacacctat gccctggaga acactatgat cttcaacagc
cagccggcga 3180acccgggcac caccgccacg tacctcgagg gcaacatgct
catcaccagc gagagcgaga 3240cgcagccggt gaaccgcgtg gcgtacaacg
tcggcgggca gatggccacc aacaaccaga 3300gctccaccac tgcccccgcg
accggcacgt acaacctcca ggaaatcgtg cccggcagcg 3360tgtggatgga
gagggacgtg tacctccaag gacccatctg ggccaagatc ccagagacgg
3420gggcgcactt tcacccctct ccggccatgg gcggattcgg actcaaacac
ccaccgccca 3480tgatgctcat caagaacacg cctgtgcccg gaaatatcac
cagcttctcg gacgtgcccg 3540tcagcagctt catcacccag tacagcaccg
ggcaggtcac cgtggagatg gagtgggagc 3600tcaagaagga aaactccaag
aggtggaacc cagagatcca gtacacaaac aactacaacg 3660acccccagtt
tgtggacttt gccccggaca gcaccgggga atacagaacc accagaccta
3720tcggaacccg ataccttacc cgaccccttt aaggcgcgcc accggttgct
tgttaatcaa 3780taaaccgttt aattcgtttc agttgaactt tggtctctgc
gtatttcttt cttatctagt 3840ttccatgctc taggatccac tagtaacggc
cgccagtgtg ctggaattcg gctttgtagt 3900taatgattaa cccgccatgc
tacttatcta cgtagccatg ctctagaggt cctgtattag 3960aggtcacgtg
agtgttttgc gacattttgc gacaccatgt ggtcacgctg ggtatttaag
4020cccgagtgag cacgcagggt ctccattttg aagcgggagg tttgaacgcg
cagccgccaa 4080gccgaattct gcagatatcc aaacactggc ggccgctcga
ctagagcggc cgccaccgcg 4140gtggagctcc agcttttgtt ccctttagtg
agggttaatt gcgcgcttgg cgtaatcatg 4200gtcatagctg tttcctgtgt
gaaattgtta tccgctcaca attccacaca acatacgagc 4260cggaagcata
aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc
4320gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc
attaatgaat 4380cggccaacgc gcggggagag gcggtttgcg tattgggcgc
tcttccgctt cctcgctcac 4440tgactcgctg cgctcggtcg ttcggctgcg
gcgagcggta tcagctcact caaaggcggt 4500aatacggtta tccacagaat
caggggataa cgcaggaaag aacatgtgag caaaaggcca 4560gcaaaaggcc
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc
4620ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc
cgacaggact 4680ataaagatac caggcgtttc cccctggaag ctccctcgtg
cgctctcctg ttccgaccct 4740gccgcttacc ggatacctgt ccgcctttct
cccttcggga agcgtggcgc tttctcatag 4800ctcacgctgt aggtatctca
gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca 4860cgaacccccc
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa
4920cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga
ttagcagagc 4980gaggtatgta ggcggtgcta cagagttctt gaagtggtgg
cctaactacg gctacactag 5040aagaacagta tttggtatct gcgctctgct
gaagccagtt accttcggaa aaagagttgg 5100tagctcttga tccggcaaac
aaaccaccgc tggtagcggt ggtttttttg tttgcaagca 5160gcagattacg
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc
5220tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat
tatcaaaaag 5280gatcttcacc tagatccttt taaattaaaa atgaagtttt
aaatcaatct aaagtatata 5340tgagtaaact tggtctgaca gttaccaatg
cttaatcagt gaggcaccta tctcagcgat 5400ctgtctattt cgttcatcca
tagttgcctg actccccgtc gtgtagataa ctacgatacg 5460ggagggctta
ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc
5520tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa
gtggtcctgc 5580aactttatcc gcctccatcc agtctattaa ttgttgccgg
gaagctagag taagtagttc 5640gccagttaat agtttgcgca acgttgttgc
cattgctaca ggcatcgtgg tgtcacgctc 5700gtcgtttggt atggcttcat
tcagctccgg ttcccaacga tcaaggcgag ttacatgatc 5760ccccatgttg
tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa
5820gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc
ttactgtcat 5880gccatccgta agatgctttt ctgtgactgg tgagtactca
accaagtcat tctgagaata 5940gtgtatgcgg cgaccgagtt gctcttgccc
ggcgtcaata cgggataata ccgcgccaca 6000tagcagaact ttaaaagtgc
tcatcattgg aaaacgttct tcggggcgaa aactctcaag 6060gatcttaccg
ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc
6120agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc
aaaatgccgc 6180aaaaaaggga ataagggcga cacggaaatg ttgaatactc
atactcttcc tttttcaata 6240ttattgaagc atttatcagg gttattgtct
catgagcgga tacatatttg aatgtattta 6300gaaaaataaa caaatagggg
ttccgcgcac atttccccga aaagtgccac ctaaattgta 6360agcgttaata
ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac
6420caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga
gatagggttg 6480agtgttgttc cagtttggaa caagagtcca ctattaaaga
acgtggactc caacgtcaaa 6540gggcgaaaaa ccgtctatca gggcgatggc
ccactacgtg aaccatcacc ctaatcaagt 6600tttttggggt cgaggtgccg
taaagcacta aatcggaacc ctaaagggag cccccgattt 6660agagcttgac
ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga
6720gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac
cacacccgcc 6780gcgcttaatg cgccgctaca gggcgcgtcc cattcgccat
tcaggctgcg caactgttgg 6840gaagggcgat cggtgcgggc ctcttcgcta
ttacgccagc tggcgaaagg gggatgtgct 6900gcaaggcgat taagttgggt
aacgccaggg ttttcccagt cacgacgttg taaaacgacg 6960gccagtgagc
gcgcgtaata cgactcacta tagggcgaat tgggtaccgg gccccccctc
7020gaggtcgacg gtatcggggg agctcgcagg gtctccattt tgaagcggga
ggtttgaacg 7080cgcagccgcc atgccggggt tttacgagat tgtgattaag
gtccccagcg accttgacga 7140gcatctgccc ggcatttctg acagctttgt
gaactgggtg gccgagaagg aatgggagtt 7200gccgccagat tctgacatgg
atctgaatct gattgagcag gcacccctga ccgtggccga 7260gaagctgcag
cgcgactttc tgacggaatg gcgccgtgtg agtaaggccc cggaggctct
7320tttctttgtg caatttgaga agggagagag ctacttccac atgcacgtgc
tcgtggaaac 7380caccggggtg aaatc 739547431DNAArtificial
SequenceCoding Strand of Plasmid pAAV-RC6 4catggttttg ggacgtttcc
tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg 60cgggatcgag ccgactttgc
caaactggtt cgcggtcaca aagaccagaa atggcgccgg 120aggcgggaac
aaggtggtgg atgagtgcta catccccaat tacttgctcc ccaaaaccca
180gcctgagctc cagtgggcgt ggactaatat ggaacagtat ttaagcgcct
gtttgaatct 240cacggagcgt aaacggttgg tggcgcagca tctgacgcac
gtgtcgcaga cgcaggagca 300gaacaaagag aatcagaatc ccaattctga
tgcgccggtg atcagatcaa aaacttcagc 360caggtacatg gagctggtcg
ggtggctcgt ggacaagggg attacctcgg agaagcagtg 420gatccaggag
gaccaggcct catacatctc cttcaatgcg gcctccaact cgcggtccca
480aatcaaggct gccttggaca atgcgggaaa gattatgagc ctgactaaaa
ccgcccccga 540ctacctggtg ggccagcagc ccgtggagga catttccagc
aatcggattt ataaaatttt 600ggaactaaac gggtacgatc cccaatatgc
ggcttccgtc tttctgggat gggccacgaa 660aaagttcggc aagaggaaca
ccatctggct gtttgggcct gcaactaccg ggaagaccaa 720catcgcggag
gccatagccc acactgtgcc cttctacggg tgcgtaaact ggaccaatga
780gaactttccc ttcaacgact gtgtcgacaa gatggtgatc tggtgggagg
aggggaagat 840gaccgccaag gtcgtggagt cggccaaagc cattctcgga
ggaagcaagg tgcgcgtgga 900ccagaaatgc aagtcctcgg cccagataga
cccgactccc gtgatcgtca cctccaacac 960caacatgtgc gccgtgattg
acgggaactc aacgaccttc gaacaccagc agccgttgca 1020agaccggatg
ttcaaatttg aactcacccg ccgtctggat catgactttg ggaaggtcac
1080caagcaggaa gtcaaagact ttttccggtg ggcaaaggat cacgtggttg
aggtggagca 1140tgaattctac gtcaaaaagg gtggagccaa gaaaagaccc
gcccccagtg acgcagatat 1200aagtgagccc aaacgggtgc gcgagtcagt
tgcgcagcca tcgacgtcag acgcggaagc 1260ttcgatcaac tacgcagaca
ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct 1320gatgctgttt
ccctgcagac aatgcgagag aatgaatcag aattcaaata tctgcttcac
1380tcacggacag aaagactgtt tagagtgctt tcccgtgtca gaatctcaac
ccgtttctgt 1440cgtcaaaaag gcgtatcaga aactgtgcta cattcatcat
atcatgggaa aggtgccaga 1500cgcttgcact gcctgcgatc tggtcaatgt
ggatttggat gactgcatct ttgaacaata 1560aatgatttaa atcaggtatg
gctgccgatg gttatcttcc agattggctc gaggacaacc 1620tctctgaggg
cattcgcgag tggtgggact tgaaacctgg agccccgaaa cccaaagcca
1680accagcaaaa gcaggacgac ggccggggtc tggtgcttcc tggctacaag
tacctcggac 1740ccttcaacgg actcgacaag ggggagcccg tcaacgcggc
ggatgcagcg gccctcgagc 1800acgacaaggc ctacgaccag cagctcaaag
cgggtgacaa tccgtacctg cggtataacc 1860acgccgacgc cgagtttcag
gagcgtctgc aagaagatac gtcttttggg ggcaacctcg 1920ggcgagcagt
cttccaggcc aagaagaggg ttctcgaacc ttttggtctg gttgaggaag
1980gtgctaagac ggctcctgga aagaaacgtc cggtagagca gtcgccacaa
gagccagact 2040cctcctcggg cattggcaag acaggccagc agcccgctaa
aaagagactc aattttggtc 2100agactggcga ctcagagtca gtccccgacc
cacaacctct cggagaacct ccagcaaccc 2160ccgctgctgt gggacctact
acaatggctt caggcggtgg cgcaccaatg gcagacaata 2220acgaaggcgc
cgacggagtg ggtaatgcct caggaaattg gcattgcgat tccacatggc
2280tgggcgacag agtcatcacc accagcaccc gaacatgggc cttgcccacc
tataacaacc 2340acctctacaa gcaaatctcc agtgcttcaa cgggggccag
caacgacaac cactacttcg 2400gctacagcac cccctggggg tattttgatt
tcaacagatt ccactgccat ttctcaccac 2460gtgactggca gcgactcatc
aacaacaatt ggggattccg gcccaagaga ctcaacttca 2520agctcttcaa
catccaagtc aaggaggtca cgacgaatga tggcgtcacg accatcgcta
2580ataaccttac cagcacggtt caagtcttct cggactcgga gtaccagttg
ccgtacgtcc 2640tcggctctgc gcaccagggc tgcctccctc cgttcccggc
ggacgtgttc atgattccgc 2700agtacggcta cctaacgctc aacaatggca
gccaggcagt gggacggtca tccttttact 2760gcctggaata tttcccatcg
cagatgctga gaacgggcaa taactttacc ttcagctaca 2820ccttcgagga
cgtgcctttc cacagcagct acgcgcacag ccagagcctg gaccggctga
2880tgaatcctct catcgaccag tacctgtatt acctgaacag aactcagaat
cagtccggaa 2940gtgcccaaaa caaggacttg ctgtttagcc gggggtctcc
agctggcatg tctgttcagc 3000ccaaaaactg gctacctgga ccctgttacc
ggcagcagcg cgtttctaaa acaaaaacag 3060acaacaacaa cagcaacttt
acctggactg gtgcttcaaa atataacctt aatgggcgtg 3120aatctataat
caaccctggc actgctatgg cctcacacaa agacgacaaa gacaagttct
3180ttcccatgag cggtgtcatg atttttggaa aggagagcgc cggagcttca
aacactgcat 3240tggacaatgt catgatcaca gacgaagagg aaatcaaagc
cactaacccc gtggccaccg 3300aaagatttgg gactgtggca gtcaatctcc
agagcagcag cacagaccct gcgaccggag 3360atgtgcatgt tatgggagcc
ttacctggaa tggtgtggca agacagagac gtatacctgc 3420agggtcctat
ttgggccaaa attcctcaca cggatggaca ctttcacccg tctcctctca
3480tgggcggctt tggacttaag cacccgcctc ctcagatcct catcaaaaac
acgcctgttc 3540ctgcgaatcc tccggcagag ttttcggcta caaagtttgc
ttcattcatc acccagtatt 3600ccacaggaca agtgagcgtg gagattgaat
gggagctgca gaaagaaaac agcaaacgct 3660ggaatcccga agtgcagtat
acatctaact atgcaaaatc tgccaacgtt gatttcactg 3720tggacaacaa
tggactttat actgagcctc gccccattgg cacccgttac ctcacccgtc
3780ccctgtaagg cgcgccaccg gttgcttgtt aatcaataaa ccgtttaatt
cgtttcagtt 3840gaactttggt ctctgcgtat ttctttctta tctagtttcc
atgctctagg atccactagt 3900aacggccgcc agtgtgctgg aattcggctt
tgtagttaat gattaacccg ccatgctact 3960tatctacgta gccatgctct
agaggtcctg tattagaggt cacgtgagtg ttttgcgaca 4020ttttgcgaca
ccatgtggtc acgctgggta tttaagcccg agtgagcacg cagggtctcc
4080attttgaagc gggaggtttg aacgcgcagc cgccaagccg aattctgcag
atatccaaac 4140actggcggcc gctcgactag agcggccgcc accgcggtgg
agctccagct tttgttccct 4200ttagtgaggg ttaattgcgc gcttggcgta
atcatggtca tagctgtttc ctgtgtgaaa 4260ttgttatccg ctcacaattc
cacacaacat acgagccgga agcataaagt gtaaagcctg 4320gggtgcctaa
tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca
4380gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg
ggagaggcgg 4440tttgcgtatt gggcgctctt ccgcttcctc gctcactgac
tcgctgcgct cggtcgttcg 4500gctgcggcga gcggtatcag ctcactcaaa
ggcggtaata cggttatcca cagaatcagg 4560ggataacgca ggaaagaaca
tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa 4620ggccgcgttg
ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg
4680acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg
cgtttccccc 4740tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg
cttaccggat acctgtccgc 4800ctttctccct tcgggaagcg tggcgctttc
tcatagctca cgctgtaggt atctcagttc 4860ggtgtaggtc gttcgctcca
agctgggctg tgtgcacgaa ccccccgttc agcccgaccg 4920ctgcgcctta
tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc
4980actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg
gtgctacaga 5040gttcttgaag tggtggccta actacggcta cactagaaga
acagtatttg gtatctgcgc 5100tctgctgaag ccagttacct tcggaaaaag
agttggtagc tcttgatccg gcaaacaaac 5160caccgctggt agcggtggtt
tttttgtttg caagcagcag attacgcgca gaaaaaaagg 5220atctcaagaa
gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc
5280acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga
tccttttaaa 5340ttaaaaatga agttttaaat caatctaaag tatatatgag
taaacttggt ctgacagtta 5400ccaatgctta atcagtgagg cacctatctc
agcgatctgt ctatttcgtt catccatagt 5460tgcctgactc cccgtcgtgt
agataactac gatacgggag ggcttaccat ctggccccag 5520tgctgcaatg
ataccgcgag acccacgctc accggctcca gatttatcag caataaacca
5580gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct
ccatccagtc 5640tattaattgt tgccgggaag ctagagtaag tagttcgcca
gttaatagtt tgcgcaacgt 5700tgttgccatt gctacaggca tcgtggtgtc
acgctcgtcg tttggtatgg cttcattcag 5760ctccggttcc caacgatcaa
ggcgagttac atgatccccc atgttgtgca aaaaagcggt 5820tagctccttc
ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat
5880ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat
gcttttctgt 5940gactggtgag tactcaacca agtcattctg agaatagtgt
atgcggcgac cgagttgctc 6000ttgcccggcg tcaatacggg ataataccgc
gccacatagc agaactttaa aagtgctcat 6060cattggaaaa cgttcttcgg
ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 6120ttcgatgtaa
cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt
6180ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa
gggcgacacg 6240gaaatgttga atactcatac tcttcctttt tcaatattat
tgaagcattt atcagggtta 6300ttgtctcatg agcggataca tatttgaatg
tatttagaaa aataaacaaa taggggttcc 6360gcgcacattt ccccgaaaag
tgccacctaa attgtaagcg ttaatatttt gttaaaattc 6420gcgttaaatt
tttgttaaat cagctcattt tttaaccaat aggccgaaat cggcaaaatc
6480ccttataaat caaaagaata gaccgagata gggttgagtg ttgttccagt
ttggaacaag 6540agtccactat taaagaacgt ggactccaac gtcaaagggc
gaaaaaccgt ctatcagggc 6600gatggcccac tacgtgaacc atcaccctaa
tcaagttttt tggggtcgag gtgccgtaaa 6660gcactaaatc ggaaccctaa
agggagcccc cgatttagag cttgacgggg aaagccggcg 6720aacgtggcga
gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc gctggcaagt
6780gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc ttaatgcgcc
gctacagggc 6840gcgtcccatt cgccattcag gctgcgcaac tgttgggaag
ggcgatcggt gcgggcctct 6900tcgctattac gccagctggc gaaaggggga
tgtgctgcaa ggcgattaag ttgggtaacg 6960ccagggtttt cccagtcacg
acgttgtaaa acgacggcca gtgagcgcgc gtaatacgac 7020tcactatagg
gcgaattggg taccgggccc cccctcgagg tcgacggtat cgggggagct
7080cgcagggtct ccattttgaa gcgggaggtt tgaacgcgca gccgccatgc
cggggtttta 7140cgagattgtg attaaggtcc ccagcgacct tgacgagcat
ctgcccggca tttctgacag 7200ctttgtgaac tgggtggccg agaaggaatg
ggagttgccg ccagattctg acatggatct 7260gaatctgatt gagcaggcac
ccctgaccgt ggccgagaag ctgcagcgcg actttctgac 7320ggaatggcgc
cgtgtgagta aggccccgga ggctcttttc tttgtgcaat ttgagaaggg
7380agagagctac ttccacatgc acgtgctcgt ggaaaccacc ggggtgaaat c
743157434DNAArtificial SequenceCoding Strand of Plasmid pAAV-RC7
5catggttttg ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga
gaatttaccg
60cgggatcgag ccgactttgc caaactggtt cgcggtcaca aagaccagaa atggcgccgg
120aggcgggaac aaggtggtgg atgagtgcta catccccaat tacttgctcc
ccaaaaccca 180gcctgagctc cagtgggcgt ggactaatat ggaacagtat
ttaagcgcct gtttgaatct 240cacggagcgt aaacggttgg tggcgcagca
tctgacgcac gtgtcgcaga cgcaggagca 300gaacaaagag aatcagaatc
ccaattctga tgcgccggtg atcagatcaa aaacttcagc 360caggtacatg
gagctggtcg ggtggctcgt ggacaagggg attacctcgg agaagcagtg
420gatccaggag gaccaggcct catacatctc cttcaatgcg gcctccaact
cgcggtccca 480aatcaaggct gccttggaca atgcgggaaa gattatgagc
ctgactaaaa ccgcccccga 540ctacctggtg ggccagcagc ccgtggagga
catttccagc aatcggattt ataaaatttt 600ggaactaaac gggtacgatc
cccaatatgc ggcttccgtc tttctgggat gggccacgaa 660aaagttcggc
aagaggaaca ccatctggct gtttgggcct gcaactaccg ggaagaccaa
720catcgcggag gccatagccc acactgtgcc cttctacggg tgcgtaaact
ggaccaatga 780gaactttccc ttcaacgact gtgtcgacaa gatggtgatc
tggtgggagg aggggaagat 840gaccgccaag gtcgtggagt cggccaaagc
cattctcgga ggaagcaagg tgcgcgtgga 900ccagaaatgc aagtcctcgg
cccagataga cccgactccc gtgatcgtca cctccaacac 960caacatgtgc
gccgtgattg acgggaactc aacgaccttc gaacaccagc agccgttgca
1020agaccggatg ttcaaatttg aactcacccg ccgtctggat catgactttg
ggaaggtcac 1080caagcaggaa gtcaaagact ttttccggtg ggcaaaggat
cacgtggttg aggtggagca 1140tgaattctac gtcaaaaagg gtggagccaa
gaaaagaccc gcccccagtg acgcagatat 1200aagtgagccc aaacgggtgc
gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc 1260ttcgatcaac
tacgcagaca ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct
1320gatgctgttt ccctgcagac aatgcgagag aatgaatcag aattcaaata
tctgcttcac 1380tcacggacag aaagactgtt tagagtgctt tcccgtgtca
gaatctcaac ccgtttctgt 1440cgtcaaaaag gcgtatcaga aactgtgcta
cattcatcat atcatgggaa aggtgccaga 1500cgcttgcact gcctgcgatc
tggtcaatgt ggatttggat gactgcatct ttgaacaata 1560aatgatttaa
atcaggtatg gctgccgatg gttatcttcc agattggctc gaggacaacc
1620tctctgaggg cattcgcgag tggtgggacc tgaaacctgg agccccgaaa
cccaaagcca 1680accagcaaaa gcaggacaac ggccggggtc tggtgcttcc
tggctacaag tacctcggac 1740ccttcaacgg actcgacaag ggggagcccg
tcaacgcggc ggacgcagcg gccctcgagc 1800acgacaaggc ctacgaccag
cagctcaaag cgggtgacaa tccgtacctg cggtataacc 1860acgccgacgc
cgagtttcag gagcgtctgc aagaagatac gtcatttggg ggcaacctcg
1920ggcgagcagt cttccaggcc aagaagcggg ttctcgaacc tctcggtctg
gttgaggaag 1980gcgctaagac ggctcctgca aagaagagac cggtagagcc
gtcacctcag cgttcccccg 2040actcctccac gggcatcggc aagaaaggcc
agcagcccgc cagaaagaga ctcaatttcg 2100gtcagactgg cgactcagag
tcagtccccg accctcaacc tctcggagaa cctccagcag 2160cgccctctag
tgtgggatct ggtacagtgg ctgcaggcgg tggcgcacca atggcagaca
2220ataacgaagg tgccgacgga gtgggtaatg cctcaggaaa ttggcattgc
gattccacat 2280ggctgggcga cagagtcatt accaccagca cccgaacctg
ggccctgccc acctacaaca 2340accacctcta caagcaaatc tccagtgaaa
ctgcaggtag taccaacgac aacacctact 2400tcggctacag caccccctgg
gggtattttg actttaacag attccactgc cacttctcac 2460cacgtgactg
gcagcgactc atcaacaaca actggggatt ccggcccaag aagctgcggt
2520tcaagctctt caacatccag gtcaaggagg tcacgacgaa tgacggcgtt
acgaccatcg 2580ctaataacct taccagcacg attcaggtat tctcggactc
ggaataccag ctgccgtacg 2640tcctcggctc tgcgcaccag ggctgcctgc
ctccgttccc ggcggacgtc ttcatgattc 2700ctcagtacgg ctacctgact
ctcaacaatg gcagtcagtc tgtgggacgt tcctccttct 2760actgcctgga
gtacttcccc tctcagatgc tgagaacggg caacaacttt gagttcagct
2820acagcttcga ggacgtgcct ttccacagca gctacgcaca cagccagagc
ctggaccggc 2880tgatgaatcc cctcatcgac cagtacttgt actacctggc
cagaacacag agtaacccag 2940gaggcacagc tggcaatcgg gaactgcagt
tttaccaggg cgggccttca actatggccg 3000aacaagccaa gaattggtta
cctggacctt gcttccggca acaaagagtc tccaaaacgc 3060tggatcaaaa
caacaacagc aactttgctt ggactggtgc caccaaatat cacctgaacg
3120gcagaaactc gttggttaat cccggcgtcg ccatggcaac tcacaaggac
gacgaggacc 3180gctttttccc atccagcgga gtcctgattt ttggaaaaac
tggagcaact aacaaaacta 3240cattggaaaa tgtgttaatg acaaatgaag
aagaaattcg tcctactaat cctgtagcca 3300cggaagaata cgggatagtc
agcagcaact tacaagcggc taatactgca gcccagacac 3360aagttgtcaa
caaccaggga gccttacctg gcatggtctg gcagaaccgg gacgtgtacc
3420tgcagggtcc catctgggcc aagattcctc acacggatgg caactttcac
ccgtctcctt 3480tgatgggcgg ctttggactt aaacatccgc ctcctcagat
cctgatcaag aacactcccg 3540ttcccgctaa tcctccggag gtgtttactc
ctgccaagtt tgcttcgttc atcacacagt 3600acagcaccgg acaagtcagc
gtggaaatcg agtgggagct gcagaaggaa aacagcaagc 3660gctggaaccc
ggagattcag tacacctcca actttgaaaa gcagactggt gtggactttg
3720ccgttgacag ccagggtgtt tactctgagc ctcgccctat tggcactcgt
tacctcaccc 3780gtaatctgta aggcgcgcca ccggttgctt gttaatcaat
aaaccgttta attcgtttca 3840gttgaacttt ggtctctgcg tatttctttc
ttatctagtt tccatgctct aggatccact 3900agtaacggcc gccagtgtgc
tggaattcgg ctttgtagtt aatgattaac ccgccatgct 3960acttatctac
gtagccatgc tctagaggtc ctgtattaga ggtcacgtga gtgttttgcg
4020acattttgcg acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc
acgcagggtc 4080tccattttga agcgggaggt ttgaacgcgc agccgccaag
ccgaattctg cagatatcca 4140aacactggcg gccgctcgac tagagcggcc
gccaccgcgg tggagctcca gcttttgttc 4200cctttagtga gggttaattg
cgcgcttggc gtaatcatgg tcatagctgt ttcctgtgtg 4260aaattgttat
ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc
4320ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac
tgcccgcttt 4380ccagtcggga aacctgtcgt gccagctgca ttaatgaatc
ggccaacgcg cggggagagg 4440cggtttgcgt attgggcgct cttccgcttc
ctcgctcact gactcgctgc gctcggtcgt 4500tcggctgcgg cgagcggtat
cagctcactc aaaggcggta atacggttat ccacagaatc 4560aggggataac
gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa
4620aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc
atcacaaaaa 4680tcgacgctca agtcagaggt ggcgaaaccc gacaggacta
taaagatacc aggcgtttcc 4740ccctggaagc tccctcgtgc gctctcctgt
tccgaccctg ccgcttaccg gatacctgtc 4800cgcctttctc ccttcgggaa
gcgtggcgct ttctcatagc tcacgctgta ggtatctcag 4860ttcggtgtag
gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga
4920ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac
acgacttatc 4980gccactggca gcagccactg gtaacaggat tagcagagcg
aggtatgtag gcggtgctac 5040agagttcttg aagtggtggc ctaactacgg
ctacactaga agaacagtat ttggtatctg 5100cgctctgctg aagccagtta
ccttcggaaa aagagttggt agctcttgat ccggcaaaca 5160aaccaccgct
ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa
5220aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt
ggaacgaaaa 5280ctcacgttaa gggattttgg tcatgagatt atcaaaaagg
atcttcacct agatcctttt 5340aaattaaaaa tgaagtttta aatcaatcta
aagtatatat gagtaaactt ggtctgacag 5400ttaccaatgc ttaatcagtg
aggcacctat ctcagcgatc tgtctatttc gttcatccat 5460agttgcctga
ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc
5520cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat
cagcaataaa 5580ccagccagcc ggaagggccg agcgcagaag tggtcctgca
actttatccg cctccatcca 5640gtctattaat tgttgccggg aagctagagt
aagtagttcg ccagttaata gtttgcgcaa 5700cgttgttgcc attgctacag
gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt 5760cagctccggt
tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc
5820ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag
tgttatcact 5880catggttatg gcagcactgc ataattctct tactgtcatg
ccatccgtaa gatgcttttc 5940tgtgactggt gagtactcaa ccaagtcatt
ctgagaatag tgtatgcggc gaccgagttg 6000ctcttgcccg gcgtcaatac
gggataatac cgcgccacat agcagaactt taaaagtgct 6060catcattgga
aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc
6120cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta
ctttcaccag 6180cgtttctggg tgagcaaaaa caggaaggca aaatgccgca
aaaaagggaa taagggcgac 6240acggaaatgt tgaatactca tactcttcct
ttttcaatat tattgaagca tttatcaggg 6300ttattgtctc atgagcggat
acatatttga atgtatttag aaaaataaac aaataggggt 6360tccgcgcaca
tttccccgaa aagtgccacc taaattgtaa gcgttaatat tttgttaaaa
6420ttcgcgttaa atttttgtta aatcagctca ttttttaacc aataggccga
aatcggcaaa 6480atcccttata aatcaaaaga atagaccgag atagggttga
gtgttgttcc agtttggaac 6540aagagtccac tattaaagaa cgtggactcc
aacgtcaaag ggcgaaaaac cgtctatcag 6600ggcgatggcc cactacgtga
accatcaccc taatcaagtt ttttggggtc gaggtgccgt 6660aaagcactaa
atcggaaccc taaagggagc ccccgattta gagcttgacg gggaaagccg
6720gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag cgggcgctag
ggcgctggca 6780agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg
cgcttaatgc gccgctacag 6840ggcgcgtccc attcgccatt caggctgcgc
aactgttggg aagggcgatc ggtgcgggcc 6900tcttcgctat tacgccagct
ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta 6960acgccagggt
tttcccagtc acgacgttgt aaaacgacgg ccagtgagcg cgcgtaatac
7020gactcactat agggcgaatt gggtaccggg ccccccctcg aggtcgacgg
tatcggggga 7080gctcgcaggg tctccatttt gaagcgggag gtttgaacgc
gcagccgcca tgccggggtt 7140ttacgagatt gtgattaagg tccccagcga
ccttgacgag catctgcccg gcatttctga 7200cagctttgtg aactgggtgg
ccgagaagga atgggagttg ccgccagatt ctgacatgga 7260tctgaatctg
attgagcagg cacccctgac cgtggccgag aagctgcagc gcgactttct
7320gacggaatgg cgccgtgtga gtaaggcccc ggaggctctt ttctttgtgc
aatttgagaa 7380gggagagagc tacttccaca tgcacgtgct cgtggaaacc
accggggtga aatc 7434611569DNAArtificial SequenceCoding Strand of
Plasmid pHelper-Kan 6ggtacccaac tccatgctta acagtcccca ggtacagccc
accctgcgtc gcaaccagga 60acagctctac agcttcctgg agcgccactc gccctacttc
cgcagccaca gtgcgcagat 120taggagcgcc acttcttttt gtcacttgaa
aaacatgtaa aaataatgta ctaggagaca 180ctttcaataa aggcaaatgt
ttttatttgt acactctcgg gtgattattt accccccacc 240cttgccgtct
gcgccgttta aaaatcaaag gggttctgcc gcgcatcgct atgcgccact
300ggcagggaca cgttgcgata ctggtgttta gtgctccact taaactcagg
cacaaccatc 360cgcggcagct cggtgaagtt ttcactccac aggctgcgca
ccatcaccaa cgcgtttagc 420aggtcgggcg ccgatatctt gaagtcgcag
ttggggcctc cgccctgcgc gcgcgagttg 480cgatacacag ggttgcagca
ctggaacact atcagcgccg ggtggtgcac gctggccagc 540acgctcttgt
cggagatcag atccgcgtcc aggtcctccg cgttgctcag ggcgaacgga
600gtcaactttg gtagctgcct tcccaaaaag ggtgcatgcc caggctttga
gttgcactcg 660caccgtagtg gcatcagaag gtgaccgtgc ccggtctggg
cgttaggata cagcgcctgc 720atgaaagcct tgatctgctt aaaagccacc
tgagcctttg cgccttcaga gaagaacatg 780ccgcaagact tgccggaaaa
ctgattggcc ggacaggccg cgtcatgcac gcagcacctt 840gcgtcggtgt
tggagatctg caccacattt cggccccacc ggttcttcac gatcttggcc
900ttgctagact gctccttcag cgcgcgctgc ccgttttcgc tcgtcacatc
catttcaatc 960acgtgctcct tatttatcat aatgctcccg tgtagacact
taagctcgcc ttcgatctca 1020gcgcagcggt gcagccacaa cgcgcagccc
gtgggctcgt ggtgcttgta ggttacctct 1080gcaaacgact gcaggtacgc
ctgcaggaat cgccccatca tcgtcacaaa ggtcttgttg 1140ctggtgaagg
tcagctgcaa cccgcggtgc tcctcgttta gccaggtctt gcatacggcc
1200gccagagctt ccacttggtc aggcagtagc ttgaagtttg cctttagatc
gttatccacg 1260tggtacttgt ccatcaacgc gcgcgcagcc tccatgccct
tctcccacgc agacacgatc 1320ggcaggctca gcgggtttat caccgtgctt
tcactttccg cttcactgga ctcttccttt 1380tcctcttgcg tccgcatacc
ccgcgccact gggtcgtctt cattcagccg ccgcaccgtg 1440cgcttacctc
ccttgccgtg cttgattagc accggtgggt tgctgaaacc caccatttgt
1500agcgccacat cttctctttc ttcctcgctg tccacgatca cctctgggga
tggcgggcgc 1560tcgggcttgg gagaggggcg cttctttttc tttttggacg
caatggccaa atccgccgtc 1620gaggtcgatg gccgcgggct gggtgtgcgc
ggcaccagcg catcttgtga cgagtcttct 1680tcgtcctcgg actcgagacg
ccgcctcagc cgcttttttg ggggcgcgcg gggaggcggc 1740ggcgacggcg
acggggacga cacgtcctcc atggttggtg gacgtcgcgc cgcaccgcgt
1800ccgcgctcgg gggtggtttc gcgctgctcc tcttcccgac tggccatttc
cttctcctat 1860aggcagaaaa agatcatgga gtcagtcgag aaggaggaca
gcctaaccgc cccctttgag 1920ttcgccacca ccgcctccac cgatgccgcc
aacgcgccta ccaccttccc cgtcgaggca 1980cccccgcttg aggaggagga
agtgattatc gagcaggacc caggttttgt aagcgaagac 2040gacgaggatc
gctcagtacc aacagaggat aaaaagcaag accaggacga cgcagaggca
2100aacgaggaac aagtcgggcg gggggaccaa aggcatggcg actacctaga
tgtgggagac 2160gacgtgctgt tgaagcatct gcagcgccag tgcgccatta
tctgcgacgc gttgcaagag 2220cgcagcgatg tgcccctcgc catagcggat
gtcagccttg cctacgaacg ccacctgttc 2280tcaccgcgcg taccccccaa
acgccaagaa aacggcacat gcgagcccaa cccgcgcctc 2340aacttctacc
ccgtatttgc cgtgccagag gtgcttgcca cctatcacat ctttttccaa
2400aactgcaaga tacccctatc ctgccgtgcc aaccgcagcc gagcggacaa
gcagctggcc 2460ttgcggcagg gcgctgtcat acctgatatc gcctcgctcg
acgaagtgcc aaaaatcttt 2520gagggtcttg gacgcgacga gaaacgcgcg
gcaaacgctc tgcaacaaga aaacagcgaa 2580aatgaaagtc actgtggagt
gctggtggaa cttgagggtg acaacgcgcg cctagccgtg 2640ctgaaacgca
gcatcgaggt cacccacttt gcctacccgg cacttaacct accccccaag
2700gttatgagca cagtcatgag cgagctgatc gtgcgccgtg cacgacccct
ggagagggat 2760gcaaacttgc aagaacaaac cgaggagggc ctacccgcag
ttggcgatga gcagctggcg 2820cgctggcttg agacgcgcga gcctgccgac
ttggaggagc gacgcaagct aatgatggcc 2880gcagtgcttg ttaccgtgga
gcttgagtgc atgcagcggt tctttgctga cccggagatg 2940cagcgcaagc
tagaggaaac gttgcactac acctttcgcc agggctacgt gcgccaggcc
3000tgcaaaattt ccaacgtgga gctctgcaac ctggtctcct accttggaat
tttgcacgaa 3060aaccgcctcg ggcaaaacgt gcttcattcc acgctcaagg
gcgaggcgcg ccgcgactac 3120gtccgcgact gcgtttactt atttctgtgc
tacacctggc aaacggccat gggcgtgtgg 3180cagcaatgcc tggaggagcg
caacctaaag gagctgcaga agctgctaaa gcaaaacttg 3240aaggacctat
ggacggcctt caacgagcgc tccgtggccg cgcacctggc ggacattatc
3300ttccccgaac gcctgcttaa aaccctgcaa cagggtctgc cagacttcac
cagtcaaagc 3360atgttgcaaa actttaggaa ctttatccta gagcgttcag
gaattctgcc cgccacctgc 3420tgtgcgcttc ctagcgactt tgtgcccatt
aagtaccgtg aatgccctcc gccgctttgg 3480ggtcactgct accttctgca
gctagccaac taccttgcct accactccga catcatggaa 3540gacgtgagcg
gtgacggcct actggagtgt cactgtcgct gcaacctatg caccccgcac
3600cgctccctgg tctgcaattc gcaactgctt agcgaaagtc aaattatcgg
tacctttgag 3660ctgcagggtc cctcgcctga cgaaaagtcc gcggctccgg
ggttgaaact cactccgggg 3720ctgtggacgt cggcttacct tcgcaaattt
gtacctgagg actaccacgc ccacgagatt 3780aggttctacg aagaccaatc
ccgcccgcca aatgcggagc ttaccgcctg cgtcattacc 3840cagggccaca
tccttggcca attgcaagcc atcaacaaag cccgccaaga gtttctgcta
3900cgaaagggac ggggggttta cctggacccc cagtccggcg aggagctcaa
cccaatcccc 3960ccgccgccgc agccctatca gcagccgcgg gcccttgctt
cccaggatgg cacccaaaaa 4020gaagctgcag ctgccgccgc cgccacccac
ggacgaggag gaatactggg acagtcaggc 4080agaggaggtt ttggacgagg
aggaggagat gatggaagac tgggacagcc tagacgaagc 4140ttccgaggcc
gaagaggtgt cagacgaaac accgtcaccc tcggtcgcat tcccctcgcc
4200ggcgccccag aaattggcaa ccgttcccag catcgctaca acctccgctc
ctcaggcgcc 4260gccggcactg cctgttcgcc gacccaaccg tagatgggac
accactggaa ccagggccgg 4320taagtctaag cagccgccgc cgttagccca
agagcaacaa cagcgccaag gctaccgctc 4380gtggcgcggg cacaagaacg
ccatagttgc ttgcttgcaa gactgtgggg gcaacatctc 4440cttcgcccgc
cgctttcttc tctaccatca cggcgtggcc ttcccccgta acatcctgca
4500ttactaccgt catctctaca gcccctactg caccggcggc agcggcagcg
gcagcaacag 4560cagcggtcac acagaagcaa aggcgaccgg atagcaagac
tctgacaaag cccaagaaat 4620ccacagcggc ggcagcagca ggaggaggag
cgctgcgtct ggcgcccaac gaacccgtat 4680cgacccgcga gcttagaaat
aggatttttc ccactctgta tgctatattt caacaaagca 4740ggggccaaga
acaagagctg aaaataaaaa acaggtctct gcgctccctc acccgcagct
4800gcctgtatca caaaagcgaa gatcagcttc ggcgcacgct ggaagacgcg
gaggctctct 4860tcagcaaata ctgcgcgctg actcttaagg actagtttcg
cgccctttct caaatttaag 4920cgcgaaaact acgtcatctc cagcggccac
acccggcgcc agcacctgtc gtcagcgcca 4980ttatgagcaa ggaaattccc
acgccctaca tgtggagtta ccagccacaa atgggacttg 5040cggctggagc
tgcccaagac tactcaaccc gaataaacta catgagcgcg ggaccccaca
5100tgatatcccg ggtcaacgga atccgcgccc accgaaaccg aattctcctc
gaacaggcgg 5160ctattaccac cacacctcgt aataacctta atccccgtag
ttggcccgct gccctggtgt 5220accaggaaag tcccgctccc accactgtgg
tacttcccag agacgcccag gccgaagttc 5280agatgactaa ctcaggggcg
cagcttgcgg gcggctttcg tcacagggtg cggtcgcccg 5340ggcgttttag
ggcggagtaa cttgcatgta ttgggaattg tagttttttt aaaatgggaa
5400gtgacgtatc gtgggaaaac ggaagtgaag atttgaggaa gttgtgggtt
ttttggcttt 5460cgtttctggg cgtaggttcg cgtgcggttt tctgggtgtt
ttttgtggac tttaaccgtt 5520acgtcatttt ttagtcctat atatactcgc
tctgtacttg gcccttttta cactgtgact 5580gattgagctg gtgccgtgtc
gagtggtgtt ttttaatagg tttttttact ggtaaggctg 5640actgttatgg
ctgccgctgt ggaagcgctg tatgttgttc tggagcggga gggtgctatt
5700ttgcctaggc aggagggttt ttcaggtgtt tatgtgtttt tctctcctat
taattttgtt 5760atacctccta tgggggctgt aatgttgtct ctacgcctgc
gggtatgtat tcccccgggc 5820tatttcggtc gctttttagc actgaccgat
gttaaccaac ctgatgtgtt taccgagtct 5880tacattatga ctccggacat
gaccgaggaa ctgtcggtgg tgctttttaa tcacggtgac 5940cagttttttt
acggtcacgc cggcatggcc gtagtccgtc ttatgcttat aagggttgtt
6000tttcctgttg taagacaggc ttctaatgtt taaatgtttt tttttttgtt
attttatttt 6060gtgtttaatg caggaacccg cagacatgtt tgagagaaaa
atggtgtctt tttctgtggt 6120ggttccggaa cttacctgcc tttatctgca
tgagcatgac tacgatgtgc ttgctttttt 6180gcgcgaggct ttgcctgatt
ttttgagcag caccttgcat tttatatcgc cgcccatgca 6240acaagcttac
ataggggcta cgctggttag catagctccg agtatgcgtg tcataatcag
6300tgtgggttct tttgtcatgg ttcctggcgg ggaagtggcc gcgctggtcc
gtgcagacct 6360gcacgattat gttcagctgg ccctgcgaag ggacctacgg
gatcgcggta tttttgttaa 6420tgttccgctt ttgaatctta tacaggtctg
tgaggaacct gaatttttgc aatcatgatt 6480cgctgcttga ggctgaaggt
ggagggcgct ctggagcaga tttttacaat ggccggactt 6540aatattcggg
atttgcttag agacatattg ataaggtggc gagatgaaaa ttatttgggc
6600atggttgaag gtgctggaat gtttatagag gagattcacc ctgaagggtt
tagcctttac 6660gtccacttgg acgtgagggc agtttgcctt ttggaagcca
ttgtgcaaca tcttacaaat 6720gccattatct gttctttggc tgtagagttt
gaccacgcca ccggagggga gcgcgttcac 6780ttaatagatc ttcattttga
ggttttggat aatcttttgg aataaaaaaa aaaaaacatg 6840gttcttccag
ctcttcccgc tcctcccgtg tgtgactcgc agaacgaatg tgtaggttgg
6900ctgggtgtgg cttattctgc ggtggtggat gttatcaggg cagcggcgca
tgaaggagtt 6960tacatagaac ccgaagccag ggggcgcctg gatgctttga
gagagtggat atactacaac 7020tactacacag agcgagctaa gcgacgagac
cggagacgca gatctgtttg tcacgcccgc 7080acctggtttt gcttcaggaa
atatgactac gtccggcgtt ccatttggca tgacactacg 7140accaacacga
tctcggttgt ctcggcgcac tccgtacagt agggatcgcc tacctccttt
7200tgagacagag acccgcgcta ccatactgga ggatcatccg ctgctgcccg
aatgtaacac 7260tttgacaatg cacaacgtga gttacgtgcg aggtcttccc
tgcagtgtgg gatttacgct 7320gattcaggaa tgggttgttc cctgggatat
ggttctgacg cgggaggagc ttgtaatcct 7380gaggaagtgt atgcacgtgt
gcctgtgttg tgccaacatt gatatcatga cgagcatgat 7440gatccatggt
tacgagtcct gggctctcca ctgtcattgt tccagtcccg gttccctgca
7500gtgcatagcc ggcgggcagg ttttggccag ctggtttagg atggtggtgg
atggcgccat 7560gtttaatcag aggtttatat ggtaccggga ggtggtgaat
tacaacatgc caaaagaggt
7620aatgtttatg tccagcgtgt ttatgagggg tcgccactta atctacctgc
gcttgtggta 7680tgatggccac gtgggttctg tggtccccgc catgagcttt
ggatacagcg ccttgcactg 7740tgggattttg aacaatattg tggtgctgtg
ctgcagttac tgtgctgatt taagtgagat 7800cagggtgcgc tgctgtgccc
ggaggacaag gcgtctcatg ctgcgggcgg tgcgaatcat 7860cgctgaggag
accactgcca tgttgtattc ctgcaggacg gagcggcggc ggcagcagtt
7920tattcgcgcg ctgctgcagc accaccgccc tatcctgatg cacgattatg
actctacccc 7980catgtaggcg tggacttccc cttcgccgcc cgttgagcaa
ccgcaagttg gacagcagcc 8040tgtggctcag cagctggaca gcgacatgaa
cttaagcgag ctgcccgggg agtttattaa 8100tatcactgat gagcgtttgg
ctcgacagga aaccgtgtgg aatataacac ctaagaatat 8160gtctgttacc
catgatatga tgctttttaa ggccagccgg ggagaaagga ctgtgtactc
8220tgtgtgttgg gagggaggtg gcaggttgaa tactagggtt ctgtgagttt
gattaaggta 8280cggtgatcaa tataagctat gtggtggtgg ggctatacta
ctgaatgaaa aatgacttga 8340aattttctgc aattgaaaaa taaacacgtt
gaaacataac atgcaacagg ttcacgattc 8400tttattcctg ggcaatgtag
gagaaggtgt aagagttggt agcaaaagtt tcagtggtgt 8460attttccact
ttcccaggac catgtaaaag acatagagta agtgcttacc tcgctagttt
8520ctgtggattc actagaatcg atgtaggatg ttgcccctcc tgacgcggta
ggagaagggg 8580agggtgccct gcatgtctgc cgctgctctt gctcttgccg
ctgctgagga ggggggcgca 8640tctgccgcag caccggatgc atctgggaaa
agcaaaaaag gggctcgtcc ctgtttccgg 8700aggaatttgc aagcggggtc
ttgcatgacg gggaggcaaa cccccgttcg ccgcagtccg 8760gccggcccga
gactcgaacc gggggtcctg cgactcaacc cttggaaaat aaccctccgg
8820ctacagggag cgagccactt aatgctttcg ctttccagcc taaccgctta
cgccgcgcgc 8880ggccagtggc caaaaaagct agcgcagcag ccgccgcgcc
tggaaggaag ccaaaaggag 8940cgctcccccg ttgtctgacg tcgcacacct
gggttcgaca cgcgggcggt aaccgcatgg 9000atcacggcgg acggccggat
ccggggttcg aaccccggtc gtccgccatg atacccttgc 9060gaatttatcc
accagaccac ggaagagtgc ccgcttacag gctctccttt tgcacggtct
9120agagcgtcaa cgactgcgca cgcctcaccg gccagagcgt cccgaccatg
gagcactttt 9180tgccgctgcg caacatctgg aaccgcgtcc gcgactttcc
gcgcgcctcc accaccgccg 9240ccggcatcac ctggatgtcc aggtacatct
acggattacg tcgacgttta aaccatatga 9300tcagctcact caaaggcggt
aatacggtta tccacagaat caggggataa cgcaggaaag 9360aacatgtgag
caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg
9420tttttccata ggctccgccc ccctgacgag catcacaaaa atcgacgctc
aagtcagagg 9480tggcgaaacc cgacaggact ataaagatac caggcgtttc
cccctggaag ctccctcgtg 9540cgctctcctg ttccgaccct gccgcttacc
ggatacctgt ccgcctttct cccttcggga 9600agcgtggcgc tttctcatag
ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc 9660tccaagctgg
gctgtgtgca cgaacccccc gttcagcccg accgctgcgc cttatccggt
9720aactatcgtc ttgagtccaa cccggtaaga cacgacttat cgccactggc
agcagccact 9780ggtaacagga ttagcagagc gaggtatgta ggcggtgcta
cagagttctt gaagtggtgg 9840cctaactacg gctacactag aagaacagta
tttggtatct gcgctctgct gaagccagtt 9900accttcggaa aaagagttgg
tagctcttga tccggcaaac aaaccaccgc tggtagcggt 9960ggtttttttg
tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct
10020ttgatctttt ctacggggtc tgacgctcag tggaacgaaa actcacgtta
agggattttg 10080gtcatgagat tatcaaaaag gatcttcacc tagatccttt
taaattaaaa atgaagtttt 10140aaatcaatct aaagtatata tgagtaaact
tggtctgaca gtcagaagaa ctcgtcaaga 10200aggcgataga aggcgatgcg
ctgcgaatcg ggagcggcga taccgtaaag cacgaggaag 10260cggtcagccc
attcgccgcc aagctcttca gcaatatcac gggtagccaa cgctatgtcc
10320tgatagcggt ccgccacacc cagccggcca cagtcgatga atccagaaaa
gcggccattt 10380tccaccatga tattcggcaa gcaggcatcg ccatgggtca
cgacgagatc ctcgccgtcg 10440ggcatgctcg ccttgagcct ggcgaacagt
tcggctggcg cgagcccctg atgctcttcg 10500tccagatcat cctgatcgac
aagaccggct tccatccgag tacgtgctcg ctcgatgcga 10560tgtttcgctt
ggtggtcgaa tgggcaggta gccggatcaa gcgtatgcag ccgccgcatt
10620gcatcagcca tgatggatac tttctcggca ggagcaaggt gagatgacag
gagatcctgc 10680cccggcactt cgcccaatag cagccagtcc cttcccgctt
cagtgacaac gtcgagtaca 10740gctgcgcaag gaacgcccgt cgtggccagc
cacgatagcc gcgctgcctc gtcttgcagt 10800tcattcaggg caccggacag
gtcggtcttg acaaaaagaa ccgggcgccc ctgcgctgac 10860agccggaaca
cggcggcatc agagcagccg attgtctgtt gtgcccagtc atagccgaat
10920agcctctcca cccaagcggc cggagaacct gcgtgcaatc catcttgttc
aatcatactc 10980ttcctttttc aatattattg aagcatttat cagggttatt
gtctcatgag cggatacata 11040tttgaatgta tttagaaaaa taaacaaata
ggggttccgc gcacatttcc ccgaaaagtg 11100ccacctaaat tgtaagcgtt
aatattttgt taaaattcgc gttaaatttt tgttaaatca 11160gctcattttt
taaccaatag gccgaaatcg gcaaaatccc ttataaatca aaagaataga
11220ccgagatagg gttgagtgtt gttccagttt ggaacaagag tccactatta
aagaacgtgg 11280actccaacgt caaagggcga aaaaccgtct atcagggcga
tggcccacta cgtgaaccat 11340caccctaatc aagttttttg gggtcgaggt
gccgtaaagc actaaatcgg aaccctaaag 11400ggagcccccg atttagagct
tgacggggaa agccggcgaa cgtggcgaga aaggaaggga 11460agaaagcgaa
aggagcgggc gctagggcgc tggcaagtgt agcggtcacg ctgcgcgtaa
11520ccaccacacc cgccgcgctt aatgcgccgc tacagggcgc gatggatcc
1156975030DNAArtificial SequenceCoding Strand of Plasmid
pAV-CMV-EGFP 7cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc
ccgggcgtcg ggcgaccttt 60ggtcgcccgg ccctccagtg agcgagcgcg cagagaggga
gtggccaact ccatcactag 120gggttcctgc ggccgcacgc gtctagttat
taatagtaat cgaattcgtg ttactcataa 180ctagtaaggt cgggcaggaa
gagggcctat ttcccatgat tccttcatat ttgcatatac 240gatacaaggc
tgttagagag ataattagaa ttaatttgac tgtaaacaca aagatattag
300tacaaaatac gtgacgtaga aagtaataat ttcttgggta gtttgcagtt
ttaaaattat 360gttttaaaat ggactatcat atgcttaccg taacttgaaa
gtatttcgat ttcttgggtt 420tatatatctt gtggaaagga cgcgggatcc
actggaccag gcagcagcgt cagaagactt 480ttttggaaaa gcttgactag
taatactgta atagtaatca attacggggt cattagttca 540tagcccatat
atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc
600gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag
taacgccaat 660agggactttc cattgacgtc aatgggtgga gtatttacgg
taaactgccc acttggcagt 720acatcaagtg tatcatatgc caagtacgcc
ccctattgac gtcaatgacg gtaaatggcc 780cgcctggcat tatgcccagt
acatgacctt atgggacttt cctacttggc agtacatcta 840cgtattagtc
atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg
900atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca
atgggagttt 960gttttgcacc aaaatcaacg ggactttcca aaatgtcgta
acaactccgc cccattgacg 1020caaatgggcg gtaggcgtgt acggtgggag
gtctatataa gcagagctgg tttagtgaac 1080cgtcagatcc gctagagatc
cggtaccgag gagatctgcc gccgcgatcg ccggcgcgcc 1140agatctcacg
cttaactagc tagcggaccg acgcgtacgc ggccgctcga gatggtgagc
1200aagggcgagg agctgttcac cggggtggtg cccatcctgg tcgagctgga
cggcgacgta 1260aacggccaca agttcagcgt gtccggcgag ggcgagggcg
atgccaccta cggcaagctg 1320accctgaagt tcatctgcac caccggcaag
ctgcccgtgc cctggcccac cctcgtgacc 1380accctgacct acggcgtgca
gtgcttcagc cgctaccccg accacatgaa gcagcacgac 1440ttcttcaagt
ccgccatgcc cgaaggctac gtccaggagc gcaccatctt cttcaaggac
1500gacggcaact acaagacccg cgccgaggtg aagttcgagg gcgacaccct
ggtgaaccgc 1560atcgagctga agggcatcga cttcaaggag gacggcaaca
tcctggggca caagctggag 1620tacaactaca acagccacaa cgtctatatc
atggccgaca agcagaagaa cggcatcaag 1680gtgaacttca agatccgcca
caacatcgag gacggcagcg tgcagctcgc cgaccactac 1740cagcagaaca
cccccatcgg cgacggcccc gtgctgctgc ccgacaacca ctacctgagc
1800acccagtccg ccctgagcaa agaccccaac gagaagcgcg atcacatggt
cctgctggag 1860ttcgtgaccg ccgccgggat cactctcggc atggacgagc
tgtacaagta agtcgaggat 1920tataaggatg acgacgataa attcgtcgag
caccaccacc accaccacta ataaggttta 1980tccgatccac cggatctaga
taagatatcc gatccaccgg atctagataa ctgatcataa 2040tcagccatac
cacatttgta gaggttttac ttgctttaaa aaacctccca cacctccccc
2100tgaacctgaa acataaaatg aatgcaattg ttgttgttaa cttgtttatt
gcagcttata 2160atggttacaa ataaagcaat agcatcacaa atttcacaaa
taaagcattt ttttcactgc 2220attctagttg tggtttgtcc aaactcatca
atgtatctta acgcggtaac cacgtgcgga 2280ccgagcggcc gcaggaaccc
ctagtgatgg agttggccac tccctctctg cgcgctcgct 2340cgctcactga
ggccgggcga ccaaaggtcg cccgacgccc gggctttgcc cgggcggcct
2400cagtgagcga gcgagcgcgc agctgcctgc aggggcgcct gatgcggtat
tttctcctta 2460cgcatctgtg cggtatttca caccgcatac gtcaaagcaa
ccatagtacg cgccctgtag 2520cggcgcatta agcgcggcgg gtgtggtggt
tacgcgcagc gtgaccgcta cacctgccag 2580cgccttagcg cccgctcctt
tcgctttctt cccttccttt ctcgccacgt tcgccggctt 2640tccccgtcaa
gctctaaatc gggggctccc tttagggttc cgatttagtg ctttacggca
2700cctcgacccc aaaaaacttg atttgggtga tggttcacgt agtgggccat
cgccctgata 2760gacggttttt cgccctttga cgttggagtc cacgttcttt
aatagtggac tcttgttcca 2820aactggaaca acactcaacc ctatctcggg
ctattctttt gatttataag ggattttgcc 2880gatttcggcc tattggttaa
aaaatgagct gatttaacaa aaatttaacg cgaattttaa 2940caaaatatta
acgtttacaa ttttatggtg cactctcagt acaatctgct ctgatgccgc
3000atagttaagc cagccccgac acccgccaac acccgctgac gcgccctgac
gggcttgtct 3060gctcccggca tccgcttaca gacaagctgt gaccgtctcc
gggagctgca tgtgtcagag 3120gttttcaccg tcatcaccga aacgcgcgag
acgaaagggc ctcgtgatac gcctattttt 3180ataggttaat gtcatgataa
taatggtttc ttagacgtca ggtggcactt ttcggggaaa 3240tgtgcgcgga
acccctattt gtttattttt ctaaatacat tcaaatatgt atccgctcat
3300gagacaataa ccctgataaa tgcttcaata atattgaaaa aggaagagta
tgagtattca 3360acatttccgt gtcgccctta ttcccttttt tgcggcattt
tgccttcctg tttttgctca 3420cccagaaacg ctggtgaaag taaaagatgc
tgaagatcag ttgggtgcac gagtgggtta 3480catcgaactg gatctcaaca
gcggtaagat ccttgagagt tttcgccccg aagaacgttt 3540tccaatgatg
agcactttta aagttctgct atgtggcgcg gtattatccc gtattgacgc
3600cgggcaagag caactcggtc gccgcataca ctattctcag aatgacttgg
ttgagtactc 3660accagtcaca gaaaagcatc ttacggatgg catgacagta
agagaattat gcagtgctgc 3720cataaccatg agtgataaca ctgcggccaa
cttacttctg acaacgatcg gaggaccgaa 3780ggagctaacc gcttttttgc
acaacatggg ggatcatgta actcgccttg atcgttggga 3840accggagctg
aatgaagcca taccaaacga cgagcgtgac accacgatgc ctgtagcaat
3900ggcaacaacg ttgcgcaaac tattaactgg cgaactactt actctagctt
cccggcaaca 3960attaatagac tggatggagg cggataaagt tgcaggacca
cttctgcgct cggcccttcc 4020ggctggctgg tttattgctg ataaatctgg
agccggtgag cgtgggtctc gcggtatcat 4080tgcagcactg gggccagatg
gtaagccctc ccgtatcgta gttatctaca cgacggggag 4140tcaggcaact
atggatgaac gaaatagaca gatcgctgag ataggtgcct cactgattaa
4200gcattggtaa ctgtcagacc aagtttactc atatatactt tagattgatt
taaaacttca 4260tttttaattt aaaaggatct aggtgaagat cctttttgat
aatctcatga ccaaaatccc 4320ttaacgtgag ttttcgttcc actgagcgtc
agaccccgta gaaaagatca aaggatcttc 4380ttgagatcct ttttttctgc
gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc 4440agcggtggtt
tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt
4500cagcagagcg cagataccaa atactgtcct tctagtgtag ccgtagttag
gccaccactt 4560caagaactct gtagcaccgc ctacatacct cgctctgcta
atcctgttac cagtggctgc 4620tgccagtggc gataagtcgt gtcttaccgg
gttggactca agacgatagt taccggataa 4680ggcgcagcgg tcgggctgaa
cggggggttc gtgcacacag cccagcttgg agcgaacgac 4740ctacaccgaa
ctgagatacc tacagcgtga gctatgagaa agcgccacgc ttcccgaagg
4800gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga acaggagagc
gcacgaggga 4860gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc
gggtttcgcc acctctgact 4920tgagcgtcga tttttgtgat gctcgtcagg
ggggcggagc ctatggaaaa acgccagcaa 4980cgcggccttt ttacggttcc
tggccttttg ctggcctttt gctcacatgt 503084742DNAArtificial
SequenceCoding Strand of Plasmid pAV-TBG-EGFP 8cctgcaggca
gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60ggtcgcccgg
cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact
120aggggttcct gcggccggtc gcgtctagta ctagtaggtt aatttttaaa
aagcagtcaa 180aagtccaagt ggcccttggc agcatttact ctctctgttt
gctctggtta ataatctcag 240gagcacaaac attccagatc caggttaatt
tttaaaaagc agtcaaaagt ccaagtggcc 300cttggcagca tttactctct
ctgtttgctc tggttaataa tctcaggagc acaaacattc 360cagatccggc
gcgccagggc tggaagctac ctttgacatc atttcctctg cgaatgcatg
420tataatttct acagaaccta ttagaaagga tcacccagcc tctgcttttg
tacaactttc 480ccttaaaaaa ctgccaattc cactgctgtt tggcccaata
gtgagaactt tttcctgctg 540cctcttggtg cttttgccta tggcccctat
tctgcctgct gaagacactc ttgccagcat 600ggacttaaac ccctccagct
ctgacaatcc tctttctctt ttgttttaca tgaagggtct 660ggcagccaaa
gcaatcactc aaagttcaaa ccttatcatt ttttgctttg ttcctcttgg
720ccttggtttt gtacatcagc tttgaaaata ccatcccagg gttaatgctg
gggttaattt 780ataactaaga gtgctctagt tttgcaatac aggacatgct
ataaaaatgg aaagatgttg 840ctttctgaga gacaggtacc gaggagatct
gccgccgcga tcgccaccat ggtgagcaag 900ggcgaggagc tgttcaccgg
ggtggtgccc atcctggtcg agctggacgg cgacgtaaac 960ggccacaagt
tcagcgtgtc cggcgagggc gagggcgatg ccacttacgg caagctgacc
1020ctgaagttca tctgcaccac cggcaagctg cccgtgccct ggcccaccct
cgtgaccacc 1080ctgacctacg gcgtgcagtg cttcagccgc taccccgacc
acatgaagca gcacgacttc 1140ttcaagtccg ccatgcccga aggctacgtc
caggagcgca ccatcttctt caaggacgac 1200ggcaactaca agacccgcgc
cgaggtgaag ttcgagggcg acaccctggt gaaccgcatc 1260gagctgaagg
gcatcgactt caaggaggac ggcaacatcc tggggcacaa gctggagtac
1320aactacaaca gccacaacgt ctatatcatg gccgacaagc agaagaacgg
catcaaggtg 1380aacttcaaga tccgccacaa catcgaggac ggcagcgtgc
agctcgccga ccactaccag 1440cagaacaccc ccatcggcga cggccccgtg
ctgctgcccg acaaccacta cctgagcacc 1500cagtccgccc tgagcaaaga
ccccaacgag aagcgcgatc acatggtcct gctggagttc 1560gtgaccgccg
ccgggatcac tctcggcatg gacgagctgt acaagtagac gcgtacgcgg
1620ccgctcgagg attataagga tgacgacgat aaattcgtcg agcaccacca
ccaccaccac 1680taataaggtt tatccgatcc accggatcta gataagatat
ccgatccacc ggatctagat 1740aactgatcat aatcagccat accacatttg
tagaggtttt acttgcttta aaaaacctcc 1800cacacctccc cctgaacctg
aaacataaaa tgaatgcaat tgttgttgtt aacttgttta 1860ttgcagctta
taatggttac aaataaagca atagcatcac aaatttcaca aataaagcat
1920ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct
taacgcggta 1980accacgtgcg gacccaacgg ccgcaggaac ccctagtgat
ggagttggcc actccctctc 2040tgcgcgctcg ctcgctcact gaggccgggc
gaccaaaggt cgcccgacgc ccgggctttg 2100cccgggcggc ctcagtgagc
gagcgagcgc gcagctgcct gcaggggcgc ctgatgcggt 2160attttctcct
tacgcatctg tgcggtattt cacaccgcat acgtcaaagc aaccatagta
2220cgcgccctgt agcggcacat taagcgcggc gggtgtggtg gttacgcgca
gcgtgaccgc 2280tacacctgcc agcgccttag cgcccgctcc tttcgctttc
ttcccttcct ttctcgccac 2340gttcgccggc tttccccgtc aagctctaaa
tcgggggctc cctttagggt tccgatttag 2400tgctttacgg cacctcgacc
ccaaaaaact tgatttgggt gatggttcac gtagtgggcc 2460atcgccctga
tagacggttt ttcgcccttt gacgttggag tccacgttct ttaatagtgg
2520actcttgttc caaactggaa caacactcaa ctctatctcg ggctattctt
ttgatttata 2580agggattttg ccgatttcgg tctattggtt aaaaaatgag
ctgatttaac aaaaatttaa 2640cgcgaatttt aacaaaatat taacgtttac
aattttatgg tgcactctca gtacaatctg 2700ctctgatgcc gcatagttaa
gccagccccg acacccgcca acacccgctg acgcgccctg 2760acgggcttgt
ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg
2820catgtgtcag aggttttcac cgtcatcacc gaaacgcgcg agacgaaagg
gcctcgtgat 2880acgcctattt ttataggtta atgtcatgat aataatggtt
tcttagacgt caggtggcac 2940ttttcgggga aatgtgcgcg gaacccctat
ttgtttattt ttctaaatac attcaaatat 3000gtatccgctc atgagacaat
aaccctgata aatgcttcaa taatattgaa aaaggaagag 3060tatgagtatt
caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc
3120tgtttttgct cacccagaaa cgctggtgaa agtaaaagat gctgaagatc
agttgggtgc 3180acgagtgggt tacatcgaac tggatctcaa cagcggtaag
atccttgaga gttttcgccc 3240cgaagaacgt tttccaatga tgagcacttt
taaagttctg ctatgtggcg cggtattatc 3300ccgtattgac gccgggcaag
agcaactcgg tcgccgcata cactattctc agaatgactt 3360ggttgagtac
tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt
3420atgcagtgct gccataacca tgagtgataa cactgcggcc aacttacttc
tgacaacgat 3480cggaggaccg aaggagctaa ccgctttttt gcacaacatg
ggggatcatg taactcgcct 3540tgatcgttgg gaaccggagc tgaatgaagc
cataccaaac gacgagcgtg acaccacgat 3600gcctgtagca atggcaacaa
cgttgcgcaa actattaact ggcgaactac ttactctagc 3660ttcccggcaa
caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg
3720ctcggccctt ccggctggct ggtttattgc tgataaatct ggagccggtg
agcgtgggtc 3780tcgcggtatc attgcagcac tggggccaga tggtaagccc
tcccgtatcg tagttatcta 3840cacgacgggg agtcaggcaa ctatggatga
acgaaataga cagatcgctg agataggtgc 3900ctcactgatt aagcattggt
aactgtcaga ccaagtttac tcatatatac tttagattga 3960tttaaaactt
catttttaat ttaaaaggat ctaggtgaag atcctttttg ataatctcat
4020gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg tcagaccccg
tagaaaagat 4080caaaggatct tcttgagatc ctttttttct gcgcgtaatc
tgctgcttgc aaacaaaaaa 4140accaccgcta ccagcggtgg tttgtttgcc
ggatcaagag ctaccaactc tttttccgaa 4200ggtaactggc ttcagcagag
cgcagatacc aaatactgtt cttctagtgt agccgtagtt 4260aggccaccac
ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taatcctgtt
4320accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact
caagacgata 4380gttaccggat aaggcgcagc ggtcgggctg aacggggggt
tcgtgcacac agcccagctt 4440ggagcgaacg acctacaccg aactgagata
cctacagcgt gagctatgag aaagcgccac 4500gcttcccgaa gggagaaagg
cggacaggta tccggtaagc ggcagggtcg gaacaggaga 4560gcgcacgagg
gagcttccag ggggaaacgc ctggtatctt tatagtcctg tcgggtttcg
4620ccacctctga cttgagcgtc gatttttgtg atgctcgtca ggggggcgga
gcctatggaa 4680aaacgccagc aacgcggcct ttttacggtt cctggccttt
tgctggcctt ttgctcacat 4740gt 47429131DNAadeno-associated virus
1misc_feature(1)..(131)P5 Promoter of AAV1 9ggtcctgtat tagctgtcac
gtgagtgctt ttgcgacatt ttgcgacacc acgtggccat 60ttagggtata tatggccgag
tgagcgagca ggatctccat tttgaccgcg aaatttgaac 120gagcagcagc c
13110131DNAadeno-associated virus 2misc_feature(1)..(131)P5
Promoter of AAV2 10ggtcctgtat tagaggtcac gtgagtgttt tgcgacattt
tgcgacacca tgtggtcacg 60ctgggtattt aagcccgagt gagcacgcag ggtctccatt
ttgaagcggg aggtttgaac 120gcgcagccgc c 13111131DNAadeno-associated
virus 3'misc_feature(1)..(131)P5 Promoter of AAV3 11ccagctgcgt
cagcagtcag gtgacccttt tgcgacagtt tgcgacacca cgtggccgct 60gagggtatat
attctcgagt gagcgaacca ggagctccat tttgaccgcg aaatttgaac
120gagcagcagc c 13112192DNAadeno-associated virus
4misc_feature(1)..(192)P5 Promoter of AAV4 12ggtccctgta ttagcagtca
cgtgagtgtc gtatttcgcg gagcgtagcg gagcgcatac 60caagctgcca cgtcacagcc
acgtggtccg tttgcgacag tttgcgacac catgtggtca 120ggagggtata
taaccgcgag tgagccagcg aggagctcca ttttgcccgc gaattttgaa
180cgagcagcag cc 19213131DNAadeno-associated virus
5misc_feature(1)..(131)P5 Promoter of AAV5 13atgtgatgtg ttttatccaa
taggaagaaa gcgcgcgtat gagttctcgc gagacttccg
60gggtataaaa gaccgagtga acgagcccgc cgccattctt tgctctggac tgctagagga
120ccctcgctgc c 13114130DNAadeno-associated virus
6misc_feature(1)..(130)P5 Promoter of AAV6 14ggtcctgtat tagaggtcac
gtgagtgttt tgcgacattt tgcgacacca tgtggtcacg 60ctgggtattt aagcccgagt
gagcacgcag ggtctccatt ttgaagcggg aggtttgaac 120gcgcagcgcc
13015131DNAadeno-associated virus 7misc_feature(1)..(131)P5
Promoter of AAV7 15ggtcctgtat tagctgtcac gtgagtgctt ttgcgacatt
ttgcgacacc acgtggccat 60ttgaggtata tatggccgag tgagcgagca ggatctccat
tttgaccgcg aaatttgaac 120gagcagcagc c 13116131DNAadeno-associated
virus 8misc_feature(1)..(131)P5 Promoter of AAV8 16ggtcctgtat
tagctgtcac gtgagtgctt ttgcggcatt ttgcgacacc acgtggccat 60ttgaggtata
tatggccgag tgagcgagca ggatctccat tttgaccgcg aaatttgaac
120gagcagcagc c 13117180DNAadeno-associated virus
1misc_feature(1)..(180)P40 Promoter of AAV1 17ggtgacaaag caggaagtca
aagagttctt ccgctgggcg caggatcacg tgaccgaggt 60ggcgcatgag ttctacgtca
gaaagggtgg agccaacaaa agacccgccc ccgatgacgc 120ggataaaagc
gagcccaagc gggcctgccc ctcagtcgcg gatccatcga cgtcagacgc
18018180DNAadeno-associated virus 2misc_feature(1)..(180)P40
Promoter of AAV2 18ggtcaccaag caggaagtca aagacttttt ccggtgggca
aaggatcacg tggttgaggt 60ggagcatgaa ttctacgtca aaaagggtgg agccaagaaa
agacccgccc ccagtgacgc 120agatataagt gagcccaaac gggtgcgcga
gtcagttgcg cagccatcga cgtcagacgc 18019180DNAadeno-associated virus
3misc_feature(1)..(180)P40 Promoter of AAV3 19ggtcaccaaa caggaagtaa
aggacttttt ccggtgggct tccgatcacg tgactgacgt 60ggctcatgag ttctacgtca
gaaagggtgg agctaagaaa cgccccgcct ccaatgacgc 120ggatgtaagc
gagccaaaac gggagtgcac gtcacttgcg cagccgacaa cgtcagacgc
18020180DNAadeno-associated virus 4misc_feature(1)..(180)P40
Promoter of AAV4 20ggtcaccaag caggaagtca aagacttttt ccggtgggcg
tcagatcacg tgaccgaggt 60gactcacgag ttttacgtca gaaagggtgg agctagaaag
aggcccgccc ccaatgacgc 120agatataagt gagcccaagc gggcctgtcc
gtcagttgcg cagccatcga cgtcagacgc 18021227DNAadeno-associated virus
5misc_feature(1)..(227)P40 Promoter of AAV5 21gattactaag caggaagtca
aggacttttt tgcttgggca aaggtcaatc aggtgccggt 60gactcacgag tttaaagttc
ccagggaatt ggcgggaact aaaggggcgg agaaatctct 120aaaacgccca
ctgggtgacg tcaccaatac tagctataaa agtctggaga agcgggcctg
180gagcatgagg ctctcatttg ttcccgagac gcctcgcagt tcagacg
22722180DNAadeno-associated virus 6misc_feature(1)..(180)P40
Promoter of AAV6 22ggtgacaaag caggaagtca aagagttctt ccgctgggcg
caggatcacg tgaccgaggt 60ggcgcatgag ttctacgtca gaaagggtgg agccaacaag
agacccgccc ccgatgacgc 120ggataaaagc gagcccaagc gggcctgccc
ctcagtcgcg gatccatcga cgtcagacgc 18023180DNAadeno-associated virus
7misc_feature(1)..(180)P40 Promoter of AAV7 23ggtgacgaag caggaagtca
aagagttctt ccgctgggcc agtgatcacg tgaccgaggt 60ggcgcatgag ttctacgtca
gaaagggcgg agccagcaaa agacccgccc ccgatgacgc 120ggatataagc
gagcccaagc gggcctgccc ctcagtcgcg gatccatcga cgtcagacgc
18024180DNAadeno-associated virus 8misc_feature(1)..(180)P40
Promoter of AAV8 24ggtgacaaag caggaagtca aagagttctt ccgctgggcc
agtgatcacg tgaccgaggt 60ggcgcatgag ttttacgtca gaaagggcgg agccagcaaa
agacccgccc ccgatgacgc 120ggataaaagc gagcccaagc gggcctgccc
ctcagtcgcg gatccatcga cgtcagacgc 180
* * * * *